Methods and compositions for modulating beta chain mediated immunity

Abstract

To provide a multispecific antibody and a pharmaceutical composition containing the multispecific antibody.SOLUTION: A multispecific antibody comprises: a VH comprising a first binding domain that binds to Vβ17 and a second binding domain that binds to a second target, which is not Vβ17, the VH comprising VH CDR1, VH CDR2, and VH CDR3, each having specific amino acid sequences; and a VL comprising VL CDR1, VL CDR2, and VL CDR3, each having specific amino acid sequences. In one aspect, the second target is CD123, DLL3, or, PSMA.SELECTED DRAWING: None

Description

[Technical Field]

[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application is a continuation of U.S. patent application Ser. No. 63 / 077,314, filed Sep. 11, 2020. , U.S. Patent Application No. 63 / 077,397, filed September 11, 2020, 2020 U.S. Patent Application No. 63 / 077,387, filed September 11, 2020, and filed October 2, 2020. U.S. Patent Application No. 63 / 104,220, filed on October 2, 2020, and issued on October 22, 2020. Application No. 63 / 104,247, filed October 22, 2020 U.S. Patent Application No. 63 / 104,265, filed January 28, 2021 Application No. 63 / 142,930, filed January 28, 2021, U.S. Patent Application No. 63 / No. 142,940, filed January 28, 2021, U.S. Patent Application No. 63 / 142,9 No. 44, U.S. Patent Application No. 63 / 165,053, filed March 23, 2021, 2 U.S. Patent Application No. 63 / 176,112, filed April 16, 2021, and This application claims the benefit of U.S. Patent Application No. 63 / 237,972, filed August 27, 2013. and US Pat. No. 6,229,099, the disclosure of each of which is incorporated herein by reference in its entirety.

[0002] (Field) The present invention relates to anti-Vβ17 molecules, including anti-Vβ17 antibodies, bispecific antibodies, and antibodies containing the antibodies. Nucleic acids and expression vectors encoding the antibodies, recombinant cells containing the vectors, and Further, the present invention relates to a method for producing the antibody and a composition comprising the antibody. Methods of using the antibodies are also provided.

[0003] (Reference to electronically submitted sequence listing) This application has been submitted electronically via EFS-Web as a Sequence Listing in ASCII format. The file name is "14620-406-228_SL.txt" and was sent on September 5, 2021. It contains a sequence table with a size of 889,896 bytes. The sequence listing submitted herewith is a part of the present specification and is incorporated herein by reference in its entirety. It can be enjoyed.

[0004] (overview) In one embodiment, T Cell Receptor Beta Variable 17 (V β17) are provided herein.

[0005] In one aspect, an antibody that binds to Vβ17 is provided, said antibody comprising (i) each of the sequences VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of No. 21 VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of DR3 and (ii) a VL having the amino acid sequence of SEQ ID NO: 677, VL CDR having the amino acid sequences of CDR1, VL CDR2, and VL CDR3 In another embodiment, the Vβ17 comprises a Vβ17 CDR1, a Vβ17 CDR2, and a Vβ17 CDR3. and (i) an antibody that binds to the amino acid sequence of SEQ ID NO: 77, respectively. The amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 of VH having and (ii) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having VL CDR1 and VL CDR2 have the amino acid sequence of SEQ ID NO: 78, respectively. and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and and a VL comprising a VL CDR3. , each of the antibodies comprises: (i) a VH CD of a VH having the amino acid sequence of SEQ ID NO: 79; VH CDR1 having the amino acid sequences of R1, VH CDR2, and VH CDR3; and (ii) a VH comprising a VH CDR2, a VH CDR3, and a VH CDR4, each of which has the sequence of SEQ ID NO: 80. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 are a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence In another aspect, an antibody that binds to Vβ17 is provided, the antibody comprising: (i) VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 81, respectively. and VH CDR3, (ii) a VH comprising CDR3 and (iii) a VL having the amino acid sequence of SEQ ID NO: 82, VL having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of and a VL comprising VL CDR1, VL CDR2, and VL CDR3. Antibodies that bind to Vβ17 are provided, said antibodies comprising (i) an amino acid sequence of SEQ ID NO: 83, respectively. The amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 of VH are a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the sequence (ii) VL CDR1, VL CDR2, VL CDR3, VL CDR4, VL CDR5, VL CDR6, VL CDR7, VL CDR8, VL CDR9, VL DDR1, VL DDR1, VL DDR2, VL DDR3, VL DDR4, VL DDR5, VL DDR6, VL DDR7, VL DDR8, VL DDR9, VL DDR1, VL DDR VL CDR1, VL CDR2, and VL CDR3 amino acid sequences In another aspect, an antibody that binds to Vβ17 comprises a VL comprising Vβ17 CDR2, and a VL comprising Vβ17 CDR3. (i) a VH VH having the amino acid sequence of SEQ ID NO: 85; VH CDR1, VH CDR2, and VH CDR3 amino acid sequences. and (ii) a VH comprising DR1, VH CDR2, and VH CDR3, each of which has SEQ ID NO: VL CDR1, VL CDR2, and VL CDR of VL having the amino acid sequence of No. 86 VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3. In another aspect, an antibody that binds to Vβ17 is provided, the antibody comprising: i) VH CDR1, VH CD of VH having the amino acid sequence of SEQ ID NO: 87, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3; and (ii) a VH comprising a VH CDR3 and a VH CDR3, each having the amino acid sequence of SEQ ID NO: 88. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of the VL are and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3. In one embodiment, an antibody that binds to Vβ17 is provided, the antibody comprising: (i) a polypeptide having a sequence similar to SEQ ID NO: 1; VH CDR1, VH CDR2, and VH CDR of VH having an amino acid sequence of 000 VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of R3 and (ii) a VL having the amino acid sequence of SEQ ID NO: 1001, VL CDR having the amino acid sequences of CDR1, VL CDR2, and VL CDR3 In another embodiment, the Vβ17 comprises a Vβ17 CDR1, a Vβ17 CDR2, and a Vβ17 CDR3. and an antibody that binds to (i) the amino acid sequence of SEQ ID NO: 1032, respectively. The amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 of VH having the sequence a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the sequence (i i) VL CDR1, VL CDR2, VL CDR3, VL CDR4, VL CDR5, VL CDR6, VL CDR7, VL CDR8, VL CDR9, VL CDR10, VL CDR11, VL CDR12, VL CDR13, VL CDR14, VL CDR15, VL CDR16, VL CDR17, VL CDR18, VL CDR19, V VL CDR1, VL CDR2, and VL CDR3 amino acid sequences In another aspect, an antibody that binds to Vβ17 comprises a VL comprising Vβ17 CDR2, and a VL comprising Vβ17 CDR3. each VH having the amino acid sequence of SEQ ID NO: 1064. VH having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 of and (ii) a VH comprising CDR1, VH CDR2, and VH CDR3, each of which has the sequence VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 1065 VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence of In another aspect, an antibody that binds to Vβ17 is provided, (i) a VH CDR1 of a VH having the amino acid sequence of SEQ ID NO: 1096, , VH CDR1, VH CDR2, and VH CDR3, and (ii) a VH comprising a VH CDR2, a VH CDR3, and a VH CDR4 of SEQ ID NO: 1097, respectively. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 are a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence In another aspect, an antibody that binds to Vβ17 is provided, the antibody comprising: (i) VH CDR1 and VH CDR2 of VH having the amino acid sequence of SEQ ID NO: 1128, respectively. and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and and (ii) a VH comprising a VH CDR3, each having the amino acid sequence of SEQ ID NO: 1129. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of the VL are and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL CDR1 , VL CDR2, and VL CDR3 amino acid sequences follow the Kabat numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL The CDR1, VL CDR2, and VL CDR3 amino acid sequences are shown in the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR17, VH CDR18, VH CDR1 R3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are shown in AbM. In some embodiments, VH CDR1, VH CDR2, VH The VL CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are In some embodiments, the VH CDR1, VH CD R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acids The sequences follow the IMGT numbering system. In some embodiments, the VH CDR1, VH VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 The amino acid sequences follow an exemplary numbering system.

[0006] In some embodiments of the Vβ17 antibodies provided herein, the antibody is a humanized antibody. In some embodiments, the antibody is an IgG antibody. In some embodiments, the IgG antibody is an IgG1 antibody. In some embodiments, the IgG antibody is an IgG3 antibody. In some embodiments, the IgG antibody is an IgG4 antibody. In some embodiments, the antibody comprises a lambda light chain. In embodiments, the antibody is a monoclonal antibody.

[0007] In some embodiments of the various Vβ17 antibodies provided herein, the antibody is Vβ17 Binds to an antigen. In some embodiments, the antibody binds to the Vβ17 epitope. In some embodiments, the antibody specifically binds to Vβ17. are VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR VL CDR2 and VL CDR3 form the binding site for Vβ17 antigen. In an embodiment, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 form the binding site for the Vβ17 epitope. In some embodiments, Vβ17 is present on the surface of a T cell.

[0008] In some embodiments of the Vβ17 antibodies provided herein, the antibodies are multivalent. In some embodiments, the antibody is capable of binding to at least three antigens. In some embodiments, the antibody is capable of binding to at least four antigens. In embodiments, the antibody is capable of binding to at least five antigens. In some embodiments of the Vβ17 antibody, the antibody is a multispecific antibody.

[0009] In another aspect, a multispecific Vβ17 antibody is provided, said multispecific Vβ17 antibody comprising: (a) a first binding domain that binds to Vβ17, wherein the first binding domain is (b) a first binding domain comprising a Vβ17 antibody provided herein; and a second binding domain that binds to a second target that does not bind to the first target;

[0010] In some embodiments of the multispecific Vβ17 antibodies provided herein, the antibodies are In some embodiments, the antibody is a trispecific antibody. In some embodiments, the antibody is a tetraspecific antibody.

[0011] In some embodiments of the multispecific Vβ17 antibodies provided herein, the second binding In some embodiments, the second binding domain binds to an antigen of a second target. In some embodiments, the second binding domain binds to an epitope of a second target. In some embodiments, the second binding domain specifically binds to a second target. VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form the binding site for a second target antigen. In this embodiment, the VH CDR1, VH CDR2, VH CDR3, VH CDR4 of the second binding domain VL CDR1, VL CDR2, and VL CDR3 are directed against an epitope of a second target. In some embodiments, the second target is present on the surface of the target cell. In some embodiments, the second binding domain that binds to the second target is multivalent. In some embodiments, the second binding domain binds to at least three antigens. In some embodiments, the second binding domain can bind to at least four antibodies. In some embodiments, the second binding domain is capable of binding to at least It can also bind to five antigens.

[0012] In some embodiments of the multispecific Vβ17 antibodies provided herein, the second target In some embodiments, the second binding arm that binds to CD123 is CD123. The VH CDR1 and VH CDR2 of VH each have the amino acid sequence of SEQ ID NO: 40. VH CDR1, VH CDR2, and VH CDR3 amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the amino acid sequence of SEQ ID NO: 41. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of VL having the sequence and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the sequence In another embodiment, a multispecific antibody that binds to Vβ17 is provided, The antibody comprises (a) a first binding domain that binds to Vβ17, wherein the first binding domain (i) a VH CDR1 of a VH having the amino acid sequence of SEQ ID NO: 25, a VH CDR2 of a VH having the amino acid sequence of SEQ ID NO: 26, and a VH CDR3 of a VH having the amino acid sequence of SEQ ID NO: 27, respectively. VH CDR1, VH CDR2, and VH CDR3 amino acid sequences and (ii) a VH comprising a VH CDR3, and a VH CDR4, each having the amino acid sequence of SEQ ID NO: 26. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of VL having the sequence and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the following structure: (b) a first binding domain, and (b) a second binding domain, which is BCMA, DLL3, PSMA, or KLK2. and a second binding domain that binds to a target of Vβ17. A multispecific antibody is provided, the multispecific antibody comprising: (a) (i) each of the amino acids of SEQ ID NO: 7; The amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 are VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence and (ii) a VL CDR1 of a VL having the amino acid sequence of SEQ ID NO: 8, a VL CDR2 of a VL having the amino acid sequence of SEQ ID NO: 8, and a VL CDR3 of a VL having the amino acid sequence of SEQ ID NO: 8. VL CDR1, VL CDR2, and VL CDR3 amino acid sequences R2, and a VL comprising a VL CDR3; and (b) BCMA, DLL3, PSMA, or K and a second binding domain that binds to a second target, which is LK2. 17, wherein the multispecific antibody comprises: (a) (i) each of and VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 9. VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of (ii) a VH comprising DR3 and a VL having the amino acid sequence of SEQ ID NO: 10, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences. (b) BCMA, DLL3; and (c) VL, including DR1, VL CDR2, and VL CDR3. and a second binding domain that binds to a second target, which is PSMA, or KLK2. In another embodiment, a multispecific antibody that binds to Vβ17 is provided, (a)(i) VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 19, , VH CDR1, VH CDR2, and VH CDR3, and (ii) a VH comprising an amino acid sequence of SEQ ID NO: 22. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of VL are a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the sequence (b) a second antibody that binds to a second target that is BCMA, DLL3, PSMA, or KLK2; In another aspect, a multispecific antibody that binds to Vβ17 is provided. (a)(i) each having the amino acid sequence of SEQ ID NO: 19 VH has the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3; (ii) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3, respectively; , VL CDR1, VL CDR2, and VL having the amino acid sequence of SEQ ID NO: 23 VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence of and (b) a second VL that is BCMA, DLL3, PSMA, or KLK2. and a second binding domain that binds to the target. and (a) a multispecific antibody comprising: (i) a nucleotide sequence corresponding to each of SEQ ID NO: 19; The amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 are VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence and (ii) a VL CDR1, VL CDR2, VL CDR3, VL CDR4, VL CDR5, VL CDR6, VL CDR7, VL CDR8, VL CDR9, VL CDR10, VL CDR11, VL CDR12, VL CDR13, VL CDR14, VL CDR15, VL CDR16, VL CDR17, VL CDR18, VL CDR19 ...9, VL CDR11, VL CDR12, VL CDR13, VL CDR14, VL CDR15, VL CDR16, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences; (b) a VL comprising a VL CDR2, and a VL CDR3; and (c) a VL comprising a BCMA, DLL3, PSMA, or and a second binding domain that binds to a second target, which is KLK2. and a multispecific antibody that binds to Vβ17, the multispecific antibody comprising: (a)(i) VH CDR1 and VH CDR2 of VH having the amino acid sequence of SEQ ID NO: 20, respectively and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and and (ii) a VH comprising a VH CDR3, each having the amino acid sequence of SEQ ID NO: 22. VL has the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3; (b) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3; and (b) BCMA; a second binding domain that binds to a second target, which is DLL3, PSMA, or KLK2; In another embodiment, a multispecific antibody that binds to Vβ17 is provided, The isomeric antibodies each comprise: (a) a VH having the amino acid sequence of SEQ ID NO: 20; VH CDR having the amino acid sequences of CDR1, VH CDR2, and VH CDR3 1, VH CDR2, and VH CDR3, and (ii) a VH comprising SEQ ID NO: 2, VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of and a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence VL and (b) a second target that binds to BCMA, DLL3, PSMA, or KLK2. and a second binding domain that binds to Vβ17. and (a)(i) each of the amino acids of SEQ ID NO: 20. The amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 of VH having the sequence a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the sequence (i i) VL CDR1, VL CDR2, VL CDR3, VL CDR4, VL CDR5, VL CDR6, VL CDR7, VL CDR8, VL CDR9, VL CDR10, VL CDR11, VL CDR12, VL CDR13, VL CDR14, VL CDR15, VL CDR16, VL CDR17, VL CDR18, VL CDR19, V VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR3, and (b) BCMA, DLL3, PSMA, or KLK2. and a second binding domain that binds to a second target, wherein the second binding domain is Vβ1. 7, wherein the multispecific antibody binds to (a)(i) each of , VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 21 VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of (ii) a VH comprising DR3 and a VL having the amino acid sequence of SEQ ID NO: 22, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences. (b) BCMA, DLL3; and (c) VL, including DR1, VL CDR2, and VL CDR3. and a second binding domain that binds to a second target, which is PSMA, or KLK2. In another embodiment, a multispecific antibody that binds to Vβ17 is provided, (a)(i) VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 21, , VH CDR1, VH CDR2, and VH CDR3, and (ii) a VH comprising an amino acid sequence of SEQ ID NO: 23, a VH comprising a CDR2, and a VH comprising a CDR3, respectively. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of VL are a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the sequence (b) a second antibody that binds to a second target that is BCMA, DLL3, PSMA, or KLK2; In another embodiment, a multispecific antibody that binds to Vβ17 is provided. and the multispecific antibodies (a) and (i) each have the amino acid sequence of SEQ ID NO: 21. The VH has the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3. and (ii) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 24, respectively. and VL CDR3, (b) a VL comprising a CDR3, and a VL comprising a CDR3 that is BCMA, DLL3, PSMA, or KLK2. and a second binding domain that binds to target Vβ17. and (a) and (i) each of the multispecific antibodies comprising: VH CDR1, VH CDR2, and VH CDR of VH having the amino acid sequence of No. 46 VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of R3 and (ii) a VL CD of a VH comprising the amino acid sequence of SEQ ID NO: 49, VL CDR1 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3; (b) a VL comprising a VL CDR2 and a VL CDR3; and (c) a BCMA, DLL3, or PSM. A, or a second binding domain that binds to a second target, which is KLK2. In this embodiment, the VH CDR1, VH CDR2, VH CDR3 of the first binding arm The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 are as described in Kabat In some embodiments, the VH CDR1 of the first binding arm, V H CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 The amino acid sequence of is according to the Chothia numbering system. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The amino acid sequences of the VL CDR2 and VL CDR3 follow the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 of the first binding arm The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 are shown in In some embodiments, the VH CD of the first binding arm follows the tact numbering system. R1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL The amino acid sequence of the CDR3 follows the IMGT numbering system. VH CDR1, VH CDR2, VH CDR3, VL CDR1 of one binding arm, The amino acid sequences of VL CDR2 and VL CDR3 follow an exemplary numbering system.

[0013] In some embodiments of the multispecific Vβ17 antibodies provided herein, the second target is BCMA. In some embodiments, the second binding arm that binds to BCMA is , (i) VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 95, VH VH CDR1, VH CDR2, and VH CDR3 amino acid sequences 2, and a VH comprising a VH CDR3, and (ii) the amino acid sequence of SEQ ID NO: 96, respectively. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of VL having and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3.

[0014] In some embodiments of the multispecific Vβ17 antibodies provided herein, the second target is DLL3. In some embodiments, the second binding arm that binds to DLL3 is , (i) VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 694, VH VH CDR1, VH CDR2, and VH CDR3 amino acid sequences and (ii) a VH comprising a VH CDR3, R2, and a VH CDR3, each of which comprises the amino acid sequence of SEQ ID NO: 695. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of VL having the sequence and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the sequence .

[0015] In some embodiments of the multispecific Vβ17 antibodies provided herein, the second target is PSMA. In some embodiments, the second binding arm that binds to PSMA is , (i) VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 730, VH VH CDR1, VH CDR2, and VH CDR3 amino acid sequences and (ii) a VH comprising a VH CDR3, R2, and a VH CDR3, each of which comprises the amino acid sequence of SEQ ID NO: 731. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of VL having the sequence and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the sequence In some embodiments, the second binding arms that bind to PSMA each comprise: (i) VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 732 VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of (ii) a VH comprising DR3, and (iii) a VL having the amino acid sequence of SEQ ID NO: 733, VL having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3. and a VL comprising VL CDR1, VL CDR2, and VL CDR3. In this embodiment, the second binding arm that binds to PSMA comprises (i) an amino acid sequence of SEQ ID NO: 734, VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequence , (ii) VL CDR1, VL CDR2, VL CDR3, VL CDR4, VL CDR5, VL CDR6, VL CDR7, VL CDR8, VL CDR9, VL CDR10, VL CDR11, VL CDR12, VL CDR13, VL CDR14, VL CDR15, VL CDR16, VL CDR17, VL CDR18, VL CDR1 VL CDR1, VL CDR2, and VL CDR3 amino acid sequences; In one embodiment, the antibody binds to PSMA. The second binding arm comprises (i) a VH having the amino acid sequence of SEQ ID NO: 736, VH CDR1, VH CDR2, and VH CDR3 amino acid sequences. and (ii) a VH comprising DR1, VH CDR2, and VH CDR3, each of which has SEQ ID NO: VL CDR1, VL CDR2, and VL CDR of VL having the amino acid sequence of No. 737 VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence of VL CDR3 and a VL comprising: , (i) VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 899, VH VH CDR1, VH CDR2, and VH CDR3 amino acid sequences and (ii) a VH comprising a VH CDR3, R2, and a VH CDR3, each comprising the amino acid sequence of SEQ ID NO: 900. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of VL having the sequence and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the sequence .

[0016] In some embodiments of the multispecific Vβ17 antibodies provided herein, the second target is KLK2. In some embodiments, the second binding arm that binds to KLK2 is , (i) VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 887, VH VH CDR1, VH CDR2, and VH CDR3 amino acid sequences and (ii) a VH comprising a VH CDR3, R2, and a VH CDR3, each of which comprises the amino acid sequence of SEQ ID NO: 888. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of VL having the sequence and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the sequence .

[0017] In some embodiments of the multispecific Vβ17 antibodies provided herein, the second binding Arm VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL C The amino acid sequences of VL CDR2 and VL CDR3 follow the Kabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 of the second binding arm 3. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 are In some embodiments, the VH CDR of the second binding arm is 1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL C The amino acid sequence of DR3 follows the AbM numbering system. VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL The amino acid sequences of CDR2 and VL CDR3 follow the Contact numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 of the second binding arm The amino acid sequences of VL CDR3, VL CDR1, VL CDR2, and VL CDR3 are: In some embodiments, the VH CD of the second binding arm is R1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL The amino acid sequence of the CDR3 follows an exemplary numbering system.

[0018] In another embodiment, a multispecific Vβ17 antibody is provided, The first is capable of binding Vβ17 on the surface of T cells, and the second is not Vβ17. and a second means capable of binding a second target. The two targets are present on the surface of the target cell.

[0019] In another aspect, there is provided a nucleic acid encoding the Vβ17 antibodies provided herein. In certain embodiments, a vector comprising a nucleic acid encoding a Vβ17 antibody provided herein is provided. In another embodiment, a vector comprising a nucleic acid encoding a Vβ17 antibody provided herein is A host cell containing the vector is provided.

[0020] In another embodiment, a vector comprising a nucleic acid encoding a Vβ17 antibody provided herein is In another aspect, a kit is provided comprising a Vβ17 antibody provided herein and a In another aspect, a kit is provided comprising the V provided herein. Pharmaceutical compositions are provided that include a β17 antibody and a pharmaceutically acceptable carrier. A pharmaceutical composition comprising a Vβ17 antibody provided herein and a pharmaceutically acceptable carrier. A method for producing the antibody is provided, the method comprising combining the antibody with a pharmaceutically acceptable carrier. The method also includes a step of obtaining the pharmaceutical composition.

[0021] In another aspect, a method of activating T cells expressing Vβ17 is provided, the method comprising: The method includes contacting a T cell with a Vβ17 antibody provided herein. In one embodiment, the contacting step increases the expression of CD69, C, as compared to control T cells that express Vβ17. D25, and / or granzyme B expression.

[0022] In another aspect, a process is provided for generating antibodies that bind to two or more target molecules. This process results in the first binding domain that binds to Vβ17 present on T cells. a step for performing the function and a second binding domain that binds to a second target on the surface of the target cell. and Vβ17 present on T cells and on the surface of target cells. and a step for providing an antibody that binds to a second target of the antibody. In embodiments, the ability to obtain a second binding domain that binds to a second target on the surface of a target cell. The above steps are repeated n times to achieve the above, and Vβ17 present on the T cell and n targets are detected. n steps to perform the function of providing a first binding domain that binds to a molecule, The method further includes the step where n is at least 2.

[0023] In another aspect, a method for directing Vβ17-expressing T cells to target cells is provided, comprising: The method comprises contacting the target cells with a multispecific Vβ17 antibody described herein. wherein the second target is present on the surface of the target cell, and the contacting step comprises contacting a T cell with the second target. The vesicles are directed to the target cells.

[0024] In another aspect, a method of inhibiting growth of a target cell is provided, said method comprising: The multispecific Vβ17 antibody is administered to the target cell, wherein the second target is present on the surface of the target cell. contacting a target cell with a T cell expressing said Vβ17; In the presence of a cell, the contacting step results in inhibition of growth of the target cell. In an aspect, a method of inhibiting proliferation of a target cell is provided, said method comprising: The bispecific Vβ17 antibody is administered to the target cell on the surface of which the second target is present. the step of contacting the T cells with the Vβ17-expressing T cells, wherein the contacting step results in inhibition of proliferation of the target cells.

[0025] In another aspect, a method of eliminating target cells in a subject is provided, said method comprising the steps of: The multispecific Vβ17 antibody described herein is administered to a target cell on the surface of which the second target is present. the step of contacting the target cell with the target cell expressing the Vβ17. In the presence of T cells that are capable of targeting the target cells, the contacting step results in the elimination of the target cells. In an aspect, a method of treating a disease in a subject is provided, the method comprising administering an effective amount of a compound of the invention as described herein. the disease comprises administering to the subject a multispecific Vβ17 antibody according to any one of claims 1 to 4, wherein the disease is a target cell The second target is caused in whole or in part by the target cell having the second target on its surface. In some embodiments, the subject is a human. This is a subject that needs this method.

[0026] In some embodiments, the second target is present on the surface of a target cell, and the target cell is a cancer In some embodiments, the cancer cells are selected from the group consisting of adrenal cancer, anal cancer, appendix cancer, bile duct cancer, bladder cancer, and the like. Bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gestational trophoblastic cancer, head and neck cancer Neck cancer, Hodgkin's lymphoma, intestinal cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple tumors Myeloma, neuroendocrine tumors, non-Hodgkin's lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, Sinus cancer, skin cancer, soft tissue sarcoma, spinal cancer, stomach cancer, testicular cancer, pharyngeal cancer, thyroid cancer, uterine cancer, intrauterine cancer In some embodiments, the second target is a uterine cancer, vaginal cancer, or vulvar cancer cell. Geopoietin, BCMA, CD19, CD20, CD22, CD25 (IL2-R), C D30, CD33, CD37, CD38, CD52, CD56, CD123(IL-3R ), cMET, DLL / Notch, EGFR, EpCAM, FGF, FGF-R, GD 2, HER2, mesothelin, nectin-4, PAP, PDGFRα, PSA, PSA3, PSMA, RANKL, SLAMF7, STEAP1, TARP, TROP2, VEGF In some embodiments, the second target is CEA, vasculitis, or VEGF-R. Mature laminin receptor, TAG-72, HPV E6, HPV E7, BING-4, calcitonin Sodium-gated chloride channel 2, cyclin-B1, 9D7, EpCAM, EphA3, He r2 / neu, telomerase, mesothelin, SAP-1, surviving, BAGE family Lee antigen, CAGE family antigen, GAGE ​​family antigen, MAGE family antigen , SAGE family antigens, XAGE family antigens, NY-ESO-1 / LAGE-1 , PRAME, SSX-2, Melan-A, MART-1, Gp100, pmel17 , tyrosinase, TRP-1, TRP-2, P. polypeptide, MC1R, prostate-specific antibody BRCA1, β-catenin, or BRCA1.

[0027] In some embodiments, the second target is CD123. In some embodiments, the second target is BCMA. In some embodiments, the second target is DLL3. In some embodiments, the second target is PSMA. The second target is KLK2.

[0028] In some embodiments, (i) the adrenal cancer is adrenocortical carcinoma ma, ACC), adrenocortical carcinoma, pheochromocytoma, or neuroblastoma; (ii) the anal cancer. is squamous cell carcinoma, cloacal carcinoma, adenocarcinoma, basal cell carcinoma, or melanoma, (iii) The appendix cancer is a neuroendocrine tumor (NET), mucinous adenocarcinoma, or carcinoma, goblet cell carcinoid, intestinal adenocarcinoma, or signet ring cell adenocarcinoma; (iv) the above Cholangiocarcinoma is classified as extrahepatic cholangiocarcinoma, adenocarcinoma, perihilar cholangiocarcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma, or (v) the bladder cancer is a transitional cell carcinoma. a, TCC), papillary carcinoma, squamous carcinoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, or (vi) the bone cancer is a primary bone cancer, a sarcoma, an osteosarcoma, a chondrosarcoma, a sarcoma, a fibro ... sarcoma, malignant fibrous histiocytoma, giant cell tumor of bone, chordoma, or metastatic bone cancer; ii) The brain cancer is astrocytoma, brainstem glioma, glioblastoma, meningioma, ependymoma, oligodendroglioma, or tumor, mixed glioma, pituitary carcinoma, pituitary adenoma, craniopharyngioma, germ cell tumor, pineal tumor, myeloma (viii) the breast cancer is breast adenocarcinoma, invasive breast cancer, or primary CNS lymphoma; Invasive breast cancer, non-invasive breast cancer, breast sarcoma, metaplastic carcinoma, adenocystic carcinoma, phyllodes tumor, angiosarcoma, HER2 (ix) the above-mentioned cervical cancer, which is a breast cancer with a positive or negative breast cancer, triple-negative breast cancer, or inflammatory breast cancer. (x) the colorectal cancer is a colorectal adenocarcinoma, , primary colorectal lymphoma, gastrointestinal stromal tumor, leiomyosarcoma, carcinoid tumor, mucinous gland carcinoma, signet ring cell adenocarcinoma, gastrointestinal carcinoid tumor, or melanoma; (xi) the above. (xii) the esophageal cancer is adenocarcinoma or squamous cell carcinoma; (xiii) the gallbladder cancer is adenocarcinoma; papillary adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, small cell carcinoma, or sarcoma; (xiii) Gestational trophoblastic disease (GTD) , hydatidiform mole, gestational trophoblastic neoplasia (GTN), choriocarcinoma, placental-site trophoblast tumor (PSTT) ), or epithelioid trophoblastic tumor (ETT) (xiv) The head and neck cancer is laryngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, nasal cavity cancer, sinus cancer, (xv) the Hodgkin's lymphoma is salivary gland cancer, oral cancer, oropharyngeal cancer, or tonsillar cancer; , classical Hodgkin lymphoma, nodular sclerosis, mixed cell type, lymphocyte-rich, lymphopenic , or nodular lymphocyte-predominant Hodgkin lymphoma (xvi) The above intestinal cancer is small intestinal cancer (small intesti cancer). ne cancer), small bowel cancer, adenocarcinoma, sarcoma, gastrointestinal stromal tumor, cultivar (xvii) the kidney cancer is renal cell carcinoma (RCC), ll carcinoma, RCC), clear cell RCC, papillary RCC, chromophobe RCC, collecting duct RCC , unclassified RCC, transitional cell carcinoma, urothelial carcinoma, renal pelvic carcinoma, or renal sarcoma, (xvi ii) the leukemia is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (chroni c lymphocytic leukemia (CLL), chronic myeloid leukemia (C ML), hairy cell leukemia (HCL), or myelodysplasia (xix) the liver cancer is hepatocellular carcinoma (HCC), hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocellular carcinoma, angiosarcoma or liver metastasis, (xx) the lung cancer is small cell lung cancer, small cell carcinoma, mixed small cell Carcinoma, non-small cell lung cancer, lung adenocarcinoma, squamous cell lung cancer, large cell undifferentiated carcinoma, lung nodule, metastasis Lung cancer, adenosquamous carcinoma, large cell neuroendocrine carcinoma, salivary gland type lung carcinoma, pulmonary carcinoid, (xxi) the melanoma is a melanoma, sarcomatoid carcinoma of the lung, or malignant granular cell lung tumor; Superficial spreading melanoma, nodular melanoma, acral lentigo melanoma, lentigo maligna melanoma, amelanotic melanoma melanoma, desmoplastic melanoma, ocular melanoma, or metastatic melanoma; (xxii) any of the above. The mesothelioma is pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, or testicular mesothelioma. i) The multiple myeloma is active or smoldering multiple myeloma, (xxiv) The neuroendocrine tumor is a gastrointestinal neuroendocrine tumor, a pancreatic neuroendocrine tumor, or a pulmonary neuroendocrine tumor. (xxv) The non-Hodgkin's lymphoma is a lymphoma, anaplastic large cell lymphoma, lymphoblastic lymphoma, or lymphoma. T-cell lymphoma, peripheral T-cell lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoid Plasmocyte lymphoma, marginal zone B-cell lymphoma, MALT lymphoma, small cell lymphocytic lymphoma lymphoma, Burkitt's lymphoma, chronic lymphocytic leukemia (CL) L), small lymphocytic lymphoma (SLL), precursor T lymphoblasts Cytic leukemia / lymphoma, acute lymphocytic leukemia (ALL) , adult T cell lymphoma / leukemia (ATLL), hair loss B-cell leukemia, B-cell lymphoma, diffuse large B-cell lymphoma DLBCL, primary mediastinal B-cell lymphoma, primary central nervous system (CNS) central nervous system (CNS) lymphoma, mantle cell lymphoma (M CL), marginal zone lymphoma, mucosa-associated lymphoid tissue (mucosa-associated lymphoid tissue, MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, lymphoid Plasma cell lymphoma, B-cell non-Hodgkin's lymphoma, T-cell non-Hodgkin's lymphoma, natural Killer cell lymphoma, cutaneous T-cell lymphoma, Alibert-Bazin syndrome, Sézary syndrome , primary cutaneous anaplastic large cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma angioimmunoblastic T cell lymphoma (AITL), anaplastic large cell lymphoma (anap lastic large-cell lymphoma (ALCL), systemic ALCL, enteropathic T-cell lymphoma (en ectopathy-type T cell lymphoma (EATL), or hepatosplenic gamma / delta T cell lymphoma (xxvi) The oral cancer is selected from the group consisting of squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinoma, and lysosome carcinoma. leiomyoma, benign oral tumor, eosinophilic granuloma, fibroma, granular cell tumor, keratoacanthoma, leiomyoma , osteochondroma, lipoma, schwannoma, neurofibroma, papilloma, condyloma acuminata, wart type Xanthomas, pyogenic granulomas, rhabdomyoma, odontogenic tumors, leukoplakia, erythroplakia, squamous cell carcinoma of the lip, (xxvii) the ovarian cancer is ovarian cancer, basal cell carcinoma of the lip, mouth, gum, or tongue. Focal epithelial carcinoma, mucinous epithelial ovarian cancer, endometrioid epithelial ovarian cancer, clear cell epithelial ovarian cancer, undifferentiated epithelial ovarian cancer Ovarian cancer, ovarian low malignant potential tumor, primary peritoneal cancer, fallopian tube cancer, germ cell tumor, teratoma, undifferentiated ovarian germ cell follicular carcinoma, endodermal sinus tumor, sex cord-stromal tumor, sex cord-gonadal stromal tumor, ovarian stromal tumor, granulosa cell tumor ovarian sarcoma, ovarian carcinosarcoma, ovarian adenomatous tumor, granulosa theca tumor, Sertoli-Leydig tumor, ovarian sarcoma, ovarian carcinosarcoma, ovarian adenomatous tumor ovarian leiomyosarcoma, ovarian fibrosarcoma, Krukenberg tumor, or ovarian cyst, xxviii) The pancreatic cancer is exocrine pancreatic cancer, endocrine pancreatic cancer, or pancreatic adenocarcinoma, islet cell carcinoma (xxix) the prostate cancer is prostatic adenocarcinoma, prostatic adenocarcinoma, or prostatic neuroendocrine tumor; adenosarcoma, transitional cell carcinoma, small cell carcinoma, or neuroendocrine tumor, (xxx) the above sinus Cancer is squamous cell carcinoma, mucosal cell carcinoma, adenoid cystic cell carcinoma, acinic cell carcinoma, undifferentiated sinus carcinoma nasal carcinoma, nasal cavity cancer, paranasal sinus cancer, maxillary sinus cancer, ethmoid sinus cancer, or nasopharyngeal cancer, (xxxi ) The above skin cancers include basal cell carcinoma, squamous cell carcinoma, melanoma, Merkel cell carcinoma, Kaposi's sarcoma ( Kaposi sarcoma (KS), actinic keratosis, cutaneous lymphoma, or keratoacanthoma ( xxxii) The above soft tissue cancers are angiosarcoma, dermatofibrosarcoma, epithelial sarcoma, and Ewing's sarcoma , fibrosarcoma, gastrointestinal stromal tumor (GIST), Kaposi's tumor sarcoma, leiomyosarcoma, liposarcoma, dedifferentiated liposarcoma (DL) , myxoid / round cell liposarcoma (MRCL), well-differentiated type Well-differentiated liposarcoma (WDL), malignant fibrous histiocytoma, nerve fibers fibrosarcoma, rhabdomyosarcoma (RMS), or synovial sarcoma (xxx (iii) the spinal cancer is a spinal metastatic tumor; (xxxiv) the gastric cancer is gastric adenocarcinoma; Gastric lymphoma, gastrointestinal stromal tumor, carcinoid tumor, gastric carcinoid tumor, type I ECL cell Carcinoid, type II ECL-cell carcinoid, or type III ECL-cell carcinoid (xxxv) The testicular cancer is seminoma, nonseminoma, embryonal carcinoma, or yolk sac carcinoma. tumor, choriocarcinoma, teratoma, gonadal stromal tumor, Leydig cell tumor, or Sertoli cell tumor (xxxiv) The above pharyngeal cancer may include squamous cell carcinoma, adenocarcinoma, sarcoma, laryngeal cancer, Head cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, laryngeal squamous cell carcinoma, laryngeal adenocarcinoma, phosphorus Paepithelioma, spindle cell carcinoma, verrucous carcinoma, undifferentiated carcinoma, or lymph node carcinoma (xxxv ) The above thyroid cancer is papillary carcinoma, follicular carcinoma, Hurthle cell carcinoma, medullary thyroid carcinoma, or (xxxvi) The uterine cancer is endometrial cancer, endometrial adenocarcinoma, or uterine carcinoma. Endometrial carcinoma, serous adenocarcinoma, adenosquamous carcinoma, uterine carcinosarcoma, uterine sarcoma, uterine leiomyosarcoma (xxxvii) the vaginal cancer is a squamous cell carcinoma, endometrial stromal sarcoma, or undifferentiated sarcoma; (xxxviii) epithelial cell carcinoma, adenocarcinoma, melanoma, or sarcoma of the vulva The neck cancer is squamous cell carcinoma or adenocarcinoma.

[0029] In some embodiments, the second target is present on the surface of a target cell, and the target cell is In some embodiments, the second target is a CD1a, CD1b, CD1 c, CD1d, CD2, CD5, CD6, CD9, CD11a, CD11b, CD11c , CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24 , CD25, CD26, CD27, CD29, CD30, CD31, CD32a, CD3 2b, CD35, CD37, CD38, CD39, CD40, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49 b, CD49c, CD49d, CD50, CD52, CD53, CD54, CD55, C D58, CD60a, CD62L, CD63, CD68, CD69, CD70, CD72 , CD73, CD74, CD75, CD75S, CD77, CD79a, CD79b, C D80, CD81, CD82, CD83, CD84, CD85E, CD85I, CD85 J, CD86, CD92, CD95, CD97, CD98, CD99, CD100, CD 102, CD108, CD119, CD120a, CD120b, CD121b, CD1 22, CD124, CD125, CD126, CD130, CD132, CD137, C D138, CD139, CD147, CD148, CD150, CD152, CD162 , CD164, CD166, CD167a, CD170, CD171, CD175, CD 175s, CD180, CD184, CD185, CD192, CD196, CD197 , CD200, CD205, CD201a, CDw210b, CD212, CD213a 1, CD213a2, CD215, CD217, CD218a, CD218b, CD22 0, CD221, CD222, CD224, CD225, CD226, CD227, CD 229, CD230, CD232, CD252, CD252, CD254, CD255, CD256, CD257 CD258, CD259, CD260, CD261, CD26 2, CD263, CD264, CD267-270, CD272, CD274, CD27 5, CD277, CD279, CD283, CD289, CD290, CD295, CD 298, CD300, CD300c, CD305, CD306, CD307a, CD30 7b, CD307c, CD307d, CD307e, CD314, CD215, CD31 6, CD317, CD319, CD321, CD327, CD328, CD329, CD 338, CD351, CD352, CD353, CD354, CD355, CD356, CD357, CD358, CD360, CD361, CD362, or CD363 In some embodiments, the second target is BCMA.

[0030] In another aspect, an antibody that binds to Vα10.2 is provided, the antibody comprising: (i) each , a VH CDR1 and a VH CDR2 of a VH having the amino acid sequence of SEQ ID NO: 568, and VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of (ii) a VH comprising a CDR3 and (iii) a VL having the amino acid sequence of SEQ ID NO: 569, VL having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of and a VL comprising VL CDR1, VL CDR2, and VL CDR3. Antibodies that bind to Vα10.2 are provided, the antibodies comprising: (i) a polypeptide selected from the group consisting of SEQ ID NO: 570 and SEQ ID NO: 570, respectively; VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequence and (ii) a VL CDR1 of a VL having the amino acid sequence of SEQ ID NO: 571, respectively. , VL CDR1, VL CDR2, and VL CDR3, In some embodiments, the VH comprises a VL CDR2, and a VL CDR3. CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and V The L CDR3 amino acid sequence follows the Kabat numbering system. , VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 , and VL CDR3 amino acid sequences follow the Chothia numbering system. In an embodiment, VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The VL CDR2 and VL CDR3 amino acid sequences follow the AbM numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL CDR1 , VL CDR2, and VL CDR3 amino acid sequences are numbered according to the Contact numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR22, VH CDR33, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR26, VH CDR37 The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are numbered according to the IMGT numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR 3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are shown in the exemplary appended drawings. In some embodiments, the Vα10.2 antibody is a humanized antibody. In some embodiments, the Vα10.2 antibody is an IgG antibody. In some cases, the antibody is of the IgG1, IgG2, IgG3, or IgG4 isotype. In some embodiments, the IgG antibody comprises a kappa light chain. In some embodiments, the Vα10.2 antibody comprises a lambda light chain. In some embodiments, the Vα10.2 antibody is a monoclonal antibody. In some embodiments, the Vα10.2 antibody binds to the Vα10.2 antigen. In some embodiments, the Vα10.2 antibody binds to an epitope. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 bind specifically to the VH CDR1, VH CDR2, and VH CDR3. Vα10.2 CDR3, VL CDR1, VL CDR2, and VL CDR3 In some embodiments, the VH CDR1, VH CD R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are Vα In some embodiments, the Vα10.2 epitope forms a binding site for the Vα10.2 epitope. Vα10.2 is present on the surface of T cells. In some embodiments, the Vα10.2 antibody is a polyclonal antibody. In some embodiments, the Vα10.2 antibody is a multispecific antibody. In some embodiments, the Vα10.2 antibody is a bispecific antibody. In the present invention, the multispecific Vα10.2 antibody further binds to a second target, which is B CMA.

[0031] In yet another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: ) VH CDR1 having the amino acid sequence of SEQ ID NO: 48, VH CDR2 having the amino acid sequence of SEQ ID NO: 49 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 50. , VH, and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 51, SEQ ID NO: 52 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 53. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO: 77. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 78. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 77. and a VL having the amino acid sequence of SEQ ID NO: 78. In embodiments, the antibody comprises a humanized antibody. In some embodiments, the antibody is an IgG antibody. In some embodiments, the antibody is an IgG1, IgG2, IgG3, or IgG G4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In some embodiments, the antibody binds to the Vβ17 epitope. , the VH CDR1, VH CDR2, VH CDR3, VL CDR1, and VL of the above antibodies CDR2 and VL CDR3 form the binding site of Vβ17 for the antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR22, VH CDR33, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR1 VL CDR1, VL CDR2, and VL CDR3 are directed against an epitope of Vβ17. In some embodiments, the antibody binds to a Vβ antigen present on the surface of a T cell. In certain embodiments, the T cell is a T cell. In some embodiments, the T cells are CD8+ T cells. In some embodiments, the T cells are CD4+ T cells. In some embodiments, the T cells are cytotoxic T lymphocytes. In some embodiments, the antibody is a multivalent, bispecific antibody. In some embodiments, the antibody is capable of binding to at least three antigens. In some embodiments, the bispecific antibody is capable of binding to at least five antigens. In some embodiments, the antibody is a multispecific antibody.

[0032] In one aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 48, VH CDR2 having the amino acid sequence of SEQ ID NO: 54 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 55; and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 56, an amino acid sequence of SEQ ID NO: 57, VL CDR2 having the amino acid sequence of SEQ ID NO: 58, and VL CDR3 having the amino acid sequence of SEQ ID NO: 59. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO: 79. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 80. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 79. and a VL having the amino acid sequence of SEQ ID NO: 80. In some embodiments, the antibody comprises a humanized antibody. In some embodiments, the antibody comprises an IgG antibody. In some embodiments, the antibody is an IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In some embodiments, the antibody binds to the Vβ17 epitope. Antibody VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR R2 and VL CDR3 form the binding site of Vβ17 for the antigen. In embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR4 and VL CDR5 of the antibody are DR1, VL CDR2, and VL CDR3 are binding sites for the Vβ17 epitope. In some embodiments, the antibody binds to Vβ17 present on the surface of a T cell. In some embodiments, the antibody comprises a multivalent bispecific antibody. In some embodiments, the antibody is capable of binding to at least three antigens. In some cases, bispecific antibodies can bind to at least five antigens. In embodiments, the antibody is a multispecific antibody.

[0033] In yet another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: ) VH CDR1 having the amino acid sequence of SEQ ID NO: 59, VH CDR2 having the amino acid sequence of SEQ ID NO: 49 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 60. , VH, and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 61, SEQ ID NO: 62 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 63. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO: 81. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 82. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 81. and a VL having the amino acid sequence of SEQ ID NO: 82. In embodiments, the antibody comprises a humanized antibody. In some embodiments, the antibody is an IgG antibody. In some embodiments, the antibody is an IgG1, IgG2, IgG3, or IgG G4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In some embodiments, the antibody binds to the Vβ17 epitope. , the VH CDR1, VH CDR2, VH CDR3, VL CDR1, and VL of the above antibodies CDR2 and VL CDR3 form the binding site of Vβ17 for the antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR22, VH CDR33, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR1 VL CDR1, VL CDR2, and VL CDR3 are directed against an epitope of Vβ17. In some embodiments, the antibody binds to a Vβ antigen present on the surface of a T cell. 17. In some embodiments, the antibody comprises a multivalent bispecific antibody. In some embodiments, the antibody is capable of binding to at least three antigens. In embodiments, the bispecific antibody is capable of binding to at least five antigens. In some embodiments, the antibody is a multispecific antibody.

[0034] In yet another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: ) VH CDR1 having the amino acid sequence of SEQ ID NO: 64, VH CDR2 having the amino acid sequence of SEQ ID NO: 65 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 66. , VH, and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 67, SEQ ID NO: 68 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 69. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO: 83. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 84. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 83. and a VL having the amino acid sequence of SEQ ID NO: 84. In embodiments, the antibody comprises a humanized antibody. In some embodiments, the antibody is an IgG antibody. In some embodiments, the antibody is an IgG1, IgG2, IgG3, or IgG G4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In some embodiments, the antibody binds to the Vβ17 epitope. , the VH CDR1, VH CDR2, VH CDR3, VL CDR1, and VL of the above antibodies CDR2 and VL CDR3 form the binding site of Vβ17 for the antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR22, VH CDR33, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR1 VL CDR1, VL CDR2, and VL CDR3 are directed against an epitope of Vβ17. In some embodiments, the antibody binds to a Vβ antigen present on the surface of a T cell. 17. In some embodiments, the antibody comprises a multivalent bispecific antibody. In some embodiments, the antibody is capable of binding to at least three antigens. In embodiments, the bispecific antibody is capable of binding to at least five antigens. In some embodiments, the antibody is a multispecific antibody.

[0035] In one aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 70, VH CDR2 having the amino acid sequence of SEQ ID NO: 49 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 71; and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 61, an amino acid sequence of SEQ ID NO: 72 VL CDR2 having the amino acid sequence of SEQ ID NO: 73, and VL CDR3 having the amino acid sequence of SEQ ID NO: 74. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO: 85. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 86. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 85. and a VL having the amino acid sequence of SEQ ID NO: 86. In some embodiments, the antibody comprises a humanized antibody. In some embodiments, the antibody comprises an IgG antibody. In some embodiments, the antibody is an IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In some embodiments, the antibody binds to the Vβ17 epitope. Antibody VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR R2 and VL CDR3 form the binding site of Vβ17 for the antigen. In embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR4 and VL CDR5 of the antibody are DR1, VL CDR2, and VL CDR3 are binding sites for the Vβ17 epitope. In some embodiments, the antibody binds to Vβ17 present on the surface of a T cell. In some embodiments, the antibody comprises a multivalent bispecific antibody. In some embodiments, the antibody is capable of binding to at least three antigens. In some cases, bispecific antibodies can bind to at least five antigens. In embodiments, the antibody is a multispecific antibody.

[0036] In one aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 48, VH CDR2 having the amino acid sequence of SEQ ID NO: 74 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 75; and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 56, an amino acid sequence of SEQ ID NO: 57, VL CDR2 having the amino acid sequence of SEQ ID NO: 76, and VL CDR3 having the amino acid sequence of SEQ ID NO: 77. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO: 87. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 88. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 87. and a VL having the amino acid sequence of SEQ ID NO: 88. In some embodiments, the antibody comprises a humanized antibody. In some embodiments, the antibody comprises an IgG antibody. In some embodiments, the antibody is an IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In some embodiments, the antibody binds to the Vβ17 epitope. Antibody VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR R2 and VL CDR3 form the binding site of Vβ17 for the antigen. In embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR4 and VL CDR5 of the antibody are DR1, VL CDR2, and VL CDR3 are binding sites for the Vβ17 epitope. In some embodiments, the antibody binds to Vβ17 present on the surface of a T cell. In some embodiments, the antibody comprises a multivalent bispecific antibody. In some embodiments, the antibody is capable of binding to at least three antigens. In some cases, bispecific antibodies can bind to at least five antigens. In embodiments, the antibody is a multispecific antibody.

[0037] In one aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1, VH having the amino acid sequence of SEQ ID NO: 2 VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3; ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 664, VL CDR2 having the amino acid sequence of SEQ ID NO: 5 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 6. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 21. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 665. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 21. and a VL having the amino acid sequence of SEQ ID NO: 665. In some embodiments, the antibody comprises a humanized antibody. In some embodiments, the antibody comprises an IgG antibody. In some embodiments, the antibody is an IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In some embodiments, the antibody binds to the Vβ17 epitope. VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 The VL CDR3 and VL CDR3 form the binding site for the Vβ17 antigen. In the form, VH CDR1, VH CDR2, VH CDR3, VL CDR of the above antibody VL CDR1, VL CDR2, and VL CDR3 define the binding site for the Vβ17 epitope. In some embodiments, the antibody comprises Vβ17 present on the surface of a T cell. In some embodiments, the antibody comprises a multivalent bispecific antibody. In some embodiments, the antibody is capable of binding to at least three antigens. In some embodiments, the bispecific antibody is capable of binding to at least five antigens. In some embodiments, the antibody is a multispecific antibody.

[0038] In one aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 979, VH CDR2 having the amino acid sequence of SEQ ID NO: 980 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 981. , VH, and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 994, SEQ ID NO: 9 VL CDR2 having the amino acid sequence of SEQ ID NO: 95, and VL CDR3 having the amino acid sequence of SEQ ID NO: 996 In some embodiments, the antibody comprises a VL comprising a VL CDR3 comprising SEQ ID NO: 1. 000. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: In some embodiments, the antibody comprises a VL having an amino acid sequence of SEQ ID NO: 1001. VH having the amino acid sequence of SEQ ID NO: 1000 and VH having the amino acid sequence of SEQ ID NO: 1001 L. In some embodiments, the antibody comprises a humanized antibody. In some embodiments, the antibody comprises an IgG antibody. In some embodiments, the antibody comprises an IgG1, IgG In some embodiments, the antibody is a Vβ17, IgG2, IgG3, or IgG4 antibody. Binds to an antigen. In some embodiments, the antibody binds to the Vβ17 epitope. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 of the antibody VL CDR1, VL CDR2, and VL CDR3 are responsible for binding to the Vβ17 antigen. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 of the antibody form a binding site. 2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are Vβ1 In some embodiments, the antibody forms a binding site for the epitope of T cell In some embodiments, the antibody comprises a multivalent, bispecific Vβ17 that is present on the surface of the In some embodiments, the antibody is capable of binding to at least three antigens. In some embodiments, the bispecific antibody binds to at least five antigens. In some embodiments, the antibody is a multispecific antibody.

[0039] In one aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1011, the amino acid sequence of SEQ ID NO: 1012 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 1013. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 1026, VL CDR2 having the amino acid sequence of SEQ ID NO: 1027 and the amino acid sequence of SEQ ID NO: 1028 In some embodiments, the antibody comprises a VL comprising a VL CDR3 having the sequence and a VH having the amino acid sequence of SEQ ID NO: 1032. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1033. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1032 and a VH having the amino acid sequence of SEQ ID NO: 1033. In some embodiments, the antibody comprises a humanized antibody. In some embodiments, the antibody comprises an IgG antibody. In some embodiments, the antibody comprises an IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR17, VH CDR18, VH CDR1 H CDR3, VL CDR1, VL CDR2, and VL CDR3 are the Vβ17 antibodies. In some embodiments, the VH CDR1 of the antibody forms a binding site for the antigen. VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR 3 forms a binding site for an epitope on Vβ17. In some embodiments, the antibody comprises Vβ17 present on the surface of a T cell. In some embodiments, the antibody is a bispecific antibody that binds to at least three antigens. In some embodiments, the bispecific antibody is capable of binding to at least five capable of binding to an antigen. In some embodiments, the antibody is a multispecific antibody. .

[0040] In one aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1043, the amino acid sequence of SEQ ID NO: 1044 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 1045. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 1058, VL CDR2 having the amino acid sequence of SEQ ID NO: 1059 and the amino acid sequence of SEQ ID NO: 1060 In some embodiments, the antibody comprises a VL comprising a VL CDR3 having the sequence and a VH having the amino acid sequence of SEQ ID NO: 1064. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1065. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1064 and a VH having the amino acid sequence of SEQ ID NO: 165. and a VL having the following structure: In some embodiments, the antibody comprises an IgG antibody. In some embodiments, the antibody In some embodiments, the antibody binds to the Vβ17 epitope. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, and VH CDR4 of the antibody bind to CDR3, VL CDR1, VL CDR2, and VL CDR3 are the antigens of Vβ17. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR17, VH CDR18, VH CDR1 H CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 forms a binding site for an epitope of Vβ17. In some embodiments, the antibody comprises Vβ17, which is present on the surface of a T cell. In some embodiments, the antibody is multivalent In some embodiments, the antibody binds to at least three antigens. In some embodiments, the bispecific antibody can be composed of at least five antibodies. In some embodiments, the antibody is a multispecific antibody.

[0041] In one aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1075, the amino acid sequence of SEQ ID NO: 1076 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 1077. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 1090, VL CDR2 having the amino acid sequence of SEQ ID NO: 1091 and the amino acid sequence of SEQ ID NO: 1092 In some embodiments, the antibody comprises a VL comprising a VL CDR3 having the sequence and a VH having the amino acid sequence of SEQ ID NO: 1096. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1097. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1096 and a VH having the amino acid sequence of SEQ ID NO: 197. and a VL having the following structure: In some embodiments, the antibody comprises an IgG antibody. In some embodiments, the antibody In some embodiments, the antibody binds to the Vβ17 epitope. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, and VH CDR4 of the antibody bind to CDR3, VL CDR1, VL CDR2, and VL CDR3 are the antigens of Vβ17. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR17, VH CDR18, VH CDR1 H CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 forms a binding site for an epitope of Vβ17. In some embodiments, the antibody comprises Vβ17, which is present on the surface of a T cell. In some embodiments, the antibody is multivalent In some embodiments, the antibody binds to at least three antigens. In some embodiments, the bispecific antibody can be composed of at least five antibodies. In some embodiments, the antibody is a multispecific antibody.

[0042] In one aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1107, the amino acid sequence of SEQ ID NO: 1108 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 1109. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 1122, VL CDR2 having the amino acid sequence of SEQ ID NO: 1123 and the amino acid sequence of SEQ ID NO: 1124 In some embodiments, the antibody comprises a VL comprising a VL CDR3 having the sequence and a VH having the amino acid sequence of SEQ ID NO: 1128. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1129. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1128 and a VH having the amino acid sequence of SEQ ID NO: 1129. In some embodiments, the antibody comprises a humanized antibody. In some embodiments, the antibody comprises an IgG antibody. In some embodiments, the antibody comprises an IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR17, VH CDR18, VH CDR1 H CDR3, VL CDR1, VL CDR2, and VL CDR3 are the Vβ17 antibodies. In some embodiments, the VH CDR1 of the antibody forms a binding site for the antigen. VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR 3 forms a binding site for an epitope on Vβ17. In some embodiments, the antibody comprises Vβ17 present on the surface of a T cell. In some embodiments, the antibody is a bispecific antibody that binds to at least three antigens. In some embodiments, the bispecific antibody is capable of binding to at least five capable of binding to an antigen. In some embodiments, the antibody is a multispecific antibody. .

[0043] In another aspect, (a) a first binding domain that binds to Vβ17, and (b) a first binding domain that binds to Vβ17. Provided herein are bispecific antibodies comprising a second binding domain that binds to a second target that does not bind to the first binding domain. It is served.

[0044] In some embodiments, the first binding domain of the bispecific antibody comprises (i) SEQ ID NO: 4 VH CDR1 having the amino acid sequence of SEQ ID NO: 8, VH CDR2 having the amino acid sequence of SEQ ID NO: 49 a VH having a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 50; i) VL CDR1 having the amino acid sequence of SEQ ID NO: 51, the amino acid sequence of SEQ ID NO: 52 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 53. In some embodiments, the bispecific antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 77. In some embodiments, the bispecific antibody comprises a VH having the sequence SEQ ID NO: 78. In some embodiments, the bispecific antibody comprises a VL having the amino acid sequence VH having the amino acid sequence of SEQ ID NO: 77 and VL having the amino acid sequence of SEQ ID NO: 78 In some embodiments, the Vβ17 of the bispecific antibody is present on the surface of a T cell. In some embodiments, the first binding domain of the bispecific antibody is humanized. or the second binding domain is humanized, or the first binding domain and the second binding domain are In some embodiments, the bispecific antibody comprises: In some embodiments, the bispecific antibody comprises an IgG1, IgG2 In some embodiments, the first of the bispecific antibodies comprises an IgG1, IgG2, or IgG3 antibody. In some embodiments, the binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain binds to the Vβ17 epitope. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The Vβ17 CDR2 and Vβ17 CDR3 form the binding site for the antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 and VH CDR4 of the bispecific antibody R3, VL CDR1, VL CDR2, and VL CDR3 are epitopes of Vβ17 In some embodiments, the second binding domain of the bispecific antibody forms a binding site for the In some embodiments, the first domain of the bispecific antibody binds to a second target antigen. The second binding domain binds to an epitope of a second target. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The L CDR2 and VL CDR3 form the binding site for a second target antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 of the bispecific antibody VL CDR3, VL CDR1, VL CDR2, and VL CDR3 are the epitopes of the second target. In some embodiments, the second target of the bispecific antibody forms a binding site for the target. The target is present on the surface of a second cell.

[0045] In some embodiments, the first binding domain of the bispecific antibody comprises (i) SEQ ID NO: 4 VH CDR1 having the amino acid sequence of SEQ ID NO: 8, VH CDR2 having the amino acid sequence of SEQ ID NO: 54 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 55; i) VL CDR1 having the amino acid sequence of SEQ ID NO: 56, the amino acid sequence of SEQ ID NO: 57 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 58. In some embodiments, the bispecific antibody comprises an amino acid sequence of SEQ ID NO: 79, and a VL comprising the amino acid sequence of SEQ ID NO: 79. In some embodiments, the bispecific antibody comprises a VH having the sequence SEQ ID NO: 80. In some embodiments, the bispecific antibody comprises a VL having the amino acid sequence VH having the amino acid sequence of SEQ ID NO: 79 and VL having the amino acid sequence of SEQ ID NO: 80 In some embodiments, the Vβ17 of the bispecific antibody is present on the surface of a T cell. In some embodiments, the first binding domain of the bispecific antibody is humanized. or the second binding domain is humanized, or the first binding domain and the second binding domain are In some embodiments, the bispecific antibody comprises: In some embodiments, the bispecific antibody comprises an IgG1, IgG2 In some embodiments, the first of the bispecific antibodies comprises an IgG1, IgG2, or IgG3 antibody. In some embodiments, the binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain binds to the Vβ17 epitope. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The Vβ17 CDR2 and Vβ17 CDR3 form the binding site for the antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 and VH CDR4 of the bispecific antibody R3, VL CDR1, VL CDR2, and VL CDR3 are epitopes of Vβ17 In some embodiments, the second binding domain of the bispecific antibody forms a binding site for the In some embodiments, the first domain of the bispecific antibody binds to a second target antigen. The second binding domain binds to an epitope of a second target. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The L CDR2 and VL CDR3 form the binding site for a second target antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 of the bispecific antibody VL CDR3, VL CDR1, VL CDR2, and VL CDR3 are the epitopes of the second target. In some embodiments, the second target of the bispecific antibody forms a binding site for the target. The target is present on the surface of a second cell.

[0046] In some embodiments, the first binding domain of the bispecific antibody comprises (i) SEQ ID NO: 5 VH CDR1 having the amino acid sequence of SEQ ID NO: 9, VH CDR2 having the amino acid sequence of SEQ ID NO: 49 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 60; i) VL CDR1 having the amino acid sequence of SEQ ID NO: 61, the amino acid sequence of SEQ ID NO: 62 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 63. In some embodiments, the bispecific antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 81. In some embodiments, the bispecific antibody comprises a VH having the sequence SEQ ID NO: 82. In some embodiments, the bispecific antibody comprises a VL having the amino acid sequence VH having the amino acid sequence of SEQ ID NO: 81 and VL having the amino acid sequence of SEQ ID NO: 82 In some embodiments, the Vβ17 of the bispecific antibody is present on the surface of a T cell. In some embodiments, the first binding domain of the bispecific antibody is humanized. or the second binding domain is humanized, or the first binding domain and the second binding domain are In some embodiments, the bispecific antibody comprises: In some embodiments, the bispecific antibody comprises an IgG1, IgG2 In some embodiments, the first of the bispecific antibodies comprises an IgG1, IgG2, or IgG3 antibody. In some embodiments, the binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain binds to the Vβ17 epitope. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The Vβ17 CDR2 and Vβ17 CDR3 form the binding site for the antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 and VH CDR4 of the bispecific antibody R3, VL CDR1, VL CDR2, and VL CDR3 are epitopes of Vβ17 In some embodiments, the second binding domain of the bispecific antibody forms a binding site for the In some embodiments, the first domain of the bispecific antibody binds to a second target antigen. The second binding domain binds to an epitope of a second target. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The L CDR2 and VL CDR3 form the binding site for a second target antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 of the bispecific antibody VL CDR3, VL CDR1, VL CDR2, and VL CDR3 are the epitopes of the second target. In some embodiments, the second target of the bispecific antibody forms a binding site for the target. The target is present on the surface of a second cell.

[0047] In some embodiments, the first binding domain of the bispecific antibody comprises (i) SEQ ID NO: 6 VH CDR1 having the amino acid sequence of SEQ ID NO: 4, VH CDR2 having the amino acid sequence of SEQ ID NO: 65 a VH having a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 66; i) VL CDR1 having the amino acid sequence of SEQ ID NO: 67, the amino acid sequence of SEQ ID NO: 68 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 69. In some embodiments, the bispecific antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 83. In some embodiments, the bispecific antibody comprises a VH having the sequence SEQ ID NO: 84. In some embodiments, the bispecific antibody comprises a VL having the amino acid sequence VH having the amino acid sequence of SEQ ID NO: 83 and VL having the amino acid sequence of SEQ ID NO: 84 In some embodiments, the Vβ17 of the bispecific antibody is present on the surface of a T cell. In some embodiments, the first binding domain of the bispecific antibody is humanized. or the second binding domain is humanized, or the first binding domain and the second binding domain are In some embodiments, the bispecific antibody comprises: In some embodiments, the bispecific antibody comprises an IgG1, IgG2 In some embodiments, the first of the bispecific antibodies comprises an IgG1, IgG2, or IgG3 antibody. In some embodiments, the binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain binds to the Vβ17 epitope. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The Vβ17 CDR2 and Vβ17 CDR3 form the binding site for the antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 and VH CDR4 of the bispecific antibody R3, VL CDR1, VL CDR2, and VL CDR3 are epitopes of Vβ17 In some embodiments, the second binding domain of the bispecific antibody forms a binding site for the In some embodiments, the first domain of the bispecific antibody binds to a second target antigen. The second binding domain binds to an epitope of a second target. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The L CDR2 and VL CDR3 form the binding site for a second target antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 of the bispecific antibody VL CDR3, VL CDR1, VL CDR2, and VL CDR3 are the epitopes of the second target. In some embodiments, the second target of the bispecific antibody forms a binding site for the target. The target is present on the surface of a second cell.

[0048] In some embodiments, the first binding domain of the bispecific antibody comprises (i) SEQ ID NO: 7 VH CDR1 having the amino acid sequence of SEQ ID NO: 49 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 71; i) VL CDR1 having the amino acid sequence of SEQ ID NO: 61, the amino acid sequence of SEQ ID NO: 72 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 73. In some embodiments, the bispecific antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 85. In some embodiments, the bispecific antibody comprises a VH having the sequence SEQ ID NO: 86. In some embodiments, the bispecific antibody comprises a VL having the amino acid sequence VH having the amino acid sequence of SEQ ID NO: 85 and VL having the amino acid sequence of SEQ ID NO: 86 In some embodiments, the Vβ17 of the bispecific antibody is present on the surface of a T cell. In some embodiments, the first binding domain of the bispecific antibody is humanized. or the second binding domain is humanized, or the first binding domain and the second binding domain are In some embodiments, the bispecific antibody comprises: In some embodiments, the bispecific antibody comprises an IgG1, IgG2 In some embodiments, the first of the bispecific antibodies comprises an IgG1, IgG2, or IgG3 antibody. In some embodiments, the binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain binds to the Vβ17 epitope. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The Vβ17 CDR2 and Vβ17 CDR3 form the binding site for the antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 and VH CDR4 of the bispecific antibody R3, VL CDR1, VL CDR2, and VL CDR3 are epitopes of Vβ17 In some embodiments, the second binding domain of the bispecific antibody forms a binding site for the In some embodiments, the first domain of the bispecific antibody binds to a second target antigen. The second binding domain binds to an epitope of a second target. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The L CDR2 and VL CDR3 form the binding site for a second target antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 of the bispecific antibody VL CDR3, VL CDR1, VL CDR2, and VL CDR3 are the epitopes of the second target. In some embodiments, the second target of the bispecific antibody forms a binding site for the target. The target is present on the surface of a second cell.

[0049] In some embodiments, the first binding domain of the bispecific antibody comprises (i) SEQ ID NO: 4 VH CDR1 having the amino acid sequence of SEQ ID NO: 8, VH CDR2 having the amino acid sequence of SEQ ID NO: 74 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 75; i) VL CDR1 having the amino acid sequence of SEQ ID NO: 56, the amino acid sequence of SEQ ID NO: 57 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 76. In some embodiments, the bispecific antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 87. In some embodiments, the bispecific antibody comprises a VH having the sequence SEQ ID NO: 88. In some embodiments, the bispecific antibody comprises a VL having the amino acid sequence VH having the amino acid sequence of SEQ ID NO: 87 and VL having the amino acid sequence of SEQ ID NO: 88 In some embodiments, the first binding domain of the bispecific antibody comprises (i) SEQ ID NO: VH CDR1 having the amino acid sequence of SEQ ID NO: 1, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3; and (ii) ) VL CDR1 having the amino acid sequence of SEQ ID NO: 664, VL CDR2 having the amino acid sequence of SEQ ID NO: 5 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6. and L. In some embodiments, the bispecific antibody comprises the amino acid sequence of SEQ ID NO: 21. In some embodiments, the bispecific antibody comprises a VH having the sequence of SEQ ID NO: 677. In some embodiments, the bispecific antibody comprises a VL having the amino acid sequence VH having the amino acid sequence of SEQ ID NO: 21 and VL having the amino acid sequence of SEQ ID NO: 677 In some embodiments, the Vβ17 of the bispecific antibody is present on the surface of a T cell. In some embodiments, the first binding domain of the bispecific antibody is humanized. or the second binding domain is humanized, or the first binding domain and the second binding domain are In some embodiments, the bispecific antibody comprises: In some embodiments, the bispecific antibody comprises an IgG1, IgG2 In some embodiments, the first of the bispecific antibodies comprises an IgG1, IgG2, or IgG3 antibody. In some embodiments, the binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain binds to the Vβ17 epitope. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The Vβ17 CDR2 and Vβ17 CDR3 form the binding site for the antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 and VH CDR4 of the bispecific antibody R3, VL CDR1, VL CDR2, and VL CDR3 are epitopes of Vβ17 In some embodiments, the second binding domain of the bispecific antibody forms a binding site for the In some embodiments, the first domain of the bispecific antibody binds to a second target antigen. The second binding domain binds to an epitope of a second target. VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The L CDR2 and VL CDR3 form the binding site for a second target antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 of the bispecific antibody VL CDR3, VL CDR1, VL CDR2, and VL CDR3 are the epitopes of the second target. In some embodiments, the second target of the bispecific antibody forms a binding site for the target. The target is present on the surface of a second cell.

[0050] In some embodiments, the first binding domain of the bispecific antibody comprises (i) SEQ ID NO: 9 VH CDR1 having the amino acid sequence of SEQ ID NO: 79, VH CDR2 having the amino acid sequence of SEQ ID NO: 980 VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 981; (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 994, VL CDR2 having the amino acid sequence of SEQ ID NO: 996, and VL CDR3 having the amino acid sequence of SEQ ID NO: 997. and a VL comprising CDR3. In some embodiments, the bispecific antibody comprises SEQ ID NO: In some embodiments, the bispecific antibody comprises a VH having a sequence of 1000 amino acids. In some embodiments, the VL comprises a VL having the amino acid sequence of SEQ ID NO: 1001. The bispecific antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1000 and a VH having the amino acid sequence of SEQ ID NO: 1001. and a VL having the amino acid sequence 7 is present on the surface of T cells. In some embodiments, the first binding site of the bispecific antibody the first binding domain is humanized, the second binding domain is humanized, or Both the first and second binding domains are humanized. In embodiments, the bispecific antibody comprises an IgG antibody. The antibody may be an IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the first binding domain of the bispecific antibody binds to the Vβ17 antigen. In embodiments, the first binding domain of the bispecific antibody binds to the Vβ17 epitope In some embodiments, the VH CDR1, VH CDR2, VH CDR3 and VH CDR4 of the bispecific antibody CDR3, VL CDR1, VL CDR2, and VL CDR3 bind to the antigen of Vβ17. In some embodiments, the VH CDR1 of the bispecific antibody forms a binding site for , VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CD R3 forms a binding site for an epitope of Vβ17. The second binding domain of the bispecific antibody binds to a second target antigen. In this configuration, the second binding domain of the bispecific antibody binds to an epitope of a second target. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 and VH CDR4 of the bispecific antibody CDR3, VL CDR1, VL CDR2, and VL CDR3 correspond to the antigen of the second target. In some embodiments, the VH CDRs of the bispecific antibody form a binding site for 1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL C DR3 forms a binding site for an epitope of a second target. The second target of the bispecific antibody is present on the surface of a second cell.

[0051] In some embodiments, the first binding domain of the bispecific antibody comprises (i) SEQ ID NO: 1 VH CDR1 having the amino acid sequence of SEQ ID NO: 1011, VH CDR2 having the amino acid sequence of SEQ ID NO: 1012 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 1013. (ii) a VH having the amino acid sequence of SEQ ID NO: 1026, and (iii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 1 VL CDR2 having the amino acid sequence of SEQ ID NO: 1027, and VL CDR3 having the amino acid sequence of SEQ ID NO: 1028 and a VL comprising a VL CDR3 having In some embodiments, the VH comprises a VH having the amino acid sequence of SEQ ID NO: 1032. The bispecific antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1033. In one embodiment, the bispecific antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1032 and a VH having the amino acid sequence of SEQ ID NO: and a VL having the amino acid sequence of SEQ ID NO: 1033. The Vβ17 of the antibody is present on the surface of T cells. The first binding domain of the antibody is humanized, or the second binding domain is humanized. Alternatively, both the first and second binding domains are humanized. In some embodiments, the bispecific antibody comprises an IgG antibody. Typically, bispecific antibodies include IgG1, IgG2, IgG3, or IgG4 antibodies. In some embodiments, the first binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain of the bispecific antibody binds to the Vβ17 epitope. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 of the bispecific antibody bind to the VH CDR1, VH CDR4, and VH CDR5 of the bispecific antibody. R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are Vβ In some embodiments, the V of the bispecific antibody forms a binding site for 17 antigens. H CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and The VL CDR3 and VL CDR3 form the binding site for the Vβ17 epitope. In some embodiments, the second binding domain of the bispecific antibody binds to a second target antigen. In some embodiments, the second binding domain of the bispecific antibody binds to an epitope of a second target. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 of the bispecific antibody bind to the VH CDR1, VH CDR4, and VH CDR5 of the bispecific antibody. R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are the second In some embodiments, the bispecific antibody forms a binding site for the target antigen. VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form the binding site for the epitope of the second target. In this embodiment, the second target of the bispecific antibody is present on the surface of a second cell.

[0052] In some embodiments, the first binding domain of the bispecific antibody comprises (i) SEQ ID NO: 1 VH CDR1 having the amino acid sequence of SEQ ID NO: 1043, VH CDR2 having the amino acid sequence of SEQ ID NO: 1044 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 1045. (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 1058; VL CDR2 having the amino acid sequence of SEQ ID NO: 1060, and a VL comprising a VL CDR3 having In some embodiments, the VH comprises a VH having the amino acid sequence of SEQ ID NO: 1064. The bispecific antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1065. In one embodiment, the bispecific antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1064 and a VH having the amino acid sequence of SEQ ID NO: and a VL having the amino acid sequence of SEQ ID NO: 1065. The Vβ17 of the antibody is present on the surface of T cells. The first binding domain of the antibody is humanized, or the second binding domain is humanized. Alternatively, both the first and second binding domains are humanized. In some embodiments, the bispecific antibody comprises an IgG antibody. Typically, bispecific antibodies include IgG1, IgG2, IgG3, or IgG4 antibodies. In some embodiments, the first binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain of the bispecific antibody binds to the Vβ17 epitope. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 of the bispecific antibody bind to the VH CDR1, VH CDR4, and VH CDR5 of the bispecific antibody. R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are Vβ In some embodiments, the V of the bispecific antibody forms a binding site for 17 antigens. H CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and The VL CDR3 and VL CDR3 form the binding site for the Vβ17 epitope. In some embodiments, the second binding domain of the bispecific antibody binds to a second target antigen. In some embodiments, the second binding domain of the bispecific antibody binds to an epitope of a second target. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 of the bispecific antibody bind to the VH CDR1, VH CDR4, and VH CDR5 of the bispecific antibody. R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are the second In some embodiments, the bispecific antibody forms a binding site for the target antigen. VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form the binding site for the epitope of the second target. In this embodiment, the second target of the bispecific antibody is present on the surface of a second cell.

[0053] In some embodiments, the first binding domain of the bispecific antibody comprises (i) SEQ ID NO: 1 VH CDR1 having the amino acid sequence of SEQ ID NO: 1075, VH CDR2 having the amino acid sequence of SEQ ID NO: 1076 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 1077. (ii) a VH having the amino acid sequence of SEQ ID NO: 1090, and (iii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 1 VL CDR2 having the amino acid sequence of SEQ ID NO: 1091, and the amino acid sequence of SEQ ID NO: 1092 and a VL comprising a VL CDR3 having In some embodiments, the VH comprises a VH having the amino acid sequence of SEQ ID NO: 1096. The bispecific antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1097. In one embodiment, the bispecific antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1096 and a VH having the amino acid sequence of SEQ ID NO: and a VL having the amino acid sequence of SEQ ID NO: 1097. The Vβ17 of the antibody is present on the surface of T cells. The first binding domain of the antibody is humanized, or the second binding domain is humanized. Alternatively, both the first and second binding domains are humanized. In some embodiments, the bispecific antibody comprises an IgG antibody. Typically, bispecific antibodies include IgG1, IgG2, IgG3, or IgG4 antibodies. In some embodiments, the first binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain of the bispecific antibody binds to the Vβ17 epitope. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 of the bispecific antibody bind to the VH CDR1, VH CDR4, and VH CDR5 of the bispecific antibody. R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are Vβ In some embodiments, the V of the bispecific antibody forms a binding site for 17 antigens. H CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and The VL CDR3 and VL CDR3 form the binding site for the Vβ17 epitope. In some embodiments, the second binding domain of the bispecific antibody binds to a second target antigen. In some embodiments, the second binding domain of the bispecific antibody binds to an epitope of a second target. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 of the bispecific antibody bind to the VH CDR1, VH CDR4, and VH CDR5 of the bispecific antibody. R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are the second In some embodiments, the bispecific antibody forms a binding site for the target antigen. VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form the binding site for the epitope of the second target. In this embodiment, the second target of the bispecific antibody is present on the surface of a second cell.

[0054] In some embodiments, the first binding domain of the bispecific antibody comprises (i) SEQ ID NO: 1 VH CDR1 having the amino acid sequence of SEQ ID NO: 107, VH CDR2 having the amino acid sequence of SEQ ID NO: 1108 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 1109. (ii) a VH having the amino acid sequence of SEQ ID NO: 1122, and (iii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 1 VL CDR2 having the amino acid sequence of SEQ ID NO: 123, and the amino acid sequence of SEQ ID NO: 1124 and a VL comprising a VL CDR3 having In some embodiments, the VH comprises a VH having the amino acid sequence of SEQ ID NO: 1128. The bispecific antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1129. In one embodiment, the bispecific antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1128 and a VH having the amino acid sequence of SEQ ID NO: and a VL having the amino acid sequence of SEQ ID NO: 1129. The Vβ17 of the antibody is present on the surface of T cells. The first binding domain of the antibody is humanized, or the second binding domain is humanized. Alternatively, both the first and second binding domains are humanized. In some embodiments, the bispecific antibody comprises an IgG antibody. Typically, bispecific antibodies include IgG1, IgG2, IgG3, or IgG4 antibodies. In some embodiments, the first binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain of the bispecific antibody binds to the Vβ17 epitope. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 of the bispecific antibody bind to the VH CDR1, VH CDR4, and VH CDR5 of the bispecific antibody. R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are Vβ In some embodiments, the V of the bispecific antibody forms a binding site for 17 antigens. H CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and The VL CDR3 and VL CDR3 form the binding site for the Vβ17 epitope. In some embodiments, the second binding domain of the bispecific antibody binds to a second target antigen. In some embodiments, the second binding domain of the bispecific antibody binds to an epitope of a second target. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 of the bispecific antibody bind to the VH CDR1, VH CDR4, and VH CDR5 of the bispecific antibody. R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are the second In some embodiments, the bispecific antibody forms a binding site for the target antigen. VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form the binding site for the epitope of the second target. In this embodiment, the second target of the bispecific antibody is present on the surface of a second cell.

[0055] In some embodiments, the Vβ17 of the bispecific antibody is present on the surface of a T cell. In some embodiments, the first binding domain of the bispecific antibody is humanized or , the second binding domain is humanized, or the first binding domain and the second binding domain are humanized. In some embodiments, the bispecific antibody comprises a fusion protein comprising both I and I domains. In some embodiments, the bispecific antibody is an IgG antibody. In some embodiments, the first binding site of the bispecific antibody comprises an IgG1 antibody, an IgG2 antibody, or an IgG3 antibody. In some embodiments, the first binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the binding domain of one binds to the Vβ17 epitope. VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL of the opposite antibody CDR2 and VL CDR3 form the binding site of Vβ17 to the antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 of the bispecific antibody VL CDR1, VL CDR2, and VL CDR3 correspond to the epitope of Vβ17. In some embodiments, the second binding domain of the bispecific antibody In some embodiments, the second target of the bispecific antibody binds to the second target antigen. The binding domain binds to an epitope of a second target. VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL of the opposite antibody CDR2 and VL CDR3 form the binding site for a second target antigen. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 of the bispecific antibody 3. VL CDR1, VL CDR2, and VL CDR3 are the epitopes of the second target. In some embodiments, the second target of the bispecific antibody forms a binding site for , present on the surface of a second cell.

[0056] In some embodiments, the second cell is a cancer cell. The two targets are tumor-specific antigens, tumor-associated antigens, or neoantigens.

[0057] In some embodiments, the cancer is adrenal cancer, anal cancer, appendix cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, Cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gestational trophoblastic, head and neck cancer, Hodgkin's Lymphoma, intestinal cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, neuro Endocrine tumors, non-Hodgkin's lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, sinus cancer, skin cancer, Soft tissue sarcoma, spinal cancer, stomach cancer, testicular cancer, pharyngeal cancer, thyroid cancer, uterine cancer, endometrial cancer, vaginal cancer, or In some embodiments, the adrenal cancer is adrenocortical carcinoma (ACC), adrenal carcinoma (ADRC), or vulvar cancer. In some embodiments, the anal cancer is: renal cortical carcinoma, pheochromocytoma, or neuroblastoma. Squamous cell carcinoma, cloacal carcinoma, adenocarcinoma, basal cell carcinoma, or melanoma. In embodiments, the appendiceal cancer is a neuroendocrine tumor (NET), mucinous adenocarcinoma, goblet cell carcinoma, or In some embodiments, the cholangiocarcinoma is hepatic, intestinal, or signet ring cell adenocarcinoma. extrahepatic bile duct cancer, adenocarcinoma, perihilar cholangiocarcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma, or intrahepatic cholangiocarcinoma. In some embodiments, the bladder cancer is transitional cell carcinoma (TCC), papillary carcinoma, squamous carcinoma, or the like. In some embodiments, the tumor is a squamous cell carcinoma, adenocarcinoma, small cell carcinoma, or sarcoma. , bone cancer, primary bone cancer, sarcoma, osteosarcoma, chondrosarcoma, sarcoma, fibrosarcoma, malignant fibrous histiocytoma In some embodiments, the brain cancer is: Astrocytoma, brainstem glioma, glioblastoma, meningioma, ependymoma, oligodendroglioma, mixed glioma, Pituitary carcinoma, pituitary adenoma, craniopharyngioma, germ cell tumor, pineal tumor, medulloblastoma, or primary C In some embodiments, the breast cancer is a breast adenocarcinoma, an invasive breast cancer, a non-invasive breast cancer, or a non-invasive breast cancer. Breast cancer, breast sarcoma, metaplastic carcinoma, adenocystic carcinoma, phyllodes tumor, angiosarcoma, HER2-positive breast cancer, avian In some embodiments, the cervical cancer is prostate-negative breast cancer or inflammatory breast cancer. It is a squamous cell carcinoma or an adenocarcinoma.

[0058] In some embodiments, the colorectal cancer is selected from the group consisting of colorectal adenocarcinoma, primary colorectal lymphoma, Gastrointestinal stromal tumor, leiomyosarcoma, carcinoid tumor, mucinous adenocarcinoma, signet ring cell adenocarcinoma, digestive In some embodiments, the esophageal cancer is an adenocarcinoma or a ductal carcinoid tumor. In some embodiments, the gallbladder cancer is a squamous cell carcinoma. The tumor is adenosquamous carcinoma, squamous cell carcinoma, small cell carcinoma, or sarcoma. In this condition, gestational trophoblastic disease (GTD) includes hydatidiform mole, gestational trophoblastic neoplasm (GTN), and trophoblastic cyst. Choriocarcinoma, placental site trophoblastic tumor (PSTT), or epithelioid trophoblastic tumor (ETT) In some embodiments, the head and neck cancer is laryngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, nasal cancer, In some embodiments, the cancer is a cancer of the paranasal sinuses, a cancer of the salivary glands, an oral cavity cancer, an oropharynx cancer, or a tonsil cancer. Hodgkin's lymphoma is classified into classical Hodgkin's lymphoma, nodular sclerosing lymphoma, mixed cell type, lymphocytic lymphoma, and Lymphocyte-rich, lymphopenic, or nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) In some embodiments, the intestinal cancer is small intestine cancer, small intestine cancer ( small bowel cancer), adenocarcinoma, sarcoma, gastrointestinal stromal tumor, carcinoid tumor, or lymphoma In some embodiments, the kidney cancer is renal cell carcinoma (RCC), clear cell RCC, breast cancer, or Head RCC, chromophobe RCC, collecting duct RCC, unclassified RCC, transitional cell carcinoma, urothelial carcinoma, In some embodiments, the leukemia is acute lymphocytic leukemia. disease (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic bone Myeloid leukemia (CML), hairy cell leukemia (HCL), or myelodysplastic syndrome (MDS) In some embodiments, the liver cancer is hepatocellular carcinoma (HCC), fibrolamellar HCC, In some embodiments, the lung cancer is a small intestine cancer, a cholangiocarcinoma, a cholangiocarcinoma, an angiosarcoma, or a liver metastasis. Cellular lung cancer, small cell carcinoma, complex small cell carcinoma, non-small cell lung cancer, lung adenocarcinoma, squamous cell lung cancer , large cell undifferentiated carcinoma, pulmonary nodule, metastatic lung cancer, adenosquamous carcinoma, large cell neuroendocrine carcinoma, salivary gland-type lung carcinoma, pulmonary carcinoid, mesothelioma, sarcomatoid carcinoma of the lung, or malignant granular cell lung tumor In some embodiments, the melanoma is superficial spreading melanoma, nodular melanoma, acral lentigo melanoma, lentigo maligna melanoma, amelanotic melanoma, desmoplastic melanoma, ocular melanoma, or metastatic melanoma In some embodiments, the mesothelioma is pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, or metastatic melanoma. In some embodiments, the multiple myeloma is active or In some embodiments, the neuroendocrine tumor is a smoldering multiple myeloma. The tumor is a neuroendocrine tumor, a pancreatic neuroendocrine tumor, or a pulmonary neuroendocrine tumor. Non-Hodgkin's lymphoma is classified into anaplastic large cell lymphoma, lymphoblastic lymphoma, and peripheral T lymphoma. Cell lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoplasmacytic lymphoma, marginal lymphoma Zone B-cell lymphoma, MALT lymphoma, small cell lymphocytic lymphoma, Burkitt lymphoma , chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), precursor T lymphoblastoid leukemia Acute lymphocytic leukemia / lymphoma, acute lymphocytic leukemia (ALL), adult T-cell lymphoma / leukemia (ATLL), hairy cell leukemia, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, primary central nervous system (CNS) lymphoma, Thrombocytopenic lymphoma (MCL), marginal zone lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma lymphoma, B-cell non-Hodgkin's lymphoma, T-cell non-Hodgkin's lymphoma, natural killer cell lymphoma cutaneous T-cell lymphoma, Alibert-Bazin syndrome, Sézary syndrome, primary cutaneous leukemia Differentiated large cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL) ), anaplastic large cell lymphoma (ALCL), systemic ALCL, enteropathic T-cell lymphoma (EA) TL), or hepatosplenic gamma / delta T-cell lymphoma. Cancers include squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinoma, lymphoma, benign oral tumors, eosinophilic Granuloma, fibroma, granular cell tumor, keratoacanthoma, leiomyoma, osteochondroma, lipoma, Schwannoma Cytoma, neurofibroma, papilloma, condyloma acuminata, verrucous xanthomas, pyogenic granuloma, striated muscle Odontogenic tumor, leukoplakia, erythroplakia, squamous cell lip cancer, basal cell lip cancer, oral cancer, gingival cancer In some embodiments, the ovarian cancer is ovarian epithelial cancer, mucinous epithelial ovarian cancer, or tongue cancer. , endometrial epithelial ovarian cancer, clear cell epithelial ovarian cancer, undifferentiated epithelial ovarian cancer, ovarian low malignant grade tumor, Primary peritoneal cancer, fallopian tube cancer, germ cell tumor, teratoma, undifferentiated ovarian germ cell cancer, endodermal sinus tumor, sex cord tumor stromal tumor, sex cord-gonadal stromal tumor, ovarian stromal tumor, granulosa cell tumor, granulosa theca tumor, cell Tori-Leydig tumor, ovarian sarcoma, ovarian carcinosarcoma, ovarian adenosarcoma, ovarian leiomyosarcoma, ovarian adenocarcinoma In some embodiments, the pancreatic cancer is a fibrosarcoma, a Krukenberg tumor, or an ovarian cyst. pancreatic exocrine adenocarcinoma, pancreatic endocrine adenocarcinoma, or pancreatic adenocarcinoma, pancreatic islet cell tumor, or neuroendocrine tumor. In some embodiments, the prostate cancer is selected from the group consisting of prostate adenocarcinoma, prostate sarcoma, transitional cell carcinoma, In some embodiments, the sinus cancer is a squamous cell carcinoma or a small cell carcinoma or a neuroendocrine tumor. cystic carcinoma, mucosal cell carcinoma, adenoid cystic cell carcinoma, acinic cell carcinoma, undifferentiated carcinoma of the paranasal sinuses, nasal cavity carcinoma, In some embodiments, the cancer is a paranasal sinus cancer, maxillary sinus cancer, ethmoid sinus cancer, or nasopharyngeal cancer. are basal cell carcinoma, squamous cell carcinoma, melanoma, Merkel cell carcinoma, Kaposi's sarcoma (KS), and sun exposure. In some embodiments, the cancer is a soft tissue cancer, such as keratosis gracilis, cutaneous lymphoma, or keratoacanthoma. are angiosarcoma, dermatofibrosarcoma, epithelioid sarcoma, Ewing's sarcoma, fibrosarcoma, and gastrointestinal stromal tumors. (GIST), Kaposi's sarcoma, leiomyosarcoma, liposarcoma, dedifferentiated liposarcoma (DL), myxoid / Round cell liposarcoma (MRCL), well-differentiated liposarcoma (WDL), malignant fibrous histiocytoma, Neurofibrosarcoma, rhabdomyosarcoma (RMS), or synovial sarcoma. In some embodiments, the spinal cancer is a spinal metastatic tumor. In some embodiments, the gastric cancer is a gastric adenocarcinoma, gastric phospholipid. gastrointestinal stromal tumor, carcinoid tumor, gastric carcinoid tumor, type I ECL cell carcinoma type II ECL-cell carcinoid, or type III ECL-cell carcinoid. In some embodiments, the testicular cancer is seminoma, non-seminoma, embryonal carcinoma, or yolk sac carcinoma. , choriocarcinoma, teratoma, gonadal stromal tumor, Leydig cell tumor, or Sertoli cell tumor. In some embodiments, the pharyngeal cancer is selected from the group consisting of squamous cell carcinoma, adenocarcinoma, sarcoma, laryngeal carcinoma, and pharyngeal carcinoma. Head cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, laryngeal squamous cell carcinoma, laryngeal adenocarcinoma, phosphorus The tumors are paedioma, spindle cell carcinoma, verrucous carcinoma, undifferentiated carcinoma, or lymph node carcinoma. Thyroid cancer can be classified into papillary carcinoma, follicular carcinoma, Hurthle cell carcinoma, medullary thyroid carcinoma, In some embodiments, the uterine cancer is endometrial cancer, endometrial adenocarcinoma, or undifferentiated carcinoma. Endometrioid carcinoma, serous adenocarcinoma, adenosquamous carcinoma, uterine carcinosarcoma, uterine sarcoma, uterine smooth carcinoma In some embodiments, the vaginal cancer is a myosinoma, an endometrial stromal sarcoma, or an undifferentiated sarcoma. In some embodiments, the tumor is a squamous cell carcinoma, adenocarcinoma, melanoma, or sarcoma. The cancer is a squamous cell carcinoma or an adenocarcinoma.

[0059] In some embodiments, the second target is angiopoietin, BCMA, CD19, C D20, CD22, CD25(IL2-R), CD30, CD33, CD37, CD38 , CD52, CD56, CD123(IL-3R), cMET, DLL / Notch, E GFR, EpCAM, FGF, FGF-R, GD2, HER2, mesothelin, nectin 4, PDGFRα, RANKL, SLAMF7, TROP2, VEGF, VEGF-R, CEA, immature laminin receptor, TAG-72, HPV E6, HPV E7, BING -4, calcium-activated chloride channel 2, cyclin-B1, 9D7, EpCAM, Ep hA3, Her2 / neu, telomerase, mesothelin, SAP-1, surviving, B AGE family antigens, CAGE family antigens, GAGE ​​family antigens, MAGE family Family antigens, SAGE family antigens, XAGE family antigens, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A, MART-1, Gp100, pmel17, tyrosinase, TRP-1, TRP-2, P. polypeptide, MC1R, Prostate-specific antigen, β-catenin, BRCA1, BRCA2, CDK4, CML66, fibronectin, MART-2, p53, Ras, TGF-βRII, or MUC1 do.

[0060] In some embodiments, the second target of the bispecific antibody is CD123. In some embodiments, the second binding domain of the bispecific antibody comprises (i) the amino acid sequence of SEQ ID NO: 34. VH CDR1 having the amino acid sequence of SEQ ID NO: 35, VH CDR2 having the amino acid sequence of SEQ ID NO: 36 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 36; and (ii) a VH having the sequence VL CDR1 having the amino acid sequence of SEQ ID NO: 37, VL CDR2 having the amino acid sequence of SEQ ID NO: 38 a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 39; , including.

[0061] In some embodiments, the second target of the bispecific antibody is BCMA. In this embodiment, the second binding domain of the bispecific antibody comprises (i) the amino acid sequence of SEQ ID NO: 89 VH CDR1 having the amino acid sequence of SEQ ID NO: 90; VH CDR2 having the amino acid sequence of SEQ ID NO: 90; and a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 91; and (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: VL CDR1 having the amino acid sequence of SEQ ID NO: 93, VL CDR2 having the amino acid sequence of SEQ ID NO: 94 a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 94; Includes.

[0062] In some embodiments, the second cell is a B cell. 2 targets CD1a, CD1b, CD1c, CD1d, CD2, CD5, CD6, CD 9, CD11a, CD11b, CD11c, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD29, CD30, CD31, CD32a, CD32b, CD35, CD37, CD38, CD3 9, CD40, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49b, CD49c, CD49d, CD50, CD 52, CD53, CD54, CD55, CD58, CD60a, CD62L, CD63, CD68, CD69, CD70, CD72, CD73, CD74, CD75, CD75S , CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD 84, CD85E, CD85I, CD85J, CD86, CD92, CD95, CD97 , CD98, CD99, CD100, CD102, CD108, CD119, CD120 a, CD120b, CD121b, CD122, CD124, CD125, CD126, CD130, CD132, CD137, CD138, CD139, CD147, CD14 8, CD150, CD152, CD162, CD164, CD166, CD167a, C D170, CD171, CD175, CD175s, CD180, CD184, CD18 5, CD192, CD196, CD197, CD200, CD205, CD201a, C Dw210b, CD212, CD213a1, CD213a2, CD215, CD217 , CD218a, CD218b, CD220, CD221, CD222, CD224, C D225, CD226, CD227, CD229, CD230, CD232, CD252 , CD252, CD254, CD255, CD256, CD257, CD258, CD2 59, CD260, CD261, CD262, CD263, CD264, CD267, C D268, CD269, CD270, CD272, CD274, CD275, CD277 , CD279, CD283, CD289, CD290, CD295, CD298, CD3 00, CD300c, CD305, CD306, CD307a, CD307b, CD30 7c, CD307d, CD307e, CD314, CD215, CD316, CD317 , CD319, CD321, CD327, CD328, CD329, CD338, CD3 51, CD352, CD353, CD354, CD355, CD356, CD357, C D358, CD360, CD361, CD362, or CD363.

[0063] In some embodiments, the bispecific antibody binds to Vβ17 on the surface of a T cell and to Vβ17 on the surface of a second cell. Upon binding to a second target on the surface of the cell, the second cell is killed.

[0064] In some embodiments, the bispecific antibody has an EC 50 So, Inbi In some embodiments, the second cell induces T cell dependent cytotoxicity in vitro. Bispecific antibodies have an EC of less than approximately 300 pM 50 In vitro T cells In some embodiments, the bispecific antibody induces cell-dependent cytotoxicity. EC< pM 50 and induce T cell-dependent cytotoxicity of second cells in vitro. do.

[0065] In some embodiments, EC 50 expressing αβ T effector cells and secondary targets In some embodiments, the effector cells are evaluated in a mixture with target cells. In some embodiments, the ratio of effector The ratio of cells to target cells is about 0.1:1 to about 5:1. The ratio of fector cells to target cells is approximately 1:1.

[0066] In some embodiments, the bispecific antibody is multivalent. A bispecific antibody is capable of binding to at least three antigens. In this case, the bispecific antibody is capable of binding to at least five antigens.

[0067] In one aspect, provided herein is a bispecific antibody, said bispecific antibody being capable of targeting T cells. A first means capable of binding Vβ17 on the surface of a cell and a second target that is not Vβ17. and a second means capable of binding the target. In some embodiments, the bispecific The second target of the antibody is present on the surface of a second cell.

[0068] In one aspect, the antibody of any one of the preceding embodiments, or Nucleic acids encoding the bispecific antibodies are provided herein. Also provided herein are host cells comprising the vectors. Also provided is a kit containing the vector and a package therefor. In some embodiments, the packaging comprises a compartment for holding the vector. Includes.

[0069] In one aspect, the antibody of any one of the preceding embodiments, or Provided herein is a pharmaceutical composition comprising a bispecific antibody and a pharmaceutically acceptable carrier. Also provided is a method for producing a pharmaceutical composition, said method comprising: and combining the compound with a suitable carrier to obtain a pharmaceutical composition.

[0070] In another aspect, a method for directing Vβ17-expressing T cells to a secondary target is described herein. and a method comprising contacting a T cell with the bispecific antibody of any of the preceding embodiments. In some embodiments, the contacting step comprises contacting the T cells with a second target. Direct it to.

[0071] In one embodiment, a method for inhibiting the growth or proliferation of a target cell that expresses a second target on the cell surface. A method is provided herein, the method comprising: subjecting a target cell to a doublet of any one of the preceding embodiments. In some embodiments, the method further comprises contacting the target cells with a pharmaceutical composition. In some embodiments, the step of inducing the target cells inhibits the growth or proliferation of the target cells. Contacting the target cells with the antibody or bispecific antibody inhibits the growth or proliferation of the target cells.

[0072] In some embodiments, the target cells express Vβ17 while in contact with the bispecific antibody. in the presence of T cells expressing

[0073] In one aspect, a method for eliminating target cells expressing a second target in a subject is provided herein. and wherein the method comprises administering an effective amount of the bispecific antibody of any one of the preceding embodiments. In some embodiments of this method, the subject has cancer. In some embodiments of this method, the subject has leukemia. In some embodiments, the subject has lymphoma.

[0074] In one embodiment, the target cell expressing the second target in the subject is induced in whole or in part by target cells expressing the second target. A method of treating a disease caused by a compound of formula (I) or (II) is provided, the method comprising administering an effective amount of any of the compounds of the preceding embodiments. Some embodiments of this method include administering any one of the bispecific antibodies to a subject. In some embodiments of this method, the disease is cancer. In some embodiments of this method, the disease is lymphoma.

[0075] In some embodiments of this method, the subject is a subject in need of the method. In some embodiments of this method, the subject is a human.

[0076] In one aspect, provided herein is a method of activating T cells that express Vβ17, comprising: The method comprises contacting a T cell with the bispecific antibody of any one of the preceding embodiments. In some embodiments of this method, the contacting step comprises contacting a cell line expressing Vβ17. Increased expression of CD69, CD25, and / or granzyme B compared to control T cells In one embodiment, the control T cells are comparable T cells that express Vβ17. In this manner, comparable T cells (e.g., control T cells) are not contacted with the bispecific antibody.

[0077] In another aspect, provided herein is a process for generating antibodies that bind to two or more target molecules. This process yields a binding domain that can bind to Vβ17 on T cells. and a binding domain capable of binding to a second target on a second cell. and performing a function of obtaining a target antigen, Vβ17 (e.g., Vβ17 antigen) on a T cell, and providing an antibody capable of binding to a second target on the second cell; In some embodiments of this process, a bond capable of binding to a second target is provided. The process of performing the function of obtaining the binding domain is repeated n times, and Vβ17 and n a step that performs the function of providing a binding domain capable of binding to a target molecule. and n is at least 2. In some embodiments of this process, the second target is on the surface of a second cell. The second cell is a cancer cell. In some embodiments, the second target is a tumor-specific antigen. In some embodiments of this process, the second cell is a tumor-associated antigen, a tumor-associated antigen, or a neoantigen. In some embodiments of this process, the second target is a CD12 3. In some embodiments of this process, the second target is BCMA. Exemplary second targets are provided herein and are contemplated as embodiments of this process. In some embodiments of this process, Vβ17 can bind to The binding domain binds to Vβ17. In some embodiments of this process, Vβ1 The binding domain capable of binding to Vβ17 binds to the Vβ17 epitope. In some embodiments of the method, the binding domain capable of binding to a second target is a second In some embodiments of this process, the antibody binds to an antigen of a second target. The binding domain capable of binding to an epitope of a second target binds to an epitope of a second target.

[0078] In another aspect, provided herein is a bispecific antibody, the bispecific antibody comprising: A first means capable of binding Vβ17 on the surface of a cell and a second means capable of binding Vβ17 on the surface of a second cell. and a second means capable of binding two targets. In some embodiments, the second In some embodiments, the second target is a tumor-specific antigen, a tumor In some embodiments of the bispecific antibody, the second cell is a tumor-associated antigen, or a neoantigen. In some embodiments of the bispecific antibody, the second target is a CD12 3. In some embodiments of the bispecific antibody, the second target is BCMA. In some embodiments of the bispecific antibody, the second target is DLL3. In some embodiments of the antibody, the second target is PSMA. In some embodiments, the secondary target is KLK2. Other exemplary secondary targets are The methods provided in the specification are contemplated as embodiments of this process.

[0079] In some embodiments, the first means of the bispecific antibody binds Vβ17 to the Vβ17 antigen. In some embodiments, the first means of the bispecific antibody is capable of binding to a Vβ 17 can bind to the Vβ17 epitope. In some embodiments, the bispecific The first means of the antibody is capable of binding to an antigen of the second target. In some embodiments, the first means of the bispecific antibody binds to the second target via an epitope on the second target. In some embodiments, the second means of the bispecific antibody is capable of binding to The second target can bind to an antigen of the second target. In some embodiments, the double The second means of specific antibody is capable of binding to an epitope of a second target. do.

[0080] Also disclosed herein are kits comprising the bispecific antibodies or antigen-binding fragments thereof. We also provide a package for this purpose. [Brief explanation of the drawings]

[0081] The foregoing summary, as well as the following detailed description of certain embodiments of the present application, is provided in conjunction with the accompanying drawings. However, the present application is not intended to be a complete translation of the invention as defined in the accompanying drawings. It should be understood that the present invention is not limited to the precise embodiment shown. [Figure 1] FIG. 1 shows how binding of an anti-Vβ17 / anti-tumor antigen bispecific antibody recruits T cells to cancer cells and induces cancer cell death. [Figure 2A] Figure 1 shows that Vβ17+ CD8+ T cells are present in healthy subjects and can be expanded in vitro by culturing with M1 peptide. Figure 2 shows FACS histograms of peripheral blood mononuclear cells (PBMCs) gated for CD8+ T cells expressing Vβ17 (Vβ17+) on the cell surface from healthy subjects. [Figure 2B]Figure 1 shows that Vβ17+CD8+ T cells are present in healthy subjects and can be expanded in vitro by culturing with M1 peptide. Figure 2 shows the HLA subtypes of various donors and the percent Vβ17+CD8+ T cell presence identified on day 0 and after 14 days of in vitro expansion with M1 peptide (day 14). [Figure 3] Figure 1 shows that Vβ17+ CD8+ T cells have the characteristics of killer cytotoxic cells. The bar graph shows the expression of CD107a, CD69, granzyme B (Gzb), and interferon-γ (IFNγ) in gated PBMCs on day 0 (without M1) and after day 14 (+M1) stimulation with M1 peptide for CD8+ T cells expressing Vβ17 on their cell surface (Vβ17+). [Figure 4] Figure 1 shows binding of VB11 [anti-Vβ17 / anti-CD123] bispecific antibody and VB13 [Vβ17 null control bispecific] antibody to CD8+ T cells. Data are presented from CD8+ T cells isolated from PBMCs from three different donors (D203517, HPU09381, and HPU08694). The table below each graph shows the EC50 values ​​for binding in nM. [Figure 5]

[0023] Figure 1 shows the binding of a Vβ17 and CD123 bispecific antibody (VB11) and a Vβ17 null control bispecific (VB13) antibody to AML cancer cell lines. The data presented show the binding of the bispecific antibody to the Kasumi3 AML cell line. The table below the graph shows the EC50 values ​​for binding in nM. [Figure 6]Figure 1 shows redirection of Vβ17+ T cells by bispecific antibodies leading to efficient killing of AML cancer cells. Data in the left graph show killing of Kasumi3 cancer cells at an effector-to-target (E:T) ratio of 0.5:1 and dose adjustment of the bispecific antibody. Data in the middle graph show killing of Kasumi3 cancer cells at an E:T ratio of 1:1 and dose adjustment of the bispecific antibody. Data in the right graph show killing of Kasumi3 cancer cells at an E:T ratio of 5:1 and dose adjustment of the bispecific antibody. The table below the graphs shows the EC50 values ​​calculated from the above graphs, given in pM. [Figure 7A] Figure 1 shows specific binding of anti-Vβ17 / anti-CD123 bispecific antibody (VB11) and Vβ17 null bispecific antibody (VB13) to CD8+ T cells isolated from PBMCs. Figure 2 shows FACS histograms of gated PBMCs for CD8+ T cells expressing Vβ17 on the cell surface (Vβ17+) from healthy subjects (left graph, Vβ17 non-depleted) and from PBMCs from which Vβ17+ T cells have been depleted using negative selection (right graph, Vβ17 depleted). [Figure 7B] Figure 7B shows the specific binding of anti-Vβ17 / anti-CD123 bispecific antibody (VB11) and Vβ17null bispecific antibody (VB13) to CD8+ T cells isolated from PBMC. Figure 7C shows the specific binding of anti-Vβ17 / anti-CD123 bispecific antibody (VB11) and Vβ17null bispecific antibody (VB13) to CD8+ T cells from Figure 7A. The dose response of the bispecific antibodies is shown in the figures. The table below the graphs shows the EC50 values ​​for binding calculated from the graphs, given in nM. [Figure 8]Figure 1 shows the specific recruitment of Vβ17 T cells by a Vβ17 bispecific antibody to kill Kasumi3 cancer cells. The left panel shows the killing of Kasumi3 AML cell line when effector cells were isolated from PBMCs containing CD8+ T cells (naive CD8 T cells) expressing Vβ17 (Vβ17+) on their cell surface. The inset shows the presence of 10.1% Vβ17+ CD8+ T cells in the effector cell population. The right panel shows the killing of Kasumi3 AML cell line when effector CD8+ T cells were isolated from PBMCs but depleted of Vβ17+ T cells by negative selection. The inset shows the presence of a minor population (0.086%) of Vβ17+ CD8+ T cells in the effector cell population. [Figure 9A] Figure 1 shows the lack of pan-activation of T cells when Vβ17 bispecific antibodies are used. FACS plots of Vβ17+ and Vβ17-gated CD8+ T cells. Activation of T cells with Vβ17 bispecific antibodies resulted in higher upregulation of CD69 in Vβ17+ (62.5%) compared to Vβ17- CD8+ T cells (1.80%). [Figure 9B] Figure 1 shows the absence of pan activation of T cells when Vβ17 bispecific antibodies are used. Figure 2 shows a bar graph of upregulation of CD69 on Vβ17+ and Vβ17-gated CD8+ T cells upon activation with Vβ17 bispecific antibodies. [Figure 10] Vβ17+ T cells from HLA A2-negative donors are also effector killer cells, and pre-stimulation of Vβ17+ cells is not required. PBMCs containing Vβ17+ T cells from an HLA A2-negative donor (HPU 09381) demonstrated efficient cytotoxicity of Kasumi3 cancer cells mediated by a Vβ17 bispecific antibody. [Figure 11]Figure 1 shows that Vβ17 antibody (Vb17_202B4D1-Fab-RF, BCMB519-scFv (B17B622.001)) binds to T cells (left panel) and mediates T cell cytotoxicity against BCMA-expressing H929 cells in vitro (right panel). EC50 values ​​were calculated as described in Methods. Representative data shown here are from a single experiment. [Figure 12] Figure 1 shows that Vβ17 antibody (Vb17_210E10A1-Fab-RF, BCMB519-scFv (B17B624.001)) binds to T cells (left panel) and mediates T cell cytotoxicity against BCMA-expressing H929 cells in vitro (right panel). EC50 values ​​were calculated as described in the Methods. Representative data shown here are from a single experiment. [Figure 13] FIG. 1 shows that the control antibody (B21M-Fab-RF x BCMB519-LH-scFv(B17B612.001) does not bind to T cells (left panel) or mediate T cell cytotoxicity against BCMA-expressing H929 cells in vitro (right panel). Representative data shown here are from a single experiment. [Figure 14] Figure 1 shows that Vα10.2 antibody (α10.2-TRVAB1-Fab-RF x BCMB519-scFv(B17B621.001) activates T cells (right panel) and mediates T cell cytotoxicity against BCMA-expressing H929 cells in vitro (left panel). EC50 values ​​were calculated as described in Methods. Representative data shown here are from a single experiment. [Figure 15] Figure 1 shows that the Vα10.2 antibody (α10.2-TRVAB2-Fab-RF x BCMB519-scFv(B17B627.001) activates T cells (right panel) and mediates T cell cytotoxicity against BCMA-expressing H929 cells in vitro (left panel). EC50 values ​​were calculated as described in Methods. Representative data shown here are from a single experiment. [Figure 16A]Figure 1 shows evaluation of cytolysis mediated by various concentrations of anti-DLL3x Vβ17 antibody under different E:T ratios of PAN-T to tumor and Vβ17 to tumor compared to HCC1833 cells alone. Figure 1 shows cytolysis of cells mediated by different concentrations of bispecific anti-DLL3x Vβ17 antibody with E:T ratios of 5:1 for PAN-T to tumor and 0.25:1 for Vβ17 to tumor. [Figure 16B] Figure 1 shows evaluation of cytolysis mediated by various concentrations of anti-DLL3x Vβ17 antibody under different E:T ratios of PAN-T to tumor and Vβ17 to tumor compared to HCC1833 cells alone. Figure 1 shows cell cytolysis mediated by different concentrations of bispecific anti-DLL3x Vβ17 antibody with E:T ratios of 10:1 for PAN-T to tumor and 0.5:1 for Vβ17 to tumor. Impedance was recorded every 15 minutes for 120 hours, and the percent cytolysis rate relative to HCC1833 tumor cells alone was calculated using RTCA software. [Figure 17A] Figure 1 shows evaluation of cytolysis mediated by various concentrations of anti-DLL3x Vβ17 antibody under different E:T ratios of PAN-T to tumor and Vβ17 to tumor compared to G361 cells alone.Figure 1 shows cytolysis of cells mediated by various concentrations of bispecific anti-DLL3 x Vβ17 antibody in G361, 5:1 for PAN-T to tumor and 0.25:1 for Vβ17 to tumor. [Figure 17B] Figure 1 shows evaluation of cytolysis mediated by various concentrations of anti-DLL3x Vβ17 antibody under different E:T ratios of PAN-T to tumor and Vβ17 to tumor compared to G361 cells alone. Figure 1 shows cytolysis of cells mediated by various concentrations of bispecific DLL3 x Vβ17 antibody in G361, 10:1 for PAN-T to tumor and 0.5:1 for Vβ17 to tumor. [Figure 18A]Figure 1 shows cytotoxicity mediated by bispecific anti-DLL3 x Vβ17 antibody.Figure 1 shows cytotoxicity mediated by 90 nM bispecific anti-DLL3xVβ17 antibody against DLL3-expressing target cells at effector to target ratios (E:T) of 0.5:1, 0.25:1, and 0.125:1, respectively. [Figure 18B] Figure 1 shows cytotoxicity mediated by bispecific anti-DLL3 x Vβ17 antibodies.Figure 1 shows cytotoxicity mediated by 30 nM bispecific anti-DLL3xVβ17 antibodies against DLL3-expressing target cells at effector to target ratios (E:T) of 0.5:1, 0.25:1, and 0.125:1, respectively. [Figure 18C] Figure 1 shows cytotoxicity mediated by bispecific anti-DLL3 x Vβ17 antibodies.Figure 1 shows cytotoxicity mediated by 10 nM bispecific anti-DLL3xVβ17 antibodies against DLL3-expressing target cells at effector to target ratios (E:T) of 0.5:1, 0.25:1, and 0.125:1, respectively. [Figure 19A] Figure 1 shows cytotoxicity mediated by bispecific anti-DLL3xVβ17 antibody against DLL3-expressing target cells. Figure 1 shows cytotoxicity mediated by bispecific anti-DLL3xVβ17 antibody against DLL3-expressing target cells. Total PBMCs from two donors were cultured with DLL3+HCC1833-NLR in the presence of anti-DLL3xVβ17 antibody at E:T ratios (Vβ17:target) of 1:1, 0.5:1, and 0.25:1, respectively. [Figure 19B] Figure 1 shows cytotoxicity mediated by bispecific anti-DLL3xVβ17 antibodies against DLL3-expressing target cells. Figure 1 shows cytotoxicity mediated by bispecific anti-DLL3xVβ17 antibodies against DLL3-expressing target cells. Total PBMCs from two donors were cultured with G361-NLR cells in the presence of anti-DLL3xVβ17 antibodies at E:T ratios (Vβ17:target) of 1:1, 0.5:1, and 0.25:1, respectively. [Figure 20A]Figure 1 shows the proliferation and frequency of Vβ17 T cells in response to different concentrations of anti-DLL3×Vβ17 antibody, and Figure 2 shows the proliferation rate (%) of Vβ17 T cells in response to different concentrations of anti-DLL3×Vβ17 antibody (DL3B588). [Figure 20B] 1 shows the proliferation and frequency of Vβ17 T cells in response to different concentrations of anti-DLL3×Vβ17 antibody, and the frequency of Vβ17 T cells in response to different concentrations of anti-DLL3×Vβ17 antibody (DL3B588). [Figure 21A] Figure 1 shows evaluation of cell lysis by four bispecific anti-PSMA x Vβ17 antibodies at a PAN-T to tumor E:T ratio of 10:1 and different Vβ17 to tumor E:T ratios (donor #1:0.5:1, donor #2:0.3:1, donor #3:0.5:1). Figure 2 shows cell lysis mediated by different concentrations of a bispecific anti-PSMA x Vβ17 antibody (VB17B3). [Figure 21B] Figure 1 shows evaluation of cell lysis by four bispecific anti-PSMA x Vβ17 antibodies at different PAN-T to tumor E:T ratios of 10:1 and Vβ17 to tumor E:T ratios (donor #1:0.5:1, donor #2:0.3:1, donor #3:0.5:1). Figure 2 shows cell lysis mediated by different concentrations of bispecific anti-PSMA x Vβ17 antibody (VB17B4). [Figure 21C] Figure 1 shows evaluation of cell lysis by four bispecific anti-PSMA x Vβ17 antibodies at a PAN-T to tumor E:T ratio of 10:1 and different Vβ17 to tumor E:T ratios (donor #1:0.5:1, donor #2:0.3:1, donor #3:0.5:1). Figure 2 shows cell lysis mediated by different concentrations of a bispecific anti-PSMA x Vβ17 antibody (VB17B5). [Figure 21D]Figure 1 shows evaluation of cytolysis by four bispecific anti-PSMA x Vβ17 antibodies at a PAN-T to tumor E:T ratio of 10:1 and different Vβ17 to tumor E:T ratios (donor #1:0.5:1, donor #2:0.3:1, donor #3:0.5:1). Figure 2 shows cytolysis mediated by different concentrations of a bispecific anti-PSMA x Vβ17 antibody (VB17B6). Impedance was recorded every 15 minutes for 120 hours, and the percentage cytolysis of C42b tumor cells alone was calculated using RTCA software. [Figure 22A] Figure 1 shows binding of Vβ17xPSMA antibody to Pan T cells, binding quantified based on MFI values. [Figure 22B] Figure 1 shows binding of Vβ17xPSMA antibody to Pan T cells. Binding was quantified based on percent binding. Both donors NHV21-07171 and NHV-07174 showed good binding of VB17B25 (Vβ17xPSMA) to Pan T cells. No binding of PSMB2951 (nullxPSMA) antibody was observed in Pan T cells. [Figure 23] Figure 1 shows binding of Vβ17xPSMA antibodies to C42B cells. Binding of VB17B25 (Vβ17xPSMA) and PSMB2951 (NullxPSMA) was observed. No binding was observed with VB17B23 (Vβ17xNull) antibody on C4-2B cells. [Figure 24A] Figure 1 shows cytotoxicity mediated by Vβ17 xPSMA bispecific antibodies against C4-2B cells. Using whole PBMCs as effector cells, donors NHV21-07171 and NHV-07174 exhibited potent, dose-dependent cytotoxicity against C4-2B cells. No cytotoxicity was observed with null antibodies (VB17B23 and PSMB2951). [Figure 24B]Figure 1 shows cytotoxicity mediated by Vβ17 xPSMA bispecific antibody against C4-2B cells. When Pan T cells were used as effector cells, donor NHV21-07171, together with VB17B25, exhibited potent dose-dependent cytotoxicity against C4-2B cells. No cytotoxicity was observed with null antibodies (VB17B23 and PSMB2951). No cytotoxicity was observed with a second donor (NHV21-07174) using the VB17B25 antibody. [Figure 24C] Figure 1 shows cytotoxicity mediated by Vβ17 xPSMA bispecific antibody against C4-2B cells. When whole PBMCs were used as effector cells, donors NHV21-08653 and NHV-08227 were cytotoxic to C4-2B cells, but donor NHV21-08227 showed a maximum target cell lysis rate of only 20%. Donor NHV21-08653 showed potent cytotoxicity. [Figure 24D] Figure 1 shows cytotoxicity mediated by Vβ17 xPSMA bispecific antibody against C4-2B cells. When Pan T cells were used as effector cells, donors NHV21-08653 and NHV-08227 exhibited cytotoxicity against C4-2B cells, but donor NHV21-08227 exhibited a maximum target cell lysis rate of only 20%. Donor NHV21-08653 exhibited potent cytotoxicity. [Figure 25] Figure 1. Vβ17xPSMA bispecific antibody-mediated T cell activation. Total PBMCs and Pan T cells were cultured with C4-2B target cells for 72 hours in the presence of the bispecific at a top concentration of 10 μg / mL, followed by a 3-fold dilution at 0.4 μg / mL. At 72 hours, cells were harvested and analyzed for CD25 and CD71, gating on CD3 T cells. [Figure 26A] Figure 26 shows a bispecific antibody with one Vβ17 binding arm. The structure of a bispecific antibody with a Vβ17 Fab is shown in Figure 26A. The structure of a bispecific antibody with a Vβ17 Fab is shown in Figure 26B. [Figure 26B] Figure 26 shows a bispecific antibody with one Vβ17 binding arm. The structure of a bispecific antibody with a Vβ17 Fab is shown in Figure 26A. The structure of a bispecific antibody with a Vβ17 Fab is shown in Figure 26B.

[0082] (Detailed description) Various publications, articles and patents are cited in the Background section and throughout this specification. or described herein, each of which is incorporated herein by reference in its entirety. Any discussion of documents, operations, materials, devices, articles or the like which has been included in the specification is without limitation in the context of the present invention. Such discussion is intended to provide a general understanding of the invention and its applications. or admitted to constitute part of the prior art to any claimed invention. It's not that.

[0083] Unless otherwise defined, all technical and scientific terms used herein refer to the It has the same meaning as commonly understood by one of ordinary skill in the art to which it pertains. Certain terms used herein have the meanings set forth herein.

[0084] As used in this specification and the appended claims, the singular forms "a," "an," and "t" It should be noted that "he" includes multiple referents unless the context makes clear otherwise. be.

[0085] Unless otherwise specified, any numerical values, such as concentrations or concentration ranges, described herein are In all cases, the terms "about" and "about" should be understood as being modified. Therefore, values ​​usually include ±10% of the stated value. For example, 1 mg / mL Concentrations of 0.9 mg / mL to 1.1 mg / mL are included. Similarly, 1% to 10% (w / v) The concentration range of is inclusive of 0.9% (w / v) to 11% (w / v). The use of a numerical range refers to the integers and numbers within that range unless the context clearly indicates otherwise. All possible subranges, including fractions of values, explicitly include all individual numbers within the range. nothing.

[0086] Unless otherwise indicated, the term "at least" preceding a series of elements refers to every element in the series. It should be understood that the term "antibody" refers to a compound that is easily identified by one skilled in the art using no more than routine experimentation. In the art, one may recognize many equivalents to the specific embodiments of the invention described herein, or Such equivalents are intended to be encompassed by this invention. do.

[0087] As used herein, the terms "comprises," "comprising," "includes," "including," "has," "having ), "contains," or "containing," or any of these Any other variations are intended to include the stated integer or groups of integers, but this It does not exclude any other integer or group of integers other than these, and is non-exclusive or non-limiting. It will be understood that the term "composition, mixture, process" is intended to include, for example, a series of elements. The terms "method, article, or apparatus" are not necessarily limited to only those elements, and should not be construed as limiting the scope of the invention. Any composition, mixture, process, method, article, or device not specifically listed or Additionally, unless expressly stated to the contrary, "Or" refers to an inclusive "or" and not to an exclusive "or." For example, condition A or B is a condition where A is true (or exists) and B is false (or does not exist). If A is false (or does not exist) and B is true (or exists), then and if both A and B are true (or exist), then can be.

[0088] As used herein, the conjunction "and / or" between multiple listed elements The term is understood to encompass both individual and combined options, e.g. When two elements are connected by "and / or," the first option is the second option, etc. The second option refers to the second option without the first option. The third option indicates that the first and second elements are applicable together. Any one of these options is included in the meaning and therefore It is understood that the terms "and / or" are satisfied when used herein. The simultaneous applicability of two or more of the alternatives is also included in the meaning, hence the term "and / or" It is understood that the requirements of "

[0089] As used herein, the term "consists of" or "consists of" Variations such as "one of" or "consisting of" are used throughout the specification and claims. When used throughout a range, any recited integer or group of integers is inclusive, but additional indicates that no integer or group of integers of the formula (I) is added to the specified method, structure, or composition. .

[0090] As used herein, the term "consists essentially of" means or "consist essentially of" or "consist essentially of" Variations such as "consisting essentially of" are used throughout the specification and claims. When used, it encompasses any enumerated integer or group of integers, and optionally includes the integers in the specified manner, structure, or both. Any enumerated integer or integers that do not materially alter the basic or novel characteristics of the structure or composition. indicates that the set of integers is also included. See MPEP §2111.03.

[0091] As used herein, a "subject" refers to any animal, preferably a mammal, most preferably a As used herein, the term "mammal" refers to any animal. Examples of mammals include, but are not limited to, cows, Horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc. and more preferably humans.

[0092] As used herein, "about" when referring to a size or feature of a component of the present invention, Terms such as "approximately," "generally," and "substantially" are used to describe The dimensions / characteristics of the products are not strict boundaries or parameters, but are functionally the same or similar, It should also be understood that this does not exclude slight variations from the minimum value. In this regard, such references, including numerical parameters, are within the scope of art-accepted principles. mathematical and engineering principles (e.g., rounding, measurement or other systematic errors, manufacturing tolerances, etc.) that govern When used, the least significant digit will contain the variant that remains unchanged.

[0093] The terms "identical" or percent "identity" refer to the identity of two or more nucleic acid or polypeptide sequences. sequences (e.g., anti-Vβ17 / anti-cancer-associated antigen bispecific antibodies and polynucleotides encoding same) Anti-Vβ17 / anti-CD123 bispecific antibody and polynucleotide encoding same Vβ17 polypeptide and Vβ17 polynucleotide encoding the same, CD123 The following sequences are related to the CD123 polypeptide and the CD123 polynucleotide encoding it: Matches are found when measured using one of the column comparison algorithms or by visual inspection. Identical when compared and aligned to maximize or a certain percentage Refers to two or more sequences or subsequences that have the same amino acid residues or nucleotides .

[0094] For sequence comparison, typically one sequence is a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are compared. The array is input to the computer, sub-array coordinates are specified as needed, and the array algorithm program The program parameters are then specified. The sequence comparison algorithm then Calculate the percent sequence identity of the test sequence relative to the reference sequence based on the system parameters .

[0095] Optimal alignment of sequences for comparison can be performed using, for example, Smith & Waterman Local homology algorithms in Adv. Appl. Math. 2:482 (1981) Zum, Needleman & Wunsch, J. Mol. Biol. 48:443 (19 70) Homology Alignment Algorithm, Pearson & Lipman, Pr Similarity search for oc. Nat'l. Acad. Sci. USA 85:2444 (1988) Methods, computerized implementations of these algorithms (Wisconsin Gen etics Software Package,Genetics Computer GAP Group, 575 Science Dr., Madison, WI , BESTFIT, FASTA, and TFASTA), or visual inspection (generally, Cu rrent Protocols in Molecular Biology,FM .Ausubel et al.,eds.,Current Protocols,a joint venture between Greene Publishing Associates, Inc. and John Wiley&Sons, Inc. , (1995 Supplement) (see Ausubel) It is possible to do so.

[0096] An example of a suitable algorithm for determining percent sequence identity and sequence similarity is Alt Schul et al.,(1990)J.Mol.Biol.215:403-41 0 and Altschul et al., (1997) Nucleic Acids R BLAST and BLAST2, respectively, as described in es.25:3389-3402. The software that performs the BLAST analysis is the National Center for Biotechnology Information. Publicly available through the National Center for Biotechnology Information The algorithm first aligns the word with a word of the same length in the database sequence. Either they match when combined, or they meet some positive threshold score T. High-scoring sequence pairs are found by identifying short words of length W in the query sequence. This involves identifying high-scoring sequence pairs (HSPs). These initial neighborhood words are called the threshold (Altschul et al., supra). The hit serves as a seed for initiating a search to find longer HSPs containing it. Then, each sequence is added as far as it can to increase the cumulative alignment score. The word hits are extended in both directions along the

[0097] For nucleotide sequences, the parameter M (reward for a pair of matching residues) The core, which is always greater than 0, and the parameter N (the penalty for mismatched residues) The cumulative score is calculated using the identity score (which is always less than 0). For , a scoring matrix is ​​used to calculate the cumulative score. When a score drops by an amount X from its maximum attainable value, one or more negative score reports When the cumulative alignment of binding residues results in a cumulative score of zero or less, or The extension of the word hits in each direction stops when the end of the sequence is reached. The parameters W, T, and X of the T algorithm determine the sensitivity and speed of the registration. The BLASTN program (for nucleotide sequences) defaults to a word length of Use (W) 11, expectation (E) 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program defaults to a word length of 3, expectation (E) 10, and using the BLOSUM62 scoring matrix (H enikoff&Henikoff,Proc.Natl.Acad.Sci.USA 89:10915 (1989).

[0098] In addition to calculating percent sequence identity, the BLAST algorithm also calculates the percent sequence identity between two sequences. Statistical analysis of similarities between columns is also performed (e.g., Karlin & Altschul, Proc. See Nat'l. Acad. Sci. USA 90:5873-5787 (1993). One measure of similarity provided by the BLAST algorithm is the minimum similarity The total probability (P(N)) between two nucleotide sequences or two amino acid sequences is For example, nucleic acids may be used to identify a test nucleic acid and a reference nucleic acid, providing an indication of the probability that a match between the test nucleic acid and the reference nucleic acid would occur by chance. The minimum sum probability in the comparison is less than about 0.1, more preferably less than about 0.01, and most preferably Preferably, an α value of less than about 0.001 is considered similar to the reference sequence.

[0099] Further indications that two nucleic acid sequences or polypeptides are substantially identical include the following: As described above, the polypeptide encoded by the first nucleic acid is a polypeptide encoded by the second nucleic acid. Therefore, the polypeptide is immunologically cross-reactive with the polypeptide The first polypeptide is typically substantially identical to the second polypeptide, e.g., the two peptides are conserved. Another indication that two nucleic acid sequences are substantially identical is that the two sequences differ only by complementary substitutions. The molecules hybridize to each other under stringent conditions.

[0100] As used herein, the term "polynucleotide" is used interchangeably with "nucleic acid molecule." , also called "nucleotides" or "nucleic acids," and may be unmodified RNA or DNA or modified RNA or DNA. Any polyribonucleotide or polydeoxyribonucleotide, which may be NA or DNA. "Polynucleotide" refers to single-stranded and double-stranded DNA, DNA, which is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and single- and double-stranded RNA. RNA that is a mixture of stranded regions, single-stranded or more typically double-stranded or single- and double-stranded Although hybrid molecules containing DNA and RNA may be a mixture of regions of In addition, "polynucleotide" refers to RNA or DNA, or The term polynucleotide refers to triple-stranded regions that contain both RNA and DNA. DNA or RNA containing one or more modified bases, and for stability or other reasons This also includes DNA or RNA with backbones modified by Examples include tritylated bases and unusual bases, such as inosine. and RNA. Thus, a "polynucleotide" is typically a naturally occurring Chemically, enzymatically, or metabolically modified forms of recognized polynucleotides, as well as viruses. Polynuclear molecules include chemical forms that have the characteristics of DNA and RNA in cells. "Tide" also includes relatively short nucleic acid strands (often referred to as oligonucleotides). do.

[0101] As used herein, the term "vector" refers to a vector that functionally carries another nucleic acid segment. A replicon into which a segment can be inserted to replicate or express that segment. And so.

[0102] As used herein, the term "host cell" refers to a cell that contains a nucleic acid molecule of the invention. A "host cell" refers to, for example, a primary cell, a cell in culture, or a cell from a cell line. In one embodiment, a "host cell" is a cell of any type disclosed herein. In another embodiment, a "host cell" is a cell that has been transfected with a nucleic acid molecule comprising the The progeny of such a transfected cell are the progeny or potential progeny of the cell. , mutations or environmental influences that may occur in subsequent generations, or nuclear changes to the host cell genome. Depending on the incorporation of acid molecules, it may or may not be identical to the parent cell.

[0103] As used herein, the term "expression" refers to the biosynthesis of a gene product. The term encompasses the transcription of a gene into RNA. The term also encompasses the transcription of one or more copies of RNA. The present invention also encompasses translation of the polypeptide into a polypeptide of interest, including all naturally occurring, post-transcriptional and post-translational modifications. The expressed bispecific antibody may be present in the cytoplasm of the host cell, in the growth medium of the cell culture, etc. It may be present in the extracellular environment or may be anchored in the cell membrane.

[0104] As used herein, the terms "peptide," "polypeptide," or "protein" The term can refer to molecules composed of amino acids and are known by those skilled in the art as proteins. In this specification, the conventional one-letter or three-letter codes for amino acid residues are used. The terms "peptide," "polypeptide," and "protein" refer to any length of peptide. and 2,3,4-trimethylamino acid (AMINOAC) and 2,4,5-trimethylamino acid (AMINOAC) can be used interchangeably herein to refer to a polymer of amino acids of a length The polymer may be linear or branched, may comprise modified amino acids, or The term may also refer to naturally modified or The present invention also includes amino acid polymers that have been modified by an intervention. Examples of such interventions include, for example, Disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other Manipulation or modification, for example, conjugation with a labeling component, may also be included. Contains one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.) Polypeptides, as well as other modifications known in the art, are included within the definition.

[0105] The peptide sequences described herein are written according to the usual convention and include the N-terminal region of the peptide. The C-terminal region is on the left and the C-terminal region is on the right. The isomeric forms of the amino acids are known, but are not shown separately. Unless explicitly stated, it is the L-form of the amino acid that is shown.

[0106] antibody Anti-Vβ17 antibody or antigen-binding fragment thereof, nucleic acid encoding said antibody and expression vector The vector, recombinant cells containing the vector, and compositions containing the antibody are described herein. In certain embodiments, an isolated anti-Vβ17 bispecific antibody or its antigen-binding fragments, nucleic acids and expression vectors encoding the antibodies, Recombinant cells comprising the bispecific antibody are provided, as well as compositions comprising the bispecific antibody. Methods for making and using the antibodies to treat disease are also provided. The disclosed antibodies include high affinity binding to Vβ17 or high specificity for Vβ17. Possess one or more desirable functional properties, including but not limited to: In some embodiments, the antibodies disclosed herein may be used alone or in combination with other therapies. When administered to an elephant, it has the ability to treat or prevent a disease or disorder.

[0107] Also, an anti-Vβ17 bispecific antibody or an antigen-binding fragment thereof, a nucleic acid encoding the antibody, Nucleic acids and expression vectors for the preparation of bispecific antibodies, recombinant cells containing the vectors, and bispecific antibodies Methods for producing such antibodies and methods for treating diseases, including cancer, are provided herein. Also provided are methods of using bispecific antibodies to , and have one or more desirable functional properties. The bispecific antibodies provided herein have high affinity binding to Vβ17. In some embodiments, the bispecific antibodies provided herein have high affinity binding to a second target antigen. In some embodiments, the bispecific antibodies provided herein target Vβ17. In some embodiments, the bispecific antibodies provided herein have high specificity. The body has high specificity for the second target antigen. The bispecific antibodies provided herein have high specificity for CD123. In embodiments, the bispecific antibodies provided herein have high specificity for BCMA. In some embodiments, the bispecific antibodies provided herein target DLL3. In some embodiments, the bispecific antibodies provided herein have high specificity. In some embodiments, the antibodies provided herein have high specificity for PSMA. The bispecific antibody has high specificity for KLK2. In other words, the bispecific antibodies provided herein are capable of treating a disease or disorder when administered alone. In some embodiments, the bispecific antibodies provided herein have the ability to treat or prevent The antibody may have the ability to treat or prevent a disease or disorder when administered in combination with other therapies. In some embodiments, the disease or disorder is cancer. In the present invention, the disease or disorder is leukemia or lymphoma.

[0108] Also, an anti-Vα10.2 antibody or an antigen-binding fragment thereof, and a nucleic acid encoding the antibody and an expression vector, a recombinant cell containing the vector, and a composition containing the antibody. In certain embodiments, an isolated anti-Vα10.2 bispecific antibody is provided herein. and the like. Recombinant cells containing the vectors are provided, as well as compositions comprising the bispecific antibodies. Methods of making the antibodies and methods of using the antibodies to treat disease are also provided. The antibodies disclosed herein have high affinity binding to Vα10.2 or Vα10.2 binding. one or more desirable functional characteristics, including but not limited to high specificity for In certain embodiments, the antibodies disclosed herein may be used alone or in combination with other antibodies. When administered to a subject in combination with a therapy, the compound has the ability to treat or prevent a disease or disorder. In some embodiments, the bispecific antibodies provided herein bind to a second target antigen. In some embodiments, the bispecific antibodies provided herein have high specificity for The specific antibody has high specificity for CD123. The bispecific antibodies provided herein have high specificity for BCMA. In one embodiment, the bispecific antibodies provided herein have high specificity for DLL3. In some embodiments, the bispecific antibodies provided herein are directed against PSMA. In some embodiments, the bispecific antibodies provided herein have high specificity. In some embodiments, the antibodies provided herein have high specificity for KLK2. The bispecific antibodies described herein have the ability to treat or prevent a disease or disorder when administered alone. In some embodiments, the bispecific antibodies provided herein are administered in combination with other therapies. When administered in combination, they have the ability to treat or prevent a disease or disorder. In some embodiments, the disease or disorder is cancer. , leukemia, or lymphoma.

[0109] As used herein, the term "antibody" is used broadly and includes human, humanized Immunoglobulin or antibody molecules, including monoclonal, composite, and chimeric antibodies, as well as monoclonal or Antibodies generally contain antibodies that are specific to a specific antigen. Antibodies are proteins or peptide chains that exhibit binding specificity. The structure of antibodies is well known. IgA is classified into five major classes (i.e., I, II, III, IV ... IgA and IgD can be assigned to IgE, IgG, and IgM. gG is a subset of the isotypes IgA1, IgA2, IgG1, IgG2, IgG3 and IgG The antibodies provided herein are therefore classified into five major classes: In certain embodiments, The antibodies provided herein are IgG1, IgG2, IgG3, or IgG4. Antibody light chains from vertebrate species are classified into two distinct classes based on the amino acid sequences of their constant domains. can be assigned to one of two types: kappa and lambda. Therefore, the antibodies provided herein may contain a kappa or lambda light chain constant domain. According to certain embodiments, the antibodies disclosed herein are derived from rat or human antibodies. The antibody comprises a heavy chain and / or a light chain constant region.

[0110] In addition to heavy and light chain constant domains, antibodies contain light chain variable regions (VL) and heavy chain variable regions (HV). (VH), each of which contains three domains ( That is, it contains complementarity determining region 1 (CDR1), CDR2, and CDR3. "DR" refers to the non-framework of the immunoglobulin (Ig or antibody) VH β-sheet framework. One of the three hypervariable regions (HCDR1, HCDR2, or H) within the CDR3), or three in the non-framework regions of the antibody VL β-sheet framework The term "LCDR1" refers to one of the hypervariable regions (LCDR1, LCDR2, or LCDR3) of the IgG1 gene. Thus, CDRs are variable region sequences interspersed within framework region sequences. Regions are well known to those skilled in the art and are described, for example, by Kabat as regions within antibody variable (V) domains. The most variable region of the chromosome is defined as the region of the chromosome that is the most variable in the chromosome (Kabat et al., J. Biol. l.Chem.252:6609-6616(1977), Kabat,Adv.Pro Chem. 32:1-75 (1978)). The CDR region sequences also contain conserved β- Residues that are not part of the sheet framework and can therefore adapt to various conformations It is structurally defined by Chothia as esk, J. Mol. Biol. 196:901-917 (1987). Both terms are CDR region sequences are also well recognized in the art. Exemplary CDR region sequences are defined herein. , for example, in the Sequence Listing and in the tables provided in the Examples below. The location of the CDRs within the region has been determined by comparison of multiple structures (Al-Lazik ani et al., J. Mol. Biol. 273:927-948 (1997), Morea et al., Methods 20:267-279(2000)). Super The number of residues in the variable region varies in different antibodies, so additional residues relative to the canonical positions Traditionally, the standard variable region numbering scheme (Al-Lazikani et al., The residue numbers are assigned by adding a, b, c, etc. to the residue numbers in (1997) above. Such nomenclature is well known to those skilled in the art.

[0111] The light chain variable region CDR1 domain is referred to herein as LCDR1 or VL CDR1 The light chain variable region CDR2 domain is referred to herein as LCDR2. The light chain variable region CDR3 domain is referred to herein as a CDR2 domain or VL CDR2. In this context, it is interchangeably referred to as LCDR3 or VL CDR3. The heavy chain CDR1 is referred to herein interchangeably as HCDR1 or VH CDR1. The variable region CDR2 domain is referred to herein interchangeably as HCDR2 or VH CDR2. The heavy chain variable region CDR1 domain is referred to herein as HCDR3 or VH It is referred to interchangeably as CDR3.

[0112] As used herein, the term "hypervariable region" such as VH or VL refers to a region that is hypervariable in sequence. Refers to the regions of an antibody variable region that are variable and / or form structurally defined loops Generally, antibodies consist of six hypervariable regions: VH (HCDR1, HCDR2, HC 3) and 3) VL (LCDR1, LCDR2, LCDR3). The following hypervariable region delineations are used and encompassed herein. The "Kabat" CDRs are , which are based on sequence variability and are the most commonly used (e.g., Kabat et al., Sequences of Proteins of Immunolo gical Interest,5th Ed.Public Health Serv ice,National Institutes of Health,Bethes (See, e.g., da, MD. (1991)). "Chothia" instead The position of the structural loop (e.g., Chothia and Lesk, J. Mol. Biology ol.196:901-917 (1987). Using the Kabat numbering convention, The ends of the Chothia CDR-HCDR1 loop, when numbered using It varies from H32 to H34 depending on the length (this is because the Kabat numbering scheme uses H3 This is to place an insertion in H35A and H35B. If neither 35A nor 35B is present, If only 35A is present, the loop ends at 33, and if only 35A is present, the loop ends at 35A and 35B. The "AbM" hypervariable region is a region of interest that is associated with Kaba It represents a compromise between the CDRs and the Chothia structural loops, and is used by AbM antibody modeling software from Quantum (e.g., Ma rtin,in Antibody Engineering,Vol.2,Chapt. (See er 3, Springer Verlag). The variable regions are based on an analysis of available complex crystal structures.

[0113] Recently, a universal numbering system, ImMunoGeneTics (IMGT) Inf ormation System (registered trademark) (Lafranc et al., Dev Comp.Immunol.27(1):55-77(2003)) has been developed and widely used. IMGT is a system for immunoglobulin (IG), T cell receptor (T cell receptor, TR), and the major histocompatibility complex (MHC) in humans and other vertebrates. The MHC is an integrated information system specializing in the human histocompatibility complex (MHC). In this context, a CDR is referred to in terms of both amino acid sequence and location within a light or heavy chain. The "position" of the CDRs within the structure of immunoglobulin variable domains is conserved among species, They exist in structures called loops, which allow the variable domain sequences to be aligned according to their structural features. By using the numbering system, CDR and framework residues are easily identified. This information is used to map CDR residues from immunoglobulins of one species, typically from human antibodies. It can be used to port and replace the acceptor framework of Honeg. Ger and Pluckthun, J. Mol. Biol. 309:657-670 (2001) developed a further numbering system (AHon). For example, K The correspondence between numbering systems, including the abat numbering and IMGT specific numbering systems, is The methods are well known to those skilled in the art (e.g., Kabat, supra; Chothia and Lesk, supra; Ma rtin, supra; Lefranc et al., supra). An exemplary system is a combination of Kabat and Chothia.

[0114] [Table 1]

[0115] The hypervariable region may also include an "extended hypervariable region" such as: 24-36 or 24-34 (LCDR1), 46-56 or 50-56 (LCDR2), and 89-9 7 or 89-96 (LCDR3), and 26-35 or 26-35A in VH (HCD R1), 50-65 or 49-65 (HCDR2), and 93-102, 94-102, or 95-102 (HCDR3). Included in the sequence listing are numbers reflecting each of the above numbering schemes. Corresponding CDR sequences are provided herein.

[0116] The term "constant region" or "constant domain" refers to the region of the antibody that is directly involved in binding to an antigen. Although they do not interact with Fc receptors, they are composed of light and heavy chains that exhibit various effector functions, such as interaction with Fc receptors. The term refers to the carboxy-terminal portion of an immunoglobulin that is the variable region containing the antigen-binding site. an immunoglobulin molecule that has a more conserved amino acid sequence compared to other parts of the immunoglobulin The constant region refers to the CH1, CH2, and CH3 regions of the heavy chain and the CL region of the light chain. It may contain a region.

[0117] The term "framework" or "FR" residues refers to the variable region residues that flank the CDRs. The FR residues are useful in, for example, chimeric antibodies, humanized antibodies, human antibodies, domain antibodies, and dialyzed antibodies. FR residues are present in antibodies, linear antibodies, and bispecific antibodies. These are variable domain residues other than the CDR residues.

[0118] As used herein, the term "isolated antibodies" refers to antibodies having different antigen specificities. refers to an antibody that is substantially free of other antibodies that bind to Vβ17 (e.g., an isolated antibody that specifically binds to Vβ17). The antibodies obtained are substantially free of antibodies that do not bind to Vβ17 and are directed against a second target (e.g., CD1 23, BCMA, DLL3, PSMA, or KLK2) The body may also target a second target (e.g., CD123, BCMA, DLL3, PSMA, or KLK2 Furthermore, isolated antibodies are free from other cellular material and and / or substantially free of chemicals.

[0119] As used herein, the term "monoclonal antibody" refers to a substantially homogeneous antibody. This refers to antibodies obtained from a population of antibodies, meaning that the individual antibodies that make up the population are present in minute amounts. The monoclonal antibodies disclosed herein are identical except for naturally occurring mutations that may occur. Hybridoma method, phage display technology, single lymphocyte gene cloning technology, or can be produced by recombinant DNA methods. For example, monoclonal antibodies can be produced by recombinant DNA technology. derived from a transgenic non-human animal, e.g., a transgenic mouse or rat. A human heavy chain transgene and a human light chain transgene can be produced by a hybridoma containing B cells. It has a genome that includes offspring.

[0120] As used herein, the term "antigen-binding fragment" refers to, for example, a diabodies Di, Fab, Fab', F(ab')2, Fv fragment, disulfide-stabilized Fv Fragment (disulfide stabilized Fv, dsFv), (dsFv)2, bispecific sFv (dsFv-dsFv'), disulfide-stabilized diabody (ds diabody ), single-chain antibody molecules (scFv), single domain antibodies (sdAb ) scFv dimers (bivalent diabodies), antibody moieties containing one or more CDRs Multispecific antibodies formed from single domains, camelized single domain antibodies, nanobodies, and domain antibodies a monoclonal antibody, a bivalent domain antibody, or any other antibody that binds to an antigen but does not contain a complete antibody structure Antigen-binding fragments refer to antibody fragments such as fragments of the parent antibody or parent anti-antigen. According to a particular embodiment, the antibody fragment is capable of binding to the same antigen to which the antibody fragment binds. The antigen-binding fragment contains a light chain variable region, a light chain constant region, and an Fd fragment of the heavy chain. According to other particular embodiments, the antigen-binding fragments include Fab and F(ab'). include.

[0121] As used herein, the term "single chain antibody" refers to a single chain antibody of about 15 to about 20 amino acids. In this field, there are known As used herein, the term "single domain antibody" refers to a single chain antibody known in the art. The term may be used in the art to refer to a heavy chain variable region and a heavy chain constant region, or to refer to a heavy chain variable region only. It refers to a single domain antibody known in the art.

[0122] As used herein, the term "human antibody" refers to an antibody produced by a human, or human-produced, produced using any technique known in the art. This definition of a human antibody refers to an antibody having an amino acid sequence corresponding to an antibody produced by the antibody. a recombinant or full-length antibody, a fragment thereof, and / or at least one human heavy chain The present invention includes antibodies comprising either a monoclonal antibody or a monoclonal antibody, including monoclonal and / or monoclonal antibody containing light chain polypeptides.

[0123] As used herein, the term "humanized antibody" refers to an antibody in which the antigen-binding properties of the antibody are retained. However, the sequence of the antibody is modified to reduce the antigenicity of the antigen in the human body. This refers to a non-human antibody that has been homogenized.

[0124] As used herein, the term "chimeric antibody" refers to an antibody that is a chimeric antibody having an amino acid sequence similar to that of an immunoglobulin molecule. It refers to an antibody whose nucleic acid sequences are derived from two or more species. The variable regions of both the light and heavy chains are , often a mammalian species (e.g., a mammalian cell) with the desired specificity, affinity, and capacity. The constant regions correspond to the variable regions of antibodies derived from mice, rats, rabbits, etc. To avoid eliciting an immune response in the target species, the antibody may be derived from another mammalian species (e.g., human). This corresponds to the sequence of the antibody that will be produced.

[0125] The term "specificity" refers to the binding of an antigen-binding protein (such as an antibody) to a particular epitope of an antigen. As used herein, the term refers to the selective recognition of a specific antibody. Natural antibodies, for example, are monospecific. The term "multispecific" refers to an antigen-binding protein (such as an antibody) that binds to two or more antigens. The term "antigen binding site" refers to a set of antigen-binding sites, at least two of which bind to different antigens. As used herein, "bispecific" refers to an antigen-binding protein that has two different antigen-binding specificities. It means that you have.

[0126] As used herein, the term "multispecific antibody" refers to a antibody that binds to multiple immunoglobulins. refers to an antibody comprising a first immunoglobulin variable domain sequence of a plurality of The antibody has binding specificity for a first epitope and is capable of binding to a second immunoglobulin of a plurality of The variant domain sequence has binding specificity for a second epitope. The first and second epitopes do not overlap or do not substantially overlap. The first and second epitopes may be located on different antigens, e.g., different proteins (or multimers). In one embodiment, the multispecific antibody comprises a third In one embodiment, the multispecific antibody comprises a first, fourth, or fifth immunoglobulin variable domain. The antibody may be a bispecific antibody molecule, a trispecific antibody molecule, or a tetraspecific antibody molecule.

[0127] As used herein, the term "bispecific antibody" refers to an antibody that targets two or fewer epitopes or refers to a multispecific antibody that binds to two or fewer antigens. A bispecific antibody binds to a first epitope and a first immunoglobulin having binding specificity for an epitope (e.g., an epitope on the Vβ17 antigen) a purine variable domain sequence and a second immunization antibody having binding specificity for a second epitope; In one embodiment, the first and second globulin variable domain sequences are Epitopes may be present on different antigens, e.g., different proteins (or different regions of a multimeric protein). In one embodiment, the bispecific antibody is located on a first epitope. a heavy chain variable domain sequence and a light chain variable domain sequence having binding specificity for a second heavy chain variable domain sequences and light chain variable domain sequences having binding specificity for a target antigen; In certain embodiments, the bispecific antibody comprises a first epitope and a second epitope. a half antibody or fragment thereof having binding specificity for a second epitope; In one embodiment, the bispecific antibody comprises a first epitope and a second epitope. an scFv or fragment thereof having binding specificity for a second epitope; In one embodiment, the scFv or fragment thereof has binding specificity for The first epitope is located on Vβ17 and the second epitope is located on CD123. In embodiments, the first epitope is located on Vβ17 and the second epitope is located on PD-1 , PD-L1, CTLA-4, EGFR, HER-2, CD19, CD20, CD3, and and / or other tumor-associated immunosuppressive factors or surface antigens. One epitope is located on Vβ17 and the second epitope is located on BCMA. In this embodiment, the first epitope is located in Vβ17 and the second epitope is located in DLL3. In one embodiment, the first epitope is located in Vβ17 and the second epitope is located in PS In one embodiment, the first epitope is located in Vβ17 and the second epitope is located in MA. Tope is located at KLK2.

[0128] As used herein, the term "valency" refers to the ability of an antigen-binding protein (such as an antibody) to bind to a specific molecule. For example, a native or full-length antibody has two binding sites. The term "trivalent," "tetravalent," "pentavalent," and "hexavalent" refers to a molecule that has a binding site and is bivalent. The term "antibody" refers to two binding sites, one of which is an antigen-binding protein (such as an antibody), and the other of which is an antibody. The presence of three binding sites, four binding sites, five binding sites, and six binding sites was demonstrated. vinegar.

[0129] As used herein, the term "half antibody" refers to an antibody that is associated with one immunoglobulin light chain. Those skilled in the art will understand that a half antibody is a fragment of an immunoglobulin heavy chain that contains the fragment. For example, an antigen-binding domain consisting of a single variable domain of Camelidae origin can be included. It will be readily apparent that the present invention may also have a main.

[0130] As used herein, the term "Vβ17" refers to the immune response to cytotoxic T cells. Vβ17-expressing CD8+ T cells generally express the following T cell receptors: Produced in response to influenza A virus exposure in a subject. Vβ17-expressing CD 8+ T cells result in greater recall in response to influenza exposure in subjects The term "Vβ17" refers to a Vβ17 that is naturally expressed by a cell (including a T cell) or On cells transfected with the gene or cDNA encoding the polypeptide This includes any Vβ17 variant, isoform, and species homolog that can be expressed in a mammal. Unless otherwise stated, preferably, the Vβ17 is human Vβ17. Exemplary Human Vβ17 The amino acid sequence is provided by GenBank accession number AAB49730.1 will be done.

[0131] The term "CD123" refers to the soluble cytokine CD123, which is important in the immune system. It refers to a molecule found on cells that helps transmit the signal of interleukin-3. D123 may also be referred to as the "interleukin-3 receptor." The receptor is a type I cytokine They belong to the CD131 receptor family and share a common beta subunit (beta c or CD131). It is a heterodimer with a unique pair of alpha chains. The CD123 receptor is a pluripotent It can be found on progenitor cells, induces tyrosine phosphorylation in cells, and promotes proliferation and proliferation in hematopoietic cell lines. CD123 can also promote differentiation of acute myeloid leukemia (AML) subtypes. The term "CD123" refers to cells (T cells) unless otherwise specified. (including the gene or gene encoding the polypeptide) Any CD123 variant that can be expressed on cells transfected with the cDNA , isoforms, and species homologues, preferably "CD123" refers to human CD12 3. The human CD123 amino acid sequence is available under GenBank accession number AY78 9109.1 provides.

[0132] As used herein, the term "BCMA" refers to a protein that is predominantly expressed in differentiated plasma cells. BCMA, a member of the tumor necrosis receptor superfamily that is differentially expressed in CD2 69, and human B, also known as TNFRSF17 (UniProt Q02223) An exemplary human BCMA nucleotide sequence is available from GenBank Accession No. 1000001444. Provided by session number BC058291. The human genome contains the BCMA gene There are four major haplotypes, and in this disclosure the term "BCMA" refers to all four (Kawasaki et al., Genes Immun 2:276-9, 2001). According to UniProt, the extracellular domain of human BCMA As used herein, "BC" refers to a sequence consisting of amino acids 1 to 54 (or 5 to 51). The term "antibody against BCMA, i.e., anti-BCMA antibody" refers to an antibody that specifically binds to BCMA. The present invention relates to antibodies.

[0133] As used herein, the term "DLL3" refers to an inhibitory Notch pathway ligand DLL3 is also known as "Delta-like ligand 3." The term "DLL3" refers to the protein naturally expressed by cells (including tumor cells). It may be naturally expressed or transfected with a gene or cDNA encoding the polypeptide. Any DLL3 variant, isoform, or polypeptide that can be expressed on infected cells. and species homologs. In certain embodiments, the DLL3 is human DLL3. According to rot, the extracellular domain of human DLL3 consists of amino acids 27 to 492. As used herein, "antibodies against DLL3," i.e., "anti-DLL3 antibodies," The term relates to an antibody that specifically binds to DLL3.

[0134] As used herein, the term "prostate-specific membrane antigen" or "PSMA" refers to The term refers to a type II membrane protein that is expressed on certain cells. The term "PSMA" refers to HGNC:3788, Entrez Gene:2346, Ensembl:ENSG00000086205, OMIM:600934, and Un The term "PSMA" includes a protein designated iProtKB:Q04609. , which are naturally expressed by cells (including prostate cells) or which encode the polypeptide. Any gene or cDNA that can be expressed on cells transfected with the gene or cDNA that encodes the gene. In certain embodiments, PSMA is a marker for PSMA expression, including PSMA variants, isoforms, and species homologs. MA is human PSMA. As used herein, "antibodies to PSMA" and Thus, the term "anti-PSMA antibody" relates to an antibody that specifically binds to PSMA.

[0135] As used herein, "KLK2" (Kallikrein-related peptidase 2) The term granular kallikrein protein (also known as granular kallikrein protein) refers to Refers to members of the family Kallikreins, clustered on chromosome 19 This family is a subgroup of serine proteases that are highly cleaved. This protein is primarily expressed in prostate tissue and is involved in a range of biological functions. It is involved in cleaving prostate-specific antigen into its enzymatically active form. HGNC:6363, Entrez Gene:3817, Ensembl:ENSG0 0000167751, OMIM:147960, and UniProtKB:P2015 The term "KLK2" refers to a protein that is naturally expressed by cells (including tumor cells). or transfected with a gene or cDNA encoding the polypeptide. Any KLK2 variant, isoform, and species that can be expressed on the injected cells. In certain embodiments, the KLK2 is human KLK2. In this case, the term "antibody against KLK2", i.e., "anti-KLK2 antibody" is used The present invention relates to an antibody that specifically binds to K2.

[0136] As used herein, an antibody that "specifically binds to Vβ17" is defined as an antibody that binds to Vβ17 in a concentration of 1×10 -7 More than M Below, for example, 1 x 10 -8 M or less, 5×10 -9 M or less, 1×10 -9 M or less, 5×10 -10 M or less, or 1 x 10 -10 Vβ17, preferably human Vβ1, with a KD of 0.1 or less. This refers to an antibody that binds to 7.

[0137] As used herein, an antibody that "specifically binds to Vα10.2" is defined as an antibody that specifically binds to Vα10.2. -7 M or less, e.g., 1×10 -8 M or less, 5×10 -9 M or less, 1×10 -9 M or less, 5× 10 -10 M or less, or 1 x 10 -10 KD of M or less, Vα10.2, preferably It refers to an antibody that binds to Vα10.2.

[0138] As used herein, an antibody that "specifically binds to a second target antigen" is an antibody that specifically binds to a second target antigen, typically in an amount of 1 x 10 - 7 M or less, e.g., 1×10 -8 M or less, 5×10 -9 M or less, 1×10 -9 M or less, 5 x10 -10 M or less, or 1 x 10 -10 Antibodies that bind to a second target antigen with a KD of ≤ M Refers to...

[0139] As used herein, an antibody that "specifically binds to CD123" is an antibody that specifically binds to CD123, and is present in an amount of 1×10 -7 M Less than 1 x 10, preferably -8 M or less, more preferably 5 × 10 -9 M or less, 1×1 0 -9 M or less, 5×10 -10 M or less, or 1 x 10 -10 KD below M, CD123 Preferably, it refers to an antibody that binds to human CD123.

[0140] As used herein, an antibody that "specifically binds to BCMA" is defined as a antibody that specifically binds to BCMA in a concentration of 1×10 -7 More than M Below, preferably 1 x 10 -8 M or less, more preferably 5 × 10 -9 M or less, 1×10 -9 M or less, 5×10 -10 M or less, or 1 x 10 -10 KD below M, BCMA, e.g. For example, it refers to an antibody that binds to human BCMA.

[0141] As used herein, an antibody that "specifically binds to DLL3" is an antibody that binds to DLL3 in an amount of 1 x 10 -7 More than M Below, preferably 1 x 10 -8 M or less, more preferably 5 × 10 -9 M or less, 1×10 -9 M or less, 5×10 -10 M or less, or 1 x 10 -10 In KD below M, DLL3, e.g. For example, it refers to an antibody that binds to human DLL3.

[0142] As used herein, an antibody that "specifically binds to PSMA" is defined as an antibody that specifically binds to PSMA in a concentration of 1×10 -7 More than M Below, preferably 1 x 10 -8 M or less, more preferably 5 × 10 -9 M or less, 1×10 -9 M or less, 5×10 -10 M or less, or 1 x 10 -10 KD below M, PSMA, e.g. For example, it refers to an antibody that binds to human PSMA.

[0143] As used herein, an antibody that "specifically binds to KLK2" is defined as an antibody that binds to KLK2 in an amount of 1×10 -7 More than M Below, preferably 1 x 10 -8 M or less, more preferably 5 × 10 -9 M or less, 1×10 -9 M or less, 5×10 -10 M or less, or 1 x 10 -10 For KD below M, KLK2, e.g. For example, it refers to an antibody that binds to human KLK2.

[0144] As used herein, an antigen-binding domain or domains that "specifically bind to a tumor-associated antigen" The antigen-binding fragment may be 1×10 M or less, e.g., 1×10 M or less, 5×10 M or less KD of 1×109M or less, 5×1010M or less, or 1×1010M or less, and tumor It refers to an antigen-binding domain or antigen-binding fragment that binds to the relevant antigen.

[0145] The term "KD" is derived from the ratio of Kd to Ka (i.e., Kd / Ka), The KD value of an antibody refers to the dissociation constant expressed as a molar concentration (M). The KD of an antibody can be determined using methods known in the art. For example, the KD of an antibody can be determined by measuring the surface protein. By using Zumon resonance, for example, Biacore® systems or the Octet RED96 system. This can be determined by using biolayer interferometry techniques such as Cut.

[0146] The smaller the KD value of an antibody, the higher the affinity with which the antibody binds to its target antigen.

[0147] According to a particular embodiment, the present invention provides a method for producing a soluble antibody comprising: (a) a first heavy chain (HC1); (b) a second heavy chain (H (C2), (c) a first light chain (LC1), and (d) a second light chain (LC2), The present invention relates to a Vβ17 bispecific antibody or antigen-binding fragment thereof. HC1 may be related to SEQ ID NO: 1, SEQ ID NO: 2, and LC2 may be related to SEQ ID NO: 3, SEQ ID NO: 4, and LC3, respectively. heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 2, and SEQ ID NO: 3; LC1 may comprise CDR2, CDR3, and HCDR4, and LC1 may comprise CDR2, CDR3, and HCDR4, respectively. and a light chain complementarity determining region 1 (LCDR1), LCDR2, comprising the amino acid sequence of SEQ ID NO: 6. and LCDR3.

[0148] In one aspect, provided herein are antibodies that bind to Vβ17. In some embodiments, the antibody comprises a heavy chain variable region and a light chain variable region. The antibody is not a single domain antibody or a nanobody. The antibody is a humanized antibody.

[0149] In certain embodiments, the VH region of any one of the antibodies described herein , VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL Provided herein are anti-Vβ17 antibodies comprising VL CDR2, and / or VL CDR3. In some embodiments, the VH region of any one of the antibodies described herein Provided herein are anti-Vβ17 antibodies comprising: Provided herein is an anti-Vβ17 antibody comprising the VL region of any one of the described antibodies. In some embodiments, the V of any one of the antibodies described herein an anti-Vβ antibody comprising the H region and the VL region of any one of the antibodies described herein; 17 antibodies are provided herein. In some embodiments, the antibodies described herein and a VH CDR1, a VH CDR2, and a VH CDR3 of any one of Anti-Vβ17 antibodies are provided herein. In some embodiments, the antibodies described herein VL CDR1, VL CDR2, and VL CDR3 of any one of the antibodies In some embodiments, an anti-Vβ17 antibody is provided herein, comprising: VH CDR1, VH CDR2, and VH CDR of any one of the antibodies described R3 and VL CDR1, VL CDR2, VL CDR3 of any one of the antibodies described herein. Provided herein is an anti-Vβ17 antibody comprising a VL CDR3, R2, and VL CDR3. VH CDR1, VH CDR2, VH CDR3, VL of the Vβ17 antibody provided Representative VH and VL CDRs, including CDR1, VL CDR2, and VL CDR3 amino acid sequences. The VL amino acid sequences are provided in the Sequence Listing, as well as Tables 1-21.

[0150] In certain embodiments, the VH region of any one of the antibodies described herein , VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL a binding domain that binds to Vβ17 and has VL CDR2 and / or VL CDR3 In some embodiments, anti-Vβ17 bispecific antibodies are provided herein. A binding domain that binds to Vβ17 and has the VH region of any one of the antibodies described herein. Provided herein are anti-Vβ17 bispecific antibodies comprising the following: In the present invention, a Vβ17-binding antibody having a VL region of any one of the antibodies described herein is Provided herein are anti-Vβ17 bispecific antibodies comprising binding domains that combine several In some embodiments, the VH region of any one of the antibodies described herein and the VH region of the present invention and a VL region of any one of the antibodies described herein. Provided herein are anti-Vβ17 bispecific antibodies comprising binding domains. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 of any one of the described antibodies may be and an anti-Vβ17 bispecific antibody comprising a binding domain that binds to Vβ17 having a VH CDR3. In some embodiments, the antibodies described herein are V having any one of VL CDR1, VL CDR2, and VL CDR3 Provided herein are anti-Vβ17 bispecific antibodies comprising a binding domain that binds to β17. In some embodiments, the VH of any one of the antibodies described herein CDR1, VH CDR2, and VH CDR3 of any of the antibodies described herein. Vβ17 having one or more VL CDR1, VL CDR2, and VL CDR3. Provided herein are anti-Vβ17 bispecific antibodies comprising binding domains that combine Vβ17 antibodies are provided in the sequence listing, as well as in the figures and tables of this Examples section. Exemplary first binding domains that bind to the nucleotides 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, It is served.

[0151] In certain embodiments, the anti-Vβ17 antibody is a bispecific antibody. In one embodiment, the anti-Vβ17 bispecific antibody comprises a VH of an anti-CD123 antibody provided herein. area, VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, a second binding domain that binds to CD123 having VL CDR2 and / or VL CDR3; In some embodiments, the anti-Vβ17 bispecific antibody further comprises a domain. a second binding domain that binds to CD123 and has the VH region of the anti-CD123 antibody provided in In some embodiments, the anti-Vβ17 bispecific antibody further comprises a A second binding domain that binds to CD123 having the VL region of the provided anti-CD123 antibody. In some embodiments, the anti-Vβ17 bispecific antibody further comprises a The VH region of the anti-CD123 antibody provided herein and the VL region of the anti-CD123 antibody provided herein and a second binding domain that binds to CD123 and has the region In one embodiment, the anti-Vβ17 bispecific antibody comprises a VH of an anti-CD123 antibody provided herein. a second antibody that binds to CD123 and has VH CDR1, VH CDR2, and VH CDR3; In some embodiments, the anti-Vβ17 bispecific antibody further comprises a binding domain of The VL CDR1, VL CDR2, and VL CDRs of the anti-CD123 antibodies provided herein It further comprises a second binding domain that binds to DR3-bearing CD123. In one embodiment, the anti-Vβ17 bispecific antibody comprises a VH of an anti-CD123 antibody provided herein. CDR1, VH CDR2, and VH CDR3 and an anti-CD12 antibody as provided herein 3 antibodies to CD123 with VL CDR1, VL CDR2, and VL CDR3 Exemplary CD123 antibodies are listed in the Sequence Listing, as well as those listed in the Sequence Listing. Exemplary second binding domains that bind to CD123 are provided in the figures and tables in the Examples section. The main points are provided in the Sequence Listing, as well as in the Figures and Tables in the Examples section.

[0152] In certain embodiments, the anti-Vβ17 antibody is a bispecific antibody. In one embodiment, the anti-Vβ17 bispecific antibody comprises a VH region of an anti-BCMA antibody provided herein. area, VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, V a second binding domain that binds to BCMA having a VL CDR2, and / or a VL CDR3; In some embodiments, the anti-Vβ17 bispecific antibody further comprises a a second binding domain that binds to BCMA and has the VH region of the provided anti-BCMA antibody; In some embodiments, the anti-Vβ17 bispecific antibody further comprises and a second binding domain that binds to BCMA and has a VL region of an anti-BCMA antibody. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-Vβ17 antibody provided herein. B having a VH region of a BCMA antibody and a VL region of an anti-BCMA antibody provided herein. In some embodiments, the antibody further comprises a second binding domain that binds to CMA. 7 Bispecific antibodies may comprise the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR17, VH CDR18, VH and a second binding domain that binds to BCMA having a VH CDR2, and a VH CDR3. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-Vβ17 antibody provided herein. BCMA with VL CDR1, VL CDR2, and VL CDR3 of CMA antibody In some embodiments, the anti-Vβ17 bispecific antibody further comprises a second binding domain that binds to the Vβ17 bispecific antibody. An isomeric antibody may comprise the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR17, VH CDR18, VH and VH CDR3 and VL CDR1, VL of the anti-BCMA antibodies provided herein. and a second binding domain that binds to BCMA and has a VL CDR2 and a VL CDR3. Exemplary BCMA antibodies are provided in the Sequence Listing, as well as in the Figures and Tables of this Examples section. Exemplary second binding domains that bind to BCMA are shown in the sequence listing, as well as in the figures and this specification. Provided in the table in the Examples section.

[0153] In certain embodiments, the anti-Vβ17 antibody is a bispecific antibody. In one embodiment, the anti-Vβ17 bispecific antibody comprises a VH region of an anti-DLL3 antibody provided herein. area, VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, V a second binding domain that binds to a DLL3 having a VL CDR2, and / or a VL CDR3; In some embodiments, the anti-Vβ17 bispecific antibody further comprises a a second binding domain that binds to DLL3 and has the VH region of the provided anti-DLL3 antibody; In some embodiments, the anti-Vβ17 bispecific antibody further comprises and a second binding domain that binds to DLL3 and has a VL region of an anti-DLL3 antibody. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-Dβ17 antibody provided herein. a D1 antibody having a VH region of an anti-DLL3 antibody and a VL region of an anti-DLL3 antibody provided herein; In some embodiments, the antibody further comprises a second binding domain that binds to LL3. 7 Bispecific antibodies may comprise the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR17, VH CDR18, VH and a second binding domain that binds to DLL3 having a VH CDR2 and a VH CDR3. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-Dβ17 antibody provided herein. DLL3 having VL CDR1, VL CDR2, and VL CDR3 of the LL3 antibody In some embodiments, the anti-Vβ17 bispecific antibody further comprises a second binding domain that binds to the Vβ17 bispecific antibody. The heterologous antibody may comprise the VH CDR1, VH CDR2, and VH CDR3 sequences of the anti-DLL3 antibodies provided herein. and VH CDR3 and VL CDR1, VL of the anti-DLL3 antibodies provided herein. and a second binding domain that binds to DLL3 and has a VL CDR2 and a VL CDR3. Exemplary DLL3 antibodies are provided in the Sequence Listing, as well as in the Figures and Tables of this Examples section. Exemplary second binding domains that bind to DLL3 are shown in the sequence listing, as well as in the figures and text. Provided in the table in the Examples section.

[0154] In certain embodiments, the anti-Vβ17 antibody is a bispecific antibody. In one embodiment, the anti-Vβ17 bispecific antibody comprises a VH region of an anti-PSMA antibody provided herein. area, VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, V a second binding domain that binds to PSMA having a VL CDR2, and / or a VL CDR3; In some embodiments, the anti-Vβ17 bispecific antibody further comprises a a second binding domain that binds to PSMA and has the VH region of the provided anti-PSMA antibody; In some embodiments, the anti-Vβ17 bispecific antibody further comprises and a second binding domain that binds to PSMA and has a VL region of an anti-PSMA antibody. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-P A P11 antibody having a VH region of an SMA antibody and a VL region of an anti-PSMA antibody provided herein. In some embodiments, the antibody further comprises a second binding domain that binds to SMA. 7 Bispecific antibodies may comprise the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR17, VH CDR18, VH and a second binding domain that binds to PSMA having a VH CDR2, and a VH CDR3. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-P to PSMA with VL CDR1, VL CDR2, and VL CDR3 of SMA antibody In some embodiments, the anti-Vβ17 bispecific antibody further comprises a second binding domain that binds to the Vβ17 bispecific antibody. An isomeric antibody may comprise the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR17, VH CDR18, VH and VH CDR3 and VL CDR1, VL of the anti-PSMA antibodies provided herein. and a second binding domain that binds to PSMA and has a VL CDR2 and a VL CDR3. Exemplary PSMA antibodies are provided in the Sequence Listing, as well as in the Figures and Tables of this Examples section. Exemplary second binding domains that bind to PSMA are listed in the Sequence Listing, as well as in the Figures and this specification. Provided in the table in the Examples section.

[0155] In certain embodiments, the anti-Vβ17 antibody is a bispecific antibody. In one embodiment, the anti-Vβ17 bispecific antibody comprises a VH region of an anti-KLK2 antibody provided herein. area, VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, V a second binding domain that binds to KLK2 having a VL CDR2 and / or a VL CDR3; In some embodiments, the anti-Vβ17 bispecific antibody further comprises a A second binding domain that binds to KLK2 and has the VH region of the provided anti-KLK2 antibody is provided. In some embodiments, the anti-Vβ17 bispecific antibody further comprises and a second binding domain that binds to KLK2 and has the VL region of an anti-KLK2 antibody. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-K antibody provided herein. A KLK2 antibody having a VH region of an anti-KLK2 antibody and a VL region of an anti-KLK2 antibody provided herein. In some embodiments, the antibody further comprises a second binding domain that binds to LK2. 7 The bispecific antibody may comprise the VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR17, VH CDR18, V and a second binding domain that binds to KLK2 having a VH CDR2 and a VH CDR3. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-K antibody provided herein. KLK2 having VL CDR1, VL CDR2, and VL CDR3 of the LK2 antibody In some embodiments, the anti-Vβ17 bispecific antibody further comprises a second binding domain that binds to the Vβ17 bispecific antibody. The heterologous antibody may comprise the VH CDR1, VH CDR2, and VH CDR3 of the anti-KLK2 antibodies provided herein. and VH CDR3 and VL CDR1, VL of the anti-KLK2 antibodies provided herein. and a second binding domain that binds to KLK2 and has VL CDR2 and VL CDR3. Exemplary KLK2 antibodies are provided in the Sequence Listing, as well as in the Figures and Tables of this Examples section. Exemplary second binding domains that bind to KLK2 are shown in the sequence listing, as well as in the figures and this specification. Provided in the table in the Examples section.

[0156] In certain embodiments, anti-Vβ17 antibodies are provided that are intact antibodies. In embodiments, an anti-Vβ17 antibody is provided, further comprising an antigen-binding fragment of the anti-Vβ17 antibody. In some embodiments, the antigen-binding fragment of an anti-Vβ17 antibody is In some embodiments, the antigen-binding fragment is a functional fragment. In some embodiments, the antigen-binding fragment is a Fab. In some embodiments, the antigen-binding fragment is a Fab'. In some embodiments, the antigen-binding fragment is F(ab')2. In some embodiments, the antigen-binding fragment is an Fv fragment. The fragment is a disulfide-stabilized Fv fragment (dsFv). In some embodiments, the antigen-binding fragment is a (dsFv)2. The original binding fragment is a bispecific dsFv (dsFv-dsFv'). In this embodiment, the antigen-binding fragment is a disulfide-stabilized diabody (ds diabody). In some embodiments, the antigen-binding fragment is a single-chain antibody molecule ( In some embodiments, the antigen-binding fragment is a single domain antigen (e.g., scFv). In some embodiments, the antigen-binding fragment is an scFv antibody. In some embodiments, the antigen-binding fragment is a divalent diabody. A multispecific antibody is formed from a portion of an antibody containing one or more CDRs. In some embodiments, the antigen-binding fragment is a camelized single domain antibody. In some embodiments, the antigen-binding fragment is a nanobody. In some embodiments, the antigen-binding fragment is a domain antibody. The binding fragment is a bivalent domain antibody. In some embodiments, the antigen-binding fragment A fragment is an antibody fragment that binds to an antigen but does not contain the entire antibody structure.

[0157] In certain embodiments, the anti-Vβ17 antibody comprises a VH region and a VL region.

[0158] In some embodiments, the anti-Vβ17 antibody is a single chain antibody. In some embodiments, the anti-Vβ17 antibody is a single domain antibody. The antibody is a nanobody. In certain embodiments, the anti-Vβ17 antibody is a VHH antibody. In certain embodiments, the anti-Vβ17 antibody is a llama antibody. In some embodiments, the anti-Vβ17 bispecific antibody comprises a single chain antibody. In certain embodiments, anti-Vβ1 bispecific antibodies include single domain antibodies. 7 Bispecific antibodies include nanobodies. In certain embodiments, anti-Vβ17 bispecific antibodies include nanobodies. Heterospecific antibodies include VHH antibodies. In certain embodiments, the anti-Vβ17 bispecific antibody is In some embodiments, the anti-Vβ17 antibody is not a single chain antibody. In some embodiments, the anti-Vβ17 antibody is not a single domain antibody. In certain embodiments, the anti-Vβ17 antibody is not a nanobody. In certain embodiments, the anti-Vβ17 antibody is not a VHH antibody. In some embodiments, the anti-Vβ17 bispecific antibody does not comprise a single chain antibody. In some embodiments, the anti-Vβ17 bispecific antibody does not comprise a single domain antibody. In certain embodiments, the anti-Vβ17 bispecific antibody does not comprise a nanobody. In certain embodiments, the anti-Vβ17 bispecific antibody does not comprise a VHH antibody. In embodiments, the anti-Vβ17 bispecific antibody does not include a llama antibody.

[0159] In some embodiments, the anti-Vβ17 antibody is a multispecific antibody. In certain embodiments, the anti-Vβ17 is a bispecific antibody. In certain embodiments, the multispecific antibody is , including antigen-binding fragments of the anti-Vβ17 antibodies provided herein. In one embodiment, the bispecific antibody comprises an antigen-binding fragment of an anti-Vβ17 antibody provided herein. In some embodiments, the anti-Vβ17 antibody is an agonist antibody. In embodiments, the anti-Vβ17 antibody activates T cells. The antibody is an antagonist antibody. In certain embodiments, the anti-Vβ17 antibody inhibits T-cell proliferation. In some embodiments, the anti-Vβ17 antibody blocks T cell activation. In some embodiments, the anti-Vβ17 antibody modulates the activity of T cells. In this embodiment, the anti-Vβ17 antibody can activate or deactivate T cell activity. In certain embodiments, the T cell is a human T cell. Bispecific antibodies, including the Vβ17 antibodies provided herein in a knob-in-hole format. In some embodiments, the anti-Vβ17 antibodies provided herein are In some embodiments, the antibodies provided herein may be included in a bispecific antibody. Vβ17 bispecific antibodies may be included in multispecific antibodies. The bispecific antibodies provided herein bind to a first Vβ17 epitope. The anti-Vβ17 antibody provided herein comprises a first binding domain and a second Vβ17 epitope. and a second binding domain comprising an anti-Vβ17 antibody provided herein that binds to The one Vβ17 epitope and the second Vβ17 epitope are not the same. In one embodiment, the Vβ17 antibodies or antigen-binding fragments thereof provided herein are Vβ1 In certain embodiments, the Vβ17 antibodies or Vβ17 antibodies provided herein specifically bind to Vβ17. The antigen-binding fragment does not bind to the Vβ17 epitope.

[0160] In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences follow the Kabat numbering system In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL The CDR1, VL CDR2, and VL CDR3 sequences are numbered according to the Chothia numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR22, VH CDR33, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR26, VH CDR37 The VL CDR1, VL CDR2, and VL CDR3 sequences are numbered according to an exemplary numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL The CDR1, VL CDR2, and VL CDR3 sequences are numbered according to the Contact numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, The VL CDR1, VL CDR2, and VL CDR3 sequences are numbered according to the IMGT numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR22, VH CDR33, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR26, VH CDR37 The VL CDR1, VL CDR2, and VL CDR3 sequences follow the AbM numbering system. The six CDRs (VH CDRs 1-3 and VL CDRs 1-3) of certain antibody embodiments are Exemplary sets are provided herein. Other sets of CDRs are contemplated and are not provided herein. It is within the scope of the antibody embodiments described herein.

[0161] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3; (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6. In another aspect, provided herein is an antibody that binds to Vβ17, The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 97, an amino acid sequence of SEQ ID NO: 98, and a VH CDR1 having the amino acid sequence of SEQ ID NO: 99. VH CDR2 having the amino acid sequence of SEQ ID NO: 99, and VH CDR3 having the amino acid sequence of SEQ ID NO: 99. (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 100; VL CDR2 having the amino acid sequence of SEQ ID NO: 101 and the amino acid sequence of SEQ ID NO: 102 In another embodiment, the VL comprises a VL CDR3 having the sequence Provided herein is an antibody, the antibody having (i) the amino acid sequence of SEQ ID NO: 103. VH CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 104, and VH CDR3 having the amino acid sequence of SEQ ID NO: 105. (ii) a VH comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 106; VL CDR1 having the amino acid sequence of SEQ ID NO: 107 and a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 108. In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: 109, VH CDR1 having the amino acid sequence of SEQ ID NO: 110, VH CDR2 having the amino acid sequence of SEQ ID NO: 111, and VH CDR3 having the amino acid sequence of SEQ ID NO: 112. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 112, the sequence VL CDR2 having the amino acid sequence of SEQ ID NO: 113, and the amino acid sequence of SEQ ID NO: 114 and a VL comprising a VL CDR3 having the following: Provided herein is an antibody comprising: (i) a VH having the amino acid sequence of SEQ ID NO: 115; CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 116, and SEQ ID NO: 11 (ii) a VH comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 118; VL CDR1 having the amino acid sequence of SEQ ID NO: 119, VL CDR2 having the amino acid sequence of SEQ ID NO: 120 R2, and a VL comprising a VL CDR3 having the amino acid sequence of SEQ ID NO: 120. In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 121, VH CDR2 having the amino acid sequence of SEQ ID NO: 122 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 123. (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 124; VL CDR2 having the amino acid sequence of SEQ ID NO: 125, and VL CDR3 having the amino acid sequence of SEQ ID NO: 126. In another embodiment, an antibody that binds to Vβ17 comprises a VL comprising a VL CDR3 that binds to Vβ17. As provided herein, the antibody comprises: (i) a VH C having the amino acid sequence of SEQ ID NO: 127; DR1 having the amino acid sequence of SEQ ID NO: 128, and VH CDR2 having the amino acid sequence of SEQ ID NO: 129 (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 130; VL CDR1 having the amino acid sequence of SEQ ID NO: 131, VL CDR2 having the amino acid sequence of SEQ ID NO: 132 and a VL comprising a VL CDR3 having the amino acid sequence of SEQ ID NO: 132. In one aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) SEQ ID NO: VH CDR1 having the amino acid sequence of SEQ ID NO: 133, VH CDR2 having the amino acid sequence of SEQ ID NO: 134 a VH CDR2 having the amino acid sequence of SEQ ID NO: 135, and a VH CDR3 having the amino acid sequence of SEQ ID NO: 136, (ii) a VH having the amino acid sequence of SEQ ID NO: 136, and (iii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 13 VL CDR2 having the amino acid sequence of SEQ ID NO: 138, and VL CDR3 having the amino acid sequence of SEQ ID NO: 139. In another aspect, an antibody that binds to Vβ17 is described herein. The antibody is provided herein, and the VH CDR1, VH CDR2, and VH CDR3 of SEQ ID NO: 25 are independently selected from the group consisting of: and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and In another embodiment, an antibody that binds to Vβ17 is described herein. The antibody is provided in the above-mentioned formula (I), wherein the antibody comprises VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 26, respectively. and VL CDR3, In another embodiment, the antibody that binds to Vβ17 is provided herein. The antibody has VH CDR1, VH CDR2, and VH CDR3 of SEQ ID NO: 7, respectively. VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of In another aspect, provided herein is an antibody that binds to Vβ17. , the above antibody has VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 8, respectively. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence of VL CDR3 In another aspect, provided herein is an antibody that binds to Vβ17, comprising the VL comprising The antibody has VH CDR1, VH CDR2, and VH CDR3 of SEQ ID NO: 9, respectively. and a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences In another aspect, provided herein is an antibody that binds to Vβ17, said antibody comprising , VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 10, respectively. a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: i) VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 25 and a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences VH and (ii) VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 26. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence of In another aspect, provided herein is an antibody that binds to Vβ17. The antibody comprises (i) VH CDR1, VH CDR2, and VH CDR3 of SEQ ID NO: 7, respectively. and VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3. and (ii) a VH comprising VL CDR1, VL CDR3, and VL CDR4, respectively, of SEQ ID NO: 8. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3; and VL CDR3. In another aspect, an antibody that binds to Vβ17 comprises As provided herein, the antibody comprises (i) a VH CDR1, a VH CDR2, a VH CDR3, a VH CDR4, a VH CDR5, a VH CDR6, a VH CDR7, a VH CDR8, a VH CDR9, a VH CDR10, a VH CDR11, a VH CDR12, a VH CDR13, a VH CDR14, a VH CDR15, a VH CDR1 VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences 2, and VH CDR3, respectively, of SEQ ID NO: 10; and (ii) VL CDR3, respectively, of SEQ ID NO: 10. a VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR2, and a VL CDR3. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 25. In some embodiments, the antibody In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 26. VH having the amino acid sequence of SEQ ID NO: 25 and VH having the amino acid sequence of SEQ ID NO: 26 In some embodiments, the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 7. In some embodiments, the antibody comprises a light chain having the amino acid sequence of SEQ ID NO:8. In some embodiments, the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 7 and a and a light chain having the amino acid sequence of sequence number 8. In some embodiments, the antibody comprises In some embodiments, the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 9. In some embodiments, the antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 9. and a light chain having the amino acid sequence of SEQ ID NO: 10. In some embodiments, the antibody has at least one amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:25. In some embodiments, the antibody comprises a VH having at least 95% of the amino acid sequence of SEQ ID NO: VL having an amino acid sequence that is at least 95% identical to the amino acid sequence of No. 26 In some embodiments, the antibody comprises a polypeptide having identity to the amino acid sequence of SEQ ID NO: 25. VH having at least 95% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 26 In some embodiments, the VL has at least 95% amino acid sequence identity. The antibody has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:7. In some embodiments, the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 8. The light chain has an amino acid sequence that is at least 95% identical to that of the target gene. In some embodiments, the antibody has an amino acid sequence that has at least 95% identity to the amino acid sequence of SEQ ID NO:7. a heavy chain having an amino acid sequence of at least 95% identity to the amino acid sequence of SEQ ID NO:8; and a light chain having the amino acid sequence of SEQ ID NO: 9. The heavy chain has an amino acid sequence that is at least 95% identical to the amino acid sequence of the heavy chain. In some embodiments, the antibody has at least one amino acid sequence identical to that of SEQ ID NO:10. In some embodiments, the antibody comprises a light chain having 95% of the amino acid sequence of SEQ ID NO: a heavy chain having an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:9; A light chain having an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 10. and a chain.

[0162] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3; (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6. In another aspect, provided herein is an antibody that binds to Vβ17, The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 139, a VH CDR2 having the amino acid sequence of SEQ ID NO: 140, VH CDR2 having the amino acid sequence of SEQ ID NO: 141 (ii) a VH comprising CDR3 and a VL CD having the amino acid sequence of SEQ ID NO: 142; R1, a VL CDR2 having the amino acid sequence of SEQ ID NO: 143, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 144 In another embodiment, the VL comprises a VL CDR3 having the amino acid sequence Provided herein is an antibody comprising: (i) an amino acid sequence of SEQ ID NO: 145; VH CDR1 having the amino acid sequence of SEQ ID NO: 146, VH CDR2 having the amino acid sequence of SEQ ID NO: 147, and (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 147; VL CDR1 having the amino acid sequence of SEQ ID NO: 148, VL CDR2 having the amino acid sequence of SEQ ID NO: 149 VL CDR2, and VL CDR3 having the amino acid sequence of SEQ ID NO: 150. and L. In another aspect, provided herein is an antibody that binds to Vβ17, said antibody comprising (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 151, VH CDR2 having the amino acid sequence of SEQ ID NO: 153, and VH CDR3 having the amino acid sequence of SEQ ID NO: 154. (ii) a VH having a CDR3 and (iii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 154; , a VL CDR2 having the amino acid sequence of SEQ ID NO: 155, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 156 In another embodiment, the Vβ17-binding fragment comprises a VL having a VL CDR3 with the sequence Provided herein is an antibody comprising: (i) an antibody having the amino acid sequence of SEQ ID NO: 157; VH CDR1 having the amino acid sequence of SEQ ID NO: 158, VH CDR2 having the amino acid sequence of SEQ ID NO: 159, and VH CDR3 having the amino acid sequence of SEQ ID NO: 160. (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 16; VL CDR1 having the amino acid sequence of SEQ ID NO: 161, VL CDR2 having the amino acid sequence of SEQ ID NO: 162, a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 162; In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: i) VH CDR1 having the amino acid sequence of SEQ ID NO: 163, the amino acid sequence of SEQ ID NO: 164 VH CDR2 having the sequence of SEQ ID NO: 165, and VH CDR3 having the amino acid sequence of SEQ ID NO: 166. 3, and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 166, VL CDR2 having the amino acid sequence of SEQ ID NO: 167 and the amino acid sequence of SEQ ID NO: 168 In another embodiment, an antibody that binds to Vβ17 comprises a VL comprising a VL CDR3 having a Vβ17 sequence.

[0013] The antibody is provided herein, the antibody comprising: (i) a VH1 antibody having the amino acid sequence of SEQ ID NO: 169; VH CDR1 having the amino acid sequence of SEQ ID NO: 170, VH CDR2 having the amino acid sequence of SEQ ID NO: 1 (ii) a VH comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 172; VL CDR1 having the amino acid sequence of SEQ ID NO: 173 and a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 174. In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 175, the amino acid sequence of SEQ ID NO: 176 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 177. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 178, VL CDR2 having the amino acid sequence of SEQ ID NO: 179, and the amino acid sequence of SEQ ID NO: 180 In another embodiment, an antibody that binds Vβ17 comprises a VL comprising a VL CDR3 having As provided herein, the antibody comprises a VH CDR1, a VH CDR2 and a VH CDR3 of SEQ ID NO: 19, respectively. VH CDR1, VH CDR2, and VH CDR3 amino acid sequences In another aspect, an antibody that binds to Vβ17 comprises a VH comprising a VH CDR3. As provided herein, the antibody comprises a VL CDR1, a VL CDR2 and a VL CDR3 of SEQ ID NO: 22, respectively. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR3. and (i) a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of SEQ ID NO: 19. VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences 2, and VH CDR3, respectively, of SEQ ID NO: 22; and (ii) VL CDR3, respectively, of SEQ ID NO: 22. a VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR2, and a VL CDR3. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 19. In some embodiments, the antibody In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 22. VH having the amino acid sequence of SEQ ID NO: 19 and VH having the amino acid sequence of SEQ ID NO: 22 In some embodiments, the antibody comprises a VL and a VL fragment thereof. In some embodiments, the VH comprises a VH having an amino acid sequence that is at least 95% identical. The antibody has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:22. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 19. VH having an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 22 and VL having an amino acid sequence that is at least 95% identical to the amino acid sequence of VL.

[0163] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3; (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6. In another aspect, provided herein is an antibody that binds to Vβ17, The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 139, a VH CDR2 having the amino acid sequence of SEQ ID NO: 140, VH CDR2 having the amino acid sequence of SEQ ID NO: 141 (ii) a VH comprising CDR3 and a VL CD having the amino acid sequence of SEQ ID NO: 184; R1, a VL CDR2 having the amino acid sequence of SEQ ID NO: 185, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 186 In another embodiment, the VL comprises a VL CDR3 having the amino acid sequence Provided herein is an antibody comprising: (i) an amino acid sequence of SEQ ID NO: 145; VH CDR1 having the amino acid sequence of SEQ ID NO: 146, VH CDR2 having the amino acid sequence of SEQ ID NO: 147, and (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 147; VL CDR1 having the amino acid sequence of SEQ ID NO: 190, VL CDR2 having the amino acid sequence of SEQ ID NO: 191 VL CDR2, and VL CDR3 having the amino acid sequence of SEQ ID NO: 192. and L. In another aspect, provided herein is an antibody that binds to Vβ17, said antibody comprising (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 151, VH CDR2 having the amino acid sequence of SEQ ID NO: 153, and VH CDR3 having the amino acid sequence of SEQ ID NO: 154. (ii) a VH CDR1 having the amino acid sequence of SEQ ID NO: 196, , a VL CDR2 having the amino acid sequence of SEQ ID NO: 197, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 198 In another embodiment, the Vβ17-binding fragment comprises a VL having a VL CDR3 with the sequence Provided herein is an antibody comprising: (i) an antibody having the amino acid sequence of SEQ ID NO: 157; VH CDR1 having the amino acid sequence of SEQ ID NO: 158, VH CDR2 having the amino acid sequence of SEQ ID NO: 159, and VH CDR3 having the amino acid sequence of SEQ ID NO: 160. (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 20; VL CDR1 having the amino acid sequence of SEQ ID NO: 203, a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 204; In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: i) VH CDR1 having the amino acid sequence of SEQ ID NO: 163, the amino acid sequence of SEQ ID NO: 164 VH CDR2 having the sequence of SEQ ID NO: 165, and VH CDR3 having the amino acid sequence of SEQ ID NO: 166. 3, and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 208, VL CDR2 having the amino acid sequence of SEQ ID NO: 209, and VL CDR3 having the amino acid sequence of SEQ ID NO: 210 In another embodiment, an antibody that binds to Vβ17 comprises a VL comprising a VL CDR3 having a Vβ17 sequence.

[0013] The antibody is provided herein, the antibody comprising: (i) a VH1 antibody having the amino acid sequence of SEQ ID NO: 169; VH CDR1 having the amino acid sequence of SEQ ID NO: 170, VH CDR2 having the amino acid sequence of SEQ ID NO: 1 (ii) a VH comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 214; VL CDR1 having the amino acid sequence of SEQ ID NO: 215 and a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 216. In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 175, the amino acid sequence of SEQ ID NO: 176 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 177. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 220, VL CDR2 having the amino acid sequence of SEQ ID NO: 221, and VL CDR2 having the amino acid sequence of SEQ ID NO: 222 In another embodiment, an antibody that binds Vβ17 comprises a VL comprising a VL CDR3 having As provided herein, the antibody comprises a VH CDR1, a VH CDR2 and a VH CDR3 of SEQ ID NO: 19, respectively. VH CDR1, VH CDR2, and VH CDR3 amino acid sequences In another aspect, an antibody that binds to Vβ17 comprises a VH comprising a VH CDR3. As provided herein, the antibody comprises a VL CDR1, a VL CDR2 and a VL CDR3 of SEQ ID NO: 23, respectively. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR3. and (i) a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of SEQ ID NO: 19. VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences 2, and VH CDR3, respectively, of SEQ ID NO: 23; and (ii) VL CDR3, respectively, of SEQ ID NO: 23. a VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR2, and a VL CDR3. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 19. In some embodiments, the antibody In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 23. VH having the amino acid sequence of SEQ ID NO: 19 and VH having the amino acid sequence of SEQ ID NO: 23 In some embodiments, the antibody comprises a VL and a VL fragment thereof. In some embodiments, the VH comprises a VH having an amino acid sequence that is at least 95% identical. The antibody has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:23. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 19. VH having an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 23 and VL having an amino acid sequence that is at least 95% identical to the amino acid sequence of VL.

[0164] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3; (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6. In another aspect, provided herein is an antibody that binds to Vβ17, The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 139, a VH CDR2 having the amino acid sequence of SEQ ID NO: 140, VH CDR2 having the amino acid sequence of SEQ ID NO: 141 (ii) a VH comprising CDR3 and a VL CD having the amino acid sequence of SEQ ID NO: 226; R1, a VL CDR2 having the amino acid sequence of SEQ ID NO: 227, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 228 In another embodiment, the VL comprises a VL CDR3 having the amino acid sequence Provided herein is an antibody comprising: (i) an amino acid sequence of SEQ ID NO: 145; VH CDR1 having the amino acid sequence of SEQ ID NO: 146, VH CDR2 having the amino acid sequence of SEQ ID NO: 147, and a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 147; and (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: VL CDR1 having the amino acid sequence of SEQ ID NO: 232, VL CDR2 having the amino acid sequence of SEQ ID NO: 233 VL CDR2, and VL CDR3 having the amino acid sequence of SEQ ID NO: 234. In another aspect, provided herein is an antibody that binds to Vβ17, comprising the above-mentioned The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 151, a VH CDR2 having the amino acid sequence of SEQ ID NO: 152, and VH CDR2 having the amino acid sequence of SEQ ID NO: 153. (ii) a VH comprising a H CDR3 and a VL C having the amino acid sequence of SEQ ID NO: 238; DR1, VL CDR2 having the amino acid sequence of SEQ ID NO: 239, and VL CDR3 having the amino acid sequence of SEQ ID NO: 240 In another embodiment, the Vβ17 comprises a VL comprising a VL CDR3 having the amino acid sequence Provided herein are antibodies that bind to (i) the amino acid sequence of SEQ ID NO: 157. a VH CDR1 having the amino acid sequence of SEQ ID NO: 158; and (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 159; and VL CDR1 having the amino acid sequence of SEQ ID NO: 244, VL CDR2 having the amino acid sequence of SEQ ID NO: 245 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 246, In another aspect, provided herein is an antibody that binds to Vβ17, (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 163, an VH CDR2 having the amino acid sequence of SEQ ID NO: 164, VH CDR2 having the amino acid sequence of SEQ ID NO: 165, and VH CDR3 having the amino acid sequence of SEQ ID NO: 166. (ii) a VH CDR having the amino acid sequence of SEQ ID NO: 250; and (iii) a VL CDR having the amino acid sequence of SEQ ID NO: 250. 1. A VL CDR2 having the amino acid sequence of SEQ ID NO: 251 and the amino acid sequence of SEQ ID NO: 252. In another embodiment, the VL comprises a VL CDR3 having the sequence Provided herein is an antibody having (i) the amino acid sequence of SEQ ID NO: 169. a VH CDR1 having the amino acid sequence of SEQ ID NO: 170, a VH CDR2 having the sequence (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 2; VL CDR1 having the amino acid sequence of SEQ ID NO: 56, VL CDR2 having the amino acid sequence of SEQ ID NO: 257 a VL CDR2, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 258; In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 175, an amino acid sequence of SEQ ID NO: 176, VH CDR2 having the amino acid sequence of SEQ ID NO: 177, and VH CDR3 having the amino acid sequence of SEQ ID NO: 178. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 262; VL CDR2 having the amino acid sequence of SEQ ID NO: 263 and the amino acid sequence of SEQ ID NO: 264 In another embodiment, the VL comprises a VL CDR3 having the sequence

[0013] An antibody is provided herein, the antibody comprising a VH CDR1, VH CDR2, VH CDR3, VH CDR4, VH CDR5, VH CDR6, VH CDR7, VH CDR8, VH CDR9, VH CDR10, VH CDR11, VH CDR12, VH CDR13, VH CDR14, VH CDR15, VH CDR16, VH CDR17, V VH CDR1, VH CDR2, and VH CDR3 amino acid sequences In another embodiment, an antibody that binds to Vβ17 comprises a VH comprising a VH CDR2, and a VH CDR3. The antibodies provided herein comprise a VL CDR1, a VL CDR2 and a VL CDR3 of SEQ ID NO: 24, respectively. VL CDR1, VL CDR2, and VL CDR3 amino acid sequences In another embodiment, the antibody binds to Vβ17. provided herein is an antibody comprising: (i) a VH CDR1 of SEQ ID NO: 19, respectively; VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of (ii) a VH comprising a VH CDR2, a VH CDR3, and a VH CDR4, respectively, of SEQ ID NO: 24; VL CDR1, VL CDR2, and VL CDR3 amino acid sequences and a VL comprising R1, VL CDR2, and VL CDR3. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 19. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 24. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 19 and a VH having the amino acid sequence of SEQ ID NO: 24. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 19. The VH has an amino acid sequence that is at least 95% identical to the VH. In some embodiments, the antibody has an amino acid sequence that has at least 95% identity to the amino acid sequence of SEQ ID NO:24. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 19. VH having an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 24 and a VL having the amino acid sequence:

[0165] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3; (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6. In another aspect, provided herein is an antibody that binds to Vβ17, The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 181, a VH CDR2 having the amino acid sequence of SEQ ID NO: 182, VH CDR2 having the amino acid sequence of SEQ ID NO: 183 (ii) a VH comprising CDR3 and a VL CD having the amino acid sequence of SEQ ID NO: 142; R1, a VL CDR2 having the amino acid sequence of SEQ ID NO: 143, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 144 In another embodiment, the VL comprises a VL CDR3 having the amino acid sequence Provided herein is an antibody comprising: (i) an amino acid sequence of SEQ ID NO: 187; VH CDR1 having the amino acid sequence of SEQ ID NO: 188, VH CDR2 having the amino acid sequence of SEQ ID NO: 189, and (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 189; VL CDR1 having the amino acid sequence of SEQ ID NO: 148, VL CDR2 having the amino acid sequence of SEQ ID NO: 149 VL CDR2, and VL CDR3 having the amino acid sequence of SEQ ID NO: 150. and L. In another aspect, provided herein is an antibody that binds to Vβ17, said antibody comprising (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 193, VH CDR2 having the amino acid sequence of SEQ ID NO: 195, and VH CDR3 having the amino acid sequence of SEQ ID NO: 196. (ii) a VH having a CDR3 and (iii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 154; , a VL CDR2 having the amino acid sequence of SEQ ID NO: 155, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 156 In another embodiment, the Vβ17-binding fragment comprises a VL having a VL CDR3 with the sequence Provided herein is an antibody comprising: (i) an antibody having the amino acid sequence of SEQ ID NO: 199; VH CDR1 having the amino acid sequence of SEQ ID NO: 200, VH CDR2 having the amino acid sequence of SEQ ID NO: 201, (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 16; VL CDR1 having the amino acid sequence of SEQ ID NO: 161, VL CDR2 having the amino acid sequence of SEQ ID NO: 162, a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 162; In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: i) VH CDR1 having the amino acid sequence of SEQ ID NO: 205, the amino acid sequence of SEQ ID NO: 206 VH CDR2 having the sequence of SEQ ID NO: 207, and VH CDR3 having the amino acid sequence of SEQ ID NO: 208. 3, and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 166, VL CDR2 having the amino acid sequence of SEQ ID NO: 167 and the amino acid sequence of SEQ ID NO: 168 In another embodiment, an antibody that binds to Vβ17 comprises a VL comprising a VL CDR3 having a Vβ17 sequence.

[0013] The antibody is provided herein, the antibody comprising: (i) a VH1 antibody having the amino acid sequence of SEQ ID NO: 211; VH CDR1 having the amino acid sequence of SEQ ID NO: 212, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 (ii) a VH comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 172; VL CDR1 having the amino acid sequence of SEQ ID NO: 173 and a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 174. In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 217, the amino acid sequence of SEQ ID NO: 218 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 219. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 178, VL CDR2 having the amino acid sequence of SEQ ID NO: 179, and the amino acid sequence of SEQ ID NO: 180 In another embodiment, an antibody that binds Vβ17 comprises a VL comprising a VL CDR3 having As provided herein, the antibody comprises a VH CDR1, a VH CDR2 and a VH CDR3 of SEQ ID NO: 20, respectively. VH CDR1, VH CDR2, and VH CDR3 amino acid sequences In another aspect, an antibody that binds to Vβ17 comprises a VH comprising a VH CDR3. As provided herein, the antibody comprises a VL CDR1, a VL CDR2 and a VL CDR3 of SEQ ID NO: 22, respectively. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR3. and (i) a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of SEQ ID NO: 20. VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences 2, and VH CDR3, respectively, of SEQ ID NO: 22; and (ii) VL CDR3, respectively, of SEQ ID NO: 22. a VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR2, and a VL CDR3. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 20. In some embodiments, the antibody In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 22. VH having the amino acid sequence of SEQ ID NO: 20 and VH having the amino acid sequence of SEQ ID NO: 22 In some embodiments, the antibody comprises a VL and a VL fragment thereof. In some embodiments, the VH comprises a VH having an amino acid sequence that is at least 95% identical. The antibody has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:22. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 20. VH having an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 22 and VL having an amino acid sequence that is at least 95% identical to the amino acid sequence of VL.

[0166] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3; (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6. In another aspect, provided herein is an antibody that binds to Vβ17, The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 181, a VH CDR2 having the amino acid sequence of SEQ ID NO: 182, VH CDR2 having the amino acid sequence of SEQ ID NO: 183 (ii) a VH comprising CDR3 and a VL CD having the amino acid sequence of SEQ ID NO: 184; R1, a VL CDR2 having the amino acid sequence of SEQ ID NO: 185, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 186 In another embodiment, the VL comprises a VL CDR3 having the amino acid sequence Provided herein is an antibody comprising: (i) an amino acid sequence of SEQ ID NO: 187; VH CDR1 having the amino acid sequence of SEQ ID NO: 188, VH CDR2 having the amino acid sequence of SEQ ID NO: 189, and (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 189; VL CDR1 having the amino acid sequence of SEQ ID NO: 190, VL CDR2 having the amino acid sequence of SEQ ID NO: 191 VL CDR2, and VL CDR3 having the amino acid sequence of SEQ ID NO: 192. and L. In another aspect, provided herein is an antibody that binds to Vβ17, said antibody comprising (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 193, VH CDR2 having the amino acid sequence of SEQ ID NO: 195, and VH CDR3 having the amino acid sequence of SEQ ID NO: 196. (ii) a VH CDR1 having the amino acid sequence of SEQ ID NO: 196, , a VL CDR2 having the amino acid sequence of SEQ ID NO: 197, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 198 In another embodiment, the Vβ17-binding fragment comprises a VL having a VL CDR3 with the sequence Provided herein is an antibody comprising: (i) an antibody having the amino acid sequence of SEQ ID NO: 199; VH CDR1 having the amino acid sequence of SEQ ID NO: 200, VH CDR2 having the amino acid sequence of SEQ ID NO: 201, (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 20; VL CDR1 having the amino acid sequence of SEQ ID NO: 203, a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 204; In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: i) VH CDR1 having the amino acid sequence of SEQ ID NO: 205, the amino acid sequence of SEQ ID NO: 206 VH CDR2 having the sequence of SEQ ID NO: 207, and VH CDR3 having the amino acid sequence of SEQ ID NO: 208. 3, and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 208, VL CDR2 having the amino acid sequence of SEQ ID NO: 209, and VL CDR3 having the amino acid sequence of SEQ ID NO: 210 In another embodiment, an antibody that binds to Vβ17 comprises a VL comprising a VL CDR3 having a Vβ17 sequence.

[0013] The antibody is provided herein, the antibody comprising: (i) a VH1 antibody having the amino acid sequence of SEQ ID NO: 211; VH CDR1 having the amino acid sequence of SEQ ID NO: 212, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 (ii) a VH comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 214; VL CDR1 having the amino acid sequence of SEQ ID NO: 215 and a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 216. In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 217, the amino acid sequence of SEQ ID NO: 218 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 219. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 220, VL CDR2 having the amino acid sequence of SEQ ID NO: 221, and VL CDR2 having the amino acid sequence of SEQ ID NO: 222 In another embodiment, an antibody that binds Vβ17 comprises a VL comprising a VL CDR3 having As provided herein, the antibody comprises a VH CDR1, a VH CDR2 and a VH CDR3 of SEQ ID NO: 20, respectively. VH CDR1, VH CDR2, and VH CDR3 amino acid sequences In another aspect, an antibody that binds to Vβ17 comprises a VH comprising a VH CDR3. As provided herein, the antibody comprises a VL CDR1, a VL CDR2 and a VL CDR3 of SEQ ID NO: 23, respectively. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR3. and (i) a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of SEQ ID NO: 20. VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences 2, and VH CDR3, respectively, of SEQ ID NO: 23; and (ii) VL CDR3, respectively, of SEQ ID NO: 23. a VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR2, and a VL CDR3. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 20. In some embodiments, the antibody In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 23. VH having the amino acid sequence of SEQ ID NO: 20 and VH having the amino acid sequence of SEQ ID NO: 23 In some embodiments, the antibody comprises a VL and a VL fragment thereof. In some embodiments, the VH comprises a VH having an amino acid sequence that is at least 95% identical. The antibody has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:23. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 20. VH having an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 23 and VL having an amino acid sequence that is at least 95% identical to the amino acid sequence of VL.

[0167] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3; (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6. In another aspect, provided herein is an antibody that binds to Vβ17, The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 181, a VH CDR2 having the amino acid sequence of SEQ ID NO: 182, VH CDR2 having the amino acid sequence of SEQ ID NO: 183 (ii) a VH comprising CDR3 and a VL CD having the amino acid sequence of SEQ ID NO: 226; R1, a VL CDR2 having the amino acid sequence of SEQ ID NO: 227, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 228 In another embodiment, the VL comprises a VL CDR3 having the amino acid sequence Provided herein is an antibody comprising: (i) an amino acid sequence of SEQ ID NO: 187; VH CDR1 having the amino acid sequence of SEQ ID NO: 188, VH CDR2 having the amino acid sequence of SEQ ID NO: 189, and (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 189; VL CDR1 having the amino acid sequence of SEQ ID NO: 232, VL CDR2 having the amino acid sequence of SEQ ID NO: 233 VL CDR2, and VL CDR3 having the amino acid sequence of SEQ ID NO: 234. and L. In another aspect, provided herein is an antibody that binds to Vβ17, said antibody comprising (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 193, VH CDR2 having the amino acid sequence of SEQ ID NO: 195, and VH CDR3 having the amino acid sequence of SEQ ID NO: 196. (ii) a VH CDR1 having the amino acid sequence of SEQ ID NO: 238, , a VL CDR2 having the amino acid sequence of SEQ ID NO: 239, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 240 In another embodiment, the Vβ17-binding fragment comprises a VL having a VL CDR3 with the sequence Provided herein is an antibody comprising: (i) an antibody having the amino acid sequence of SEQ ID NO: 199; VH CDR1 having the amino acid sequence of SEQ ID NO: 200, VH CDR2 having the amino acid sequence of SEQ ID NO: 201, (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 24; VL CDR1 having the amino acid sequence of SEQ ID NO: 4, VL CDR2 having the amino acid sequence of SEQ ID NO: 245 a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 246; In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: i) VH CDR1 having the amino acid sequence of SEQ ID NO: 205, the amino acid sequence of SEQ ID NO: 206 VH CDR2 having the sequence of SEQ ID NO: 207, and VH CDR3 having the amino acid sequence of SEQ ID NO: 208. 3, and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 250, VL CDR2 having the amino acid sequence of SEQ ID NO: 251 and the amino acid sequence of SEQ ID NO: 252 In another embodiment, an antibody that binds to Vβ17 comprises a VL comprising a VL CDR3 having a Vβ17 sequence.

[0013] The antibody is provided herein, the antibody comprising: (i) a VH1 antibody having the amino acid sequence of SEQ ID NO: 211; VH CDR1 having the amino acid sequence of SEQ ID NO: 212, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 (ii) a VH comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 256; VL CDR1 having the amino acid sequence of SEQ ID NO: 257 and a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 258. In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 217, the amino acid sequence of SEQ ID NO: 218 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 219. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 262; VL CDR2 having the amino acid sequence of SEQ ID NO: 263, and VL CDR2 having the amino acid sequence of SEQ ID NO: 264 In another embodiment, an antibody that binds Vβ17 comprises a VL comprising a VL CDR3 having As provided herein, the antibody comprises a VH CDR1, a VH CDR2 and a VH CDR3 of SEQ ID NO: 20, respectively. VH CDR1, VH CDR2, and VH CDR3 amino acid sequences In another aspect, an antibody that binds to Vβ17 comprises a VH comprising a VH CDR3. As provided herein, the antibody comprises a VL CDR1, a VL CDR2 and a VL CDR3 of SEQ ID NO: 24, respectively. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR3. and (i) a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of SEQ ID NO: 20. VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences 2, and VH CDR3, respectively, of SEQ ID NO: 24; and (ii) VL CDR3, respectively, of SEQ ID NO: 24. a VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR2, and a VL CDR3. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 20. In some embodiments, the antibody In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 24. VH having the amino acid sequence of SEQ ID NO: 20 and VH having the amino acid sequence of SEQ ID NO: 24 In some embodiments, the antibody comprises a VL and a VL fragment thereof. In some embodiments, the VH comprises a VH having an amino acid sequence that is at least 95% identical. The antibody has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:24. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 20. VH having an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 24 and VL having an amino acid sequence that is at least 95% identical to the amino acid sequence of VL.

[0168] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3; (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6. In another aspect, provided herein is an antibody that binds to Vβ17, The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 223, a VH CDR2 having the amino acid sequence of SEQ ID NO: 224, VH CDR2 having the amino acid sequence of SEQ ID NO: 225 (ii) a VH comprising CDR3 and a VL CD having the amino acid sequence of SEQ ID NO: 142; R1, a VL CDR2 having the amino acid sequence of SEQ ID NO: 143, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 144 In another embodiment, the VL comprises a VL CDR3 having the amino acid sequence Provided herein is an antibody comprising: (i) an amino acid sequence of SEQ ID NO: 229; a VH CDR1 having the amino acid sequence of SEQ ID NO: 230, a VH CDR2 having the amino acid sequence of SEQ ID NO: 231, and a VH CDR3 having the amino acid sequence of SEQ ID NO: 232. (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 231; VL CDR1 having the amino acid sequence of SEQ ID NO: 148, VL CDR2 having the amino acid sequence of SEQ ID NO: 149 VL CDR2, and VL CDR3 having the amino acid sequence of SEQ ID NO: 150. and L. In another aspect, provided herein is an antibody that binds to Vβ17, said antibody comprising (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 235, VH CDR2 having the amino acid sequence of SEQ ID NO: 237, and VH CDR3 having the amino acid sequence of SEQ ID NO: 238. (ii) a VH having a CDR3 and (iii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 154; , a VL CDR2 having the amino acid sequence of SEQ ID NO: 155, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 156 In another embodiment, the Vβ17-binding fragment comprises a VL having a VL CDR3 with the sequence Provided herein is an antibody comprising: (i) an antibody having the amino acid sequence of SEQ ID NO: 241; VH CDR1 having the amino acid sequence of SEQ ID NO: 242, VH CDR2 having the amino acid sequence of SEQ ID NO: 243, and VH CDR3 having the amino acid sequence of SEQ ID NO: 244. (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 16; VL CDR1 having the amino acid sequence of SEQ ID NO: 161, VL CDR2 having the amino acid sequence of SEQ ID NO: 162, a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 162; In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: i) VH CDR1 having the amino acid sequence of SEQ ID NO: 247, the amino acid sequence of SEQ ID NO: 248 VH CDR2 having the sequence of SEQ ID NO: 249, and VH CDR3 having the amino acid sequence of SEQ ID NO: 249 3, and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 166, VL CDR2 having the amino acid sequence of SEQ ID NO: 167 and the amino acid sequence of SEQ ID NO: 168 In another embodiment, an antibody that binds to Vβ17 comprises a VL comprising a VL CDR3 having a Vβ17 sequence.

[0013] The antibody is provided herein, the antibody comprising: (i) a VH1 antibody having the amino acid sequence of SEQ ID NO: 253; VH CDR1 having the amino acid sequence of SEQ ID NO: 254, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 (ii) a VH comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 172; VL CDR1 having the amino acid sequence of SEQ ID NO: 173 and a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 174. In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 259, the amino acid sequence of SEQ ID NO: 260 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 261. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 178, VL CDR2 having the amino acid sequence of SEQ ID NO: 179, and the amino acid sequence of SEQ ID NO: 180 In another embodiment, an antibody that binds Vβ17 comprises a VL comprising a VL CDR3 having As provided herein, the antibody comprises a VH CDR1, a VH CDR2 and a VH CDR3 of SEQ ID NO: 21, respectively. VH CDR1, VH CDR2, and VH CDR3 amino acid sequences In another aspect, an antibody that binds to Vβ17 comprises a VH comprising a VH CDR3. As provided herein, the antibody comprises a VL CDR1, a VL CDR2 and a VL CDR3 of SEQ ID NO: 22, respectively. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR3. and (i) a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of SEQ ID NO: 21. VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences 2, and VH CDR3, respectively, of SEQ ID NO: 22; and (ii) VL CDR3, respectively, of SEQ ID NO: 22. a VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR2, and a VL CDR3. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 21. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 22. VH having the amino acid sequence of SEQ ID NO: 21 and VH having the amino acid sequence of SEQ ID NO: 22 In some embodiments, the antibody comprises a VL and a VL fragment thereof. In some embodiments, the VH comprises a VH having an amino acid sequence that is at least 95% identical. The antibody has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:22. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 21. VH having an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 22 and VL having an amino acid sequence that is at least 95% identical to the amino acid sequence of VL.

[0169] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3; (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6. In another aspect, provided herein is an antibody that binds to Vβ17, The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 223, a VH CDR2 having the amino acid sequence of SEQ ID NO: 224, VH CDR2 having the amino acid sequence of SEQ ID NO: 225 (ii) a VH comprising CDR3 and a VL CD having the amino acid sequence of SEQ ID NO: 184; R1, a VL CDR2 having the amino acid sequence of SEQ ID NO: 185, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 186 In another embodiment, the VL comprises a VL CDR3 having the amino acid sequence Provided herein is an antibody comprising: (i) an amino acid sequence of SEQ ID NO: 229; a VH CDR1 having the amino acid sequence of SEQ ID NO: 230, a VH CDR2 having the amino acid sequence of SEQ ID NO: 231, and a VH CDR3 having the amino acid sequence of SEQ ID NO: 232. (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 231; VL CDR1 having the amino acid sequence of SEQ ID NO: 190, VL CDR2 having the amino acid sequence of SEQ ID NO: 191 VL CDR2, and VL CDR3 having the amino acid sequence of SEQ ID NO: 192. and L. In another aspect, provided herein is an antibody that binds to Vβ17, said antibody comprising (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 235, VH CDR2 having the amino acid sequence of SEQ ID NO: 237, and VH CDR3 having the amino acid sequence of SEQ ID NO: 238. (ii) a VH CDR1 having the amino acid sequence of SEQ ID NO: 196, , a VL CDR2 having the amino acid sequence of SEQ ID NO: 197, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 198 In another embodiment, the Vβ17-binding fragment comprises a VL having a VL CDR3 with the sequence Provided herein is an antibody comprising: (i) an antibody having the amino acid sequence of SEQ ID NO: 241; VH CDR1 having the amino acid sequence of SEQ ID NO: 242, VH CDR2 having the amino acid sequence of SEQ ID NO: 243, and VH CDR3 having the amino acid sequence of SEQ ID NO: 244. (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 20; VL CDR1 having the amino acid sequence of SEQ ID NO: 203, a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 204; In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: i) VH CDR1 having the amino acid sequence of SEQ ID NO: 247, VH CDR2 having the sequence of SEQ ID NO: 249, and VH CDR3 having the amino acid sequence of SEQ ID NO: 249 3, and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 208, VL CDR2 having the amino acid sequence of SEQ ID NO: 209, and VL CDR3 having the amino acid sequence of SEQ ID NO: 210 In another embodiment, an antibody that binds to Vβ17 comprises a VL comprising a VL CDR3 having a Vβ17 sequence.

[0013] The antibody is provided herein, the antibody comprising: (i) a VH1 antibody having the amino acid sequence of SEQ ID NO: 253; VH CDR1 having the amino acid sequence of SEQ ID NO: 254, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 (ii) a VH comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 214; VL CDR1 having the amino acid sequence of SEQ ID NO: 215 and a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 216. In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 259, the amino acid sequence of SEQ ID NO: 260 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 261. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 220, VL CDR2 having the amino acid sequence of SEQ ID NO: 221, and VL CDR2 having the amino acid sequence of SEQ ID NO: 222 In another embodiment, an antibody that binds Vβ17 comprises a VL comprising a VL CDR3 having As provided herein, the antibody comprises a VH CDR1, a VH CDR2 and a VH CDR3 of SEQ ID NO: 21, respectively. VH CDR1, VH CDR2, and VH CDR3 amino acid sequences In another aspect, an antibody that binds to Vβ17 comprises a VH comprising a VH CDR3. As provided herein, the antibody comprises a VL CDR1, a VL CDR2 and a VL CDR3 of SEQ ID NO: 23, respectively. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR3. and (i) a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of SEQ ID NO: 21. VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences 2, and VH CDR3, respectively, of SEQ ID NO: 23; and (ii) VL CDR3, respectively, of SEQ ID NO: 23. a VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR2, and a VL CDR3. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 21. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 23. VH having the amino acid sequence of SEQ ID NO: 21 and VH having the amino acid sequence of SEQ ID NO: 23 In some embodiments, the antibody comprises a VL and a VL fragment thereof. In some embodiments, the VH comprises a VH having an amino acid sequence that is at least 95% identical. The antibody has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:23. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 21. VH having an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 23 and VL having an amino acid sequence that is at least 95% identical to the amino acid sequence of VL.

[0170] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 1, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 a VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3; (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6. In another aspect, provided herein is an antibody that binds to Vβ17, The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 223, a VH CDR2 having the amino acid sequence of SEQ ID NO: 224, VH CDR2 having the amino acid sequence of SEQ ID NO: 225 (ii) a VH comprising CDR3 and a VL CD having the amino acid sequence of SEQ ID NO: 226; R1, a VL CDR2 having the amino acid sequence of SEQ ID NO: 227, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 228 In another embodiment, the VL comprises a VL CDR3 having the amino acid sequence Provided herein is an antibody comprising: (i) an amino acid sequence of SEQ ID NO: 229; a VH CDR1 having the amino acid sequence of SEQ ID NO: 230, a VH CDR2 having the amino acid sequence of SEQ ID NO: 231, and a VH CDR3 having the amino acid sequence of SEQ ID NO: 232. (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 231; VL CDR1 having the amino acid sequence of SEQ ID NO: 232, VL CDR2 having the amino acid sequence of SEQ ID NO: 233 VL CDR2, and VL CDR3 having the amino acid sequence of SEQ ID NO: 234. and L. In another aspect, provided herein is an antibody that binds to Vβ17, said antibody comprising (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 235, VH CDR2 having the amino acid sequence of SEQ ID NO: 237, and VH CDR3 having the amino acid sequence of SEQ ID NO: 238. (ii) a VH CDR1 having the amino acid sequence of SEQ ID NO: 238, , a VL CDR2 having the amino acid sequence of SEQ ID NO: 239, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 240 In another embodiment, the Vβ17-binding fragment comprises a VL having a VL CDR3 with the sequence Provided herein is an antibody comprising: (i) an antibody having the amino acid sequence of SEQ ID NO: 241; VH CDR1 having the amino acid sequence of SEQ ID NO: 242, VH CDR2 having the amino acid sequence of SEQ ID NO: 243, and VH CDR3 having the amino acid sequence of SEQ ID NO: 244. (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 24 VL CDR1 having the amino acid sequence of SEQ ID NO: 4, VL CDR2 having the amino acid sequence of SEQ ID NO: 245 a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 246; In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: i) VH CDR1 having the amino acid sequence of SEQ ID NO: 247, VH CDR2 having the sequence of SEQ ID NO: 249, and VH CDR3 having the amino acid sequence of SEQ ID NO: 249 3, and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 250, VL CDR2 having the amino acid sequence of SEQ ID NO: 251 and the amino acid sequence of SEQ ID NO: 252 In another embodiment, an antibody that binds to Vβ17 comprises a VL comprising a VL CDR3 having a Vβ17 sequence.

[0013] The antibody is provided herein, the antibody comprising: (i) a VH1 antibody having the amino acid sequence of SEQ ID NO: 253; VH CDR1 having the amino acid sequence of SEQ ID NO: 254, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 (ii) a VH comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 256; VL CDR1 having the amino acid sequence of SEQ ID NO: 257 and a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 258. In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 259, the amino acid sequence of SEQ ID NO: 260 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 261. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 262; VL CDR2 having the amino acid sequence of SEQ ID NO: 263, and VL CDR2 having the amino acid sequence of SEQ ID NO: 264 In another embodiment, an antibody that binds Vβ17 comprises a VL comprising a VL CDR3 having As provided herein, the antibody comprises a VH CDR1, a VH CDR2 and a VH CDR3 of SEQ ID NO: 21, respectively. VH CDR1, VH CDR2, and VH CDR3 amino acid sequences In another aspect, an antibody that binds to Vβ17 comprises a VH comprising a VH CDR3. As provided herein, the antibody comprises a VL CDR1, a VL CDR2 and a VL CDR3 of SEQ ID NO: 24, respectively. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR3. and (i) a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of SEQ ID NO: 21. VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences 2, and VH CDR3, respectively, of SEQ ID NO: 24; and (ii) VL CDR3, respectively, of SEQ ID NO: 24. a VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3; and a VL comprising a VL CDR2, and a VL CDR3. The antibody comprises a VH having the amino acid sequence of SEQ ID NO: 21. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 24. VH having the amino acid sequence of SEQ ID NO: 21 and VH having the amino acid sequence of SEQ ID NO: 24 In some embodiments, the antibody comprises a VL and a VL fragment thereof. In some embodiments, the VH comprises a VH having an amino acid sequence that is at least 95% identical. The antibody has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:24. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 21. VH having an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 24 and VL having an amino acid sequence that is at least 95% identical to the amino acid sequence of VL.

[0171] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 45, VH CDR2 having the amino acid sequence of SEQ ID NO: 2 VH comprising a VH CDR2 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3. (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 4, a VL CDR2 having the amino acid sequence of SEQ ID NO: 5, and a VL CDR2 having the amino acid sequence of SEQ ID NO: 6. In another aspect, an antibody that binds to Vβ17 is provided herein, comprising the above-mentioned Vβ17 and VL. The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 265, a VH CDR2 having the amino acid sequence of SEQ ID NO: 266 and VH CDR2 having the amino acid sequence of SEQ ID NO: 267. (ii) a VH comprising a H CDR3 and a VL C having the amino acid sequence of SEQ ID NO: 268; DR1, VL CDR2 having the amino acid sequence of SEQ ID NO: 269, and VL CDR3 having the amino acid sequence of SEQ ID NO: 270 In another embodiment, the Vβ17 comprises a VL comprising a VL CDR3 having the amino acid sequence Provided herein are antibodies that bind to (i) the amino acid sequence of SEQ ID NO: 271. a VH CDR1 having the amino acid sequence of SEQ ID NO: 272; and (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 273; and VL CDR1 having the amino acid sequence of SEQ ID NO: 274, VL CDR2 having the amino acid sequence of SEQ ID NO: 275 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 276, In another aspect, provided herein is an antibody that binds to Vβ17, (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 277, an VH CDR2 having the amino acid sequence of SEQ ID NO: 278 VH CDR2 having the amino acid sequence of SEQ ID NO: 279, and VH CDR3 having the amino acid sequence of SEQ ID NO: 279. (ii) a VH CDR having the amino acid sequence of SEQ ID NO: 280; and (iii) a VL CDR having the amino acid sequence of SEQ ID NO: 280. 1. A VL CDR2 having the amino acid sequence of SEQ ID NO: 281 and the amino acid sequence of SEQ ID NO: 282. In another embodiment, the VL comprises a VL CDR3 having the sequence Provided herein is an antibody having (i) the amino acid sequence of SEQ ID NO: 283. a VH CDR1 having the amino acid sequence of SEQ ID NO: 284, a VH CDR2 having the sequence (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 2; VL CDR1 having the amino acid sequence of SEQ ID NO: 86, VL CDR2 having the amino acid sequence of SEQ ID NO: 287 a VL CDR2, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 288; In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 289, an amino acid sequence of SEQ ID NO: 290 VH CDR2 having the amino acid sequence of SEQ ID NO: 291, and VH CDR3 having the amino acid sequence of SEQ ID NO: 292. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 292; VL CDR2 having the amino acid sequence of SEQ ID NO: 293 and the amino acid sequence of SEQ ID NO: 294 In another embodiment, the VL comprises a VL CDR3 having the sequence Provided herein is an antibody, the antibody having (i) the amino acid sequence of SEQ ID NO: 295. VH CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 296, and VH CDR3 having the amino acid sequence of SEQ ID NO: 304. (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 298; VL CDR1 having the amino acid sequence of SEQ ID NO: 299 and a VL comprising a VL CDR2 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 300. In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: 301, VH CDR1 having the amino acid sequence of SEQ ID NO: 302, VH CDR2 having the amino acid sequence of SEQ ID NO: 303, and VH CDR3 having the amino acid sequence of SEQ ID NO: 304. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 304, the sequence VL CDR2 having the amino acid sequence of SEQ ID NO: 305, and the amino acid sequence of SEQ ID NO: 306 and a VL comprising a VL CDR3 having the following: provided herein are antibodies comprising a VH CDR1, a VH CDR2 and a VH CDR3 of SEQ ID NO: 46, respectively. VH CDR1, VH CDR2, and VH CDR3 amino acid sequences In another aspect, an antibody that binds to Vβ17 comprises a VH comprising Vβ17 CDR2, and a VH comprising Vβ17 CDR3. As provided herein, the antibody comprises a VL CDR1, a VL CDR2 and a VL CDR3 of SEQ ID NO: 49, respectively. VL CDR1, VL CDR2, and VL CDR3 amino acid sequences In another aspect, an antibody that binds to Vβ17 comprises a VL comprising a VL CDR3. As provided herein, the antibody comprises (i) a VH CDR1, a VH CDR2, a VH CDR3, a VH CDR4, a VH CDR5, a VH CDR6, a VH CDR7, a VH CDR8, a VH CDR9, a VH CDR10, a VH CDR11, a VH CDR12, a VH CDR13, a VH CDR14, a VH CDR15, a VH CDR1 VH CDR1, VH CDR2, and VH CDR3 amino acid sequences and (ii) a VH comprising a VL CDR2, a VL CDR3, and a VL CDR4 of SEQ ID NO: 49, respectively. VL CDR1 having the amino acid sequences of CDR1, VL CDR2, and VL CDR3 , VL CDR2, and VL CDR3. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 46. The antibody comprises a VL having the amino acid sequence of SEQ ID NO: 47. The antibody has a VH having the amino acid sequence of SEQ ID NO: 46 and a VH having the amino acid sequence of SEQ ID NO: 47. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 11. In some embodiments, the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 12. In some embodiments, the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO:11. and a light chain having the amino acid sequence of SEQ ID NO: 12. The subject has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:46. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 47. In some embodiments, the VL has an amino acid sequence that is at least 95% identical to the VL. In the present specification, the antibody has an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:46. VH having an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 47 and a VL having the amino acid sequence of SEQ ID NO: 11. The heavy chain has an amino acid sequence that is at least 95% identical to the amino acid sequence of In some embodiments, the antibody has less than about 100% identity to the amino acid sequence of SEQ ID NO:12. In some embodiments, the antibody comprises a light chain having 95% of the amino acid sequence of the sequence A heavy chain having an amino acid sequence that is at least 95% identical to the amino acid sequence of No. 11. and an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 12. and a light chain that binds to the ribosomal receptor.

[0172] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 48, VH CDR2 having the amino acid sequence of SEQ ID NO: 49 and a VH CDR2 having the amino acid sequence of SEQ ID NO: 50. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 51, an amino acid sequence of SEQ ID NO: 52. VL CDR2 having the amino acid sequence of SEQ ID NO: 53, and VL CDR3 having the amino acid sequence of SEQ ID NO: 54. In another aspect, an antibody that binds to Vβ17 is provided herein. and wherein the antibody comprises: (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 307; VH CDR2 having the amino acid sequence of SEQ ID NO: 308, and the amino acid sequence of SEQ ID NO: 309 and (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 310. VL CDR1 having the amino acid sequence of SEQ ID NO: 311, VL CDR2 having the amino acid sequence of SEQ ID NO: 312, and VL CDR3 having the amino acid sequence of SEQ ID NO: 313. and a VL comprising a VL CDR3 having the amino acid sequence of SEQ ID NO:312. Provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) an antibody of SEQ ID NO: 313 VH CDR1 having the amino acid sequence of SEQ ID NO: 314 R2, and a VH CDR3 having the amino acid sequence of SEQ ID NO: 315; i) VL CDR1 having the amino acid sequence of SEQ ID NO: 316, amino acid sequence of SEQ ID NO: 317 VL CDR2 having the sequence of SEQ ID NO: 318, and VL CDR3 having the amino acid sequence of SEQ ID NO: 319. In another aspect, provided herein is an antibody that binds to Vβ17. , the antibody comprising: (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 319; VH CDR2 having the amino acid sequence of SEQ ID NO: 320, and VH CDR3 having the amino acid sequence of SEQ ID NO: 321. and (ii) a VH having the amino acid sequence of SEQ ID NO: 322. L CDR1, VL CDR2 having the amino acid sequence of SEQ ID NO: 323, and VL CDR3 having the amino acid sequence of SEQ ID NO: 3 and a VL comprising a VL CDR3 having a sequence of 24 amino acids. Provided herein is an antibody that binds to 17, the antibody comprising (i) amino acid sequence of SEQ ID NO: 325. VH CDR1 having the amino acid sequence of SEQ ID NO: 326, VH CDR2 having the amino acid sequence of SEQ ID NO: 326 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 327; and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 328, the amino acid sequence of SEQ ID NO: 329 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 330. In another aspect, provided herein is an antibody that binds to Vβ17, comprising The antibody comprises: (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 331; VH CDR2 having the amino acid sequence of SEQ ID NO: 333, (ii) a VH comprising a VH CDR3; and (iii) a VL having the amino acid sequence of SEQ ID NO: 334. CDR1, VL CDR2 having the amino acid sequence of SEQ ID NO: 335, and SEQ ID NO: 336 In another embodiment, the Vβ17 comprises a VL CDR3 having the amino acid sequence Provided herein is an antibody that binds to the amino acid sequence of SEQ ID NO: 337. VH CDR1 having the amino acid sequence of SEQ ID NO: 338, VH CDR2 having the amino acid sequence of SEQ ID NO: 339, and and a VH CDR3 having the amino acid sequence of SEQ ID NO: 339; and (ii) a VH having the sequence VL CDR1 having the amino acid sequence of SEQ ID NO: 340, VL CDR2 having the amino acid sequence of SEQ ID NO: 341 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 342. In another aspect, provided herein is an antibody that binds to Vβ17, The antibody comprises (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 343, a VH CDR2 having the amino acid sequence of SEQ ID NO: 344, VH CDR2 having the amino acid sequence of SEQ ID NO: 345 (ii) a VH comprising CDR3 and a VL CD having the amino acid sequence of SEQ ID NO: 346; R1, a VL CDR2 having the amino acid sequence of SEQ ID NO: 347, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 348 In another embodiment, the VL comprises a VL CDR3 having the amino acid sequence Provided herein are antibodies comprising the VH CDRs of SEQ ID NO: 77, respectively. VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of In another embodiment, the antibody binds to Vβ17. and a VL CDR1 of SEQ ID NO: 78, each of which is selected from the group consisting of: , VL CDR1, VL CDR2, and VL CDR3, In another embodiment, the VL comprises a Vβ17-binding domain, a VL comprising a Vβ17 CDR2, and a VL comprising a Vβ17 CDR3. Provided herein is an antibody comprising: (i) a VH C region of SEQ ID NO: 77, respectively; VH CDR1 having the amino acid sequences of DR1, VH CDR2, and VH CDR3; (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which is of SEQ ID NO: 78; and a VL having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3. Some embodiments include a VL, including CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 77. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 78. In one embodiment, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 77 and a VH having the amino acid sequence of SEQ ID NO: 78. and a VL having the sequence of SEQ ID NO: 664. In some embodiments, the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 665. In some embodiments, the antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 664. and a light chain having the amino acid sequence of SEQ ID NO: 665. In one embodiment, the antibody has at least 95% identity to the amino acid sequence of SEQ ID NO: 77. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 78. and VL having an amino acid sequence that is at least 95% identical to the amino acid sequence of VL. In some embodiments, the antibody has less than about 100% identity to the amino acid sequence of SEQ ID NO: 77. VH has an amino acid sequence with 95% identity to the amino acid sequence of SEQ ID NO: 78 and a VL having at least 95% amino acid sequence of The antibody has an amino acid sequence that has at least 95% identity to the amino acid sequence of SEQ ID NO: 664. In some embodiments, the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 665. In some embodiments, the light chain has an amino acid sequence that is at least 95% identical to that of In one embodiment, the antibody has at least 95% identity to the amino acid sequence of SEQ ID NO: 664. a heavy chain having an amino acid sequence that has at least one amino acid sequence identical to the amino acid sequence of SEQ ID NO: 665; The IgG1A-specific ...

[0173] In another aspect, provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) a sequence VH CDR1 having the amino acid sequence of SEQ ID NO: 48, VH CDR2 having the amino acid sequence of SEQ ID NO: 54 and a VH CDR2 having the amino acid sequence of SEQ ID NO: 55. and (ii) a VL CDR1 having the amino acid sequence of SEQ ID NO: 56, an amino acid sequence of SEQ ID NO: 57. VL CDR2 having the amino acid sequence of SEQ ID NO: 58, and VL CDR3 having the amino acid sequence of SEQ ID NO: 59. In another aspect, an antibody that binds to Vβ17 is provided herein. and wherein the antibody comprises: (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 349; VH CDR2 having the amino acid sequence of SEQ ID NO: 350, and the amino acid sequence of SEQ ID NO: 351 and (ii) a VH comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 352. VL CDR1 having the amino acid sequence of SEQ ID NO: 353, VL CDR2 having the amino acid sequence of SEQ ID NO: 354, and VL CDR3 having the amino acid sequence of SEQ ID NO: 355. and a VL comprising a VL CDR3 having the amino acid sequence of SEQ ID NO:354. Provided herein is an antibody that binds to Vβ17, the antibody comprising: (i) an antibody of SEQ ID NO: 355 VH CDR1 having the amino acid sequence of SEQ ID NO: 356 R2, and a VH CDR3 having the amino acid sequence of SEQ ID NO: 357; i) VL CDR1 having the amino acid sequence of SEQ ID NO: 358, amino acid sequence of SEQ ID NO: 359 VL CDR2 having the amino acid sequence of SEQ ID NO: 360 In another aspect, provided herein is an antibody that binds to Vβ17. , the antibody comprising: (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 361; VH CDR2 having the amino acid sequence of SEQ ID NO: 362, and VH CDR3 having the amino acid sequence of SEQ ID NO: 363. and (ii) a VH having the amino acid sequence of SEQ ID NO: 364. L CDR1, VL CDR2 having the amino acid sequence of SEQ ID NO: 365, and VL CDR3 having the amino acid sequence of SEQ ID NO: 3 and a VL comprising a VL CDR3 having a sequence of 66 amino acids. Provided herein is an antibody that binds to 17, the antibody comprising (i) amino acid sequence of SEQ ID NO: 367. VH CDR1 having the amino acid sequence of SEQ ID NO: 368, VH CDR2 having the amino acid sequence of SEQ ID NO: 369 and a VH CDR3 having the amino acid sequence of SEQ ID NO: 369; and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 370, the amino acid sequence of SEQ ID NO: 371 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 372. In another aspect, provided herein is an antibody that binds to Vβ17, comprising The antibody comprises: (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 373; VH CDR2 having the amino acid sequence of SEQ ID NO: 4, and VH CDR3 having the amino acid sequence of SEQ ID NO: 375 (ii) a VH comprising a VH CDR3; and (iii) a VL having the amino acid sequence of SEQ I...

Claims

1. An antibody that binds to Vβ17, (1) (i) a VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 21, VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of SEQ ID NO:

677. The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence 、 (2) (i) a VH CDR1 of a VH having the amino acid sequence of SEQ ID NO: 77, VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequences and (ii) a VH comprising a VH CDR2, a VH CDR3, and a VH comprising a VH CDR4, The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the acid sequence (3) (i) a VH CDR1 of a VH having the amino acid sequence of SEQ ID NO: 79, VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequences and (ii) a VH comprising a VH CDR2, a VH CDR3, and a VH comprising a VH CDR4, The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the acid sequence (4) (i) a VH CDR1 of a VH having the amino acid sequence of SEQ ID NO: 81, VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequences and (ii) a VH comprising a VH CDR2, a VH CDR3, and a VH comprising a VH CDR4, The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the acid sequence (5) (i) a VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 83, VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequences and (ii) a VH comprising a VH CDR2, a VH CDR3, and a VH comprising a VH CDR4, The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the acid sequence (6) (i) a VH CDR1 of a VH having the amino acid sequence of SEQ ID NO: 85, VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequences and (ii) a VH comprising a VH CDR2, a VH CDR3, and a VH comprising a VH CDR4, The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the acid sequence (7) (i) a VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 87, VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequences and (ii) a VH comprising a VH CDR2, a VH CDR3, and a VH comprising a VH CDR4, The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the acid sequence (8) (i) VH CDRs of VH having the amino acid sequence of SEQ ID NO: 1000, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2 and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

10. VL CDR1, VL CDR2, and VL CDR3 of VL having an amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 having three amino acid sequences. Mu VL, (9) (i) a VH CDR of a VH having the amino acid sequence of SEQ ID NO: 1032, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2 and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

10. VL CDR1, VL CDR2, and VL CDR of VL having 33 amino acid sequence VL CDR1, VL CDR2, and VL CDR3 having three amino acid sequences. Mu VL, (10) (i) a VH CD of VH having the amino acid sequence of SEQ ID NO: 1064, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences: and (ii) a VH comprising a VH CDR2 and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

1. VL CDR1, VL CDR2, and VL CDR3 of VL having an amino acid sequence of 065 VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence of VL, (11) (i) a VH CD of VH having the amino acid sequence of SEQ ID NO: 1096, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences: and (ii) a VH comprising a VH CDR2 and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

1. VL CDR1, VL CDR2, and VL CDR of VL having an amino acid sequence of 097 VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence of VL comprising, or (12) (i) a VH CD of VH having the amino acid sequence of SEQ ID NO: 1128, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences: and (ii) a VH comprising a VH CDR2 and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

1. VL CDR1, VL CDR2, and VL CDR of VL having 129 amino acid sequence VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence of An antibody comprising a VL comprising:

2. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The VL CDR2, VL CDR3, and VL CDR4 amino acid sequences are according to the Kabat numbering system. The antibody described.

3. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The VL CDR2, VL CDR3 and VL CDR4 amino acid sequences are numbered according to the Chothia numbering system.

2. The antibody described in 1.

4. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The VL CDR2, VL CDR3 and VL CDR4 amino acid sequences according to the AbM numbering system. antibodies.

5. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The VL CDR2, VL CDR3 and VL CDR4 amino acid sequences are according to the Contact numbering system.

2. The antibody described in 1.

6. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The VL CDR2, VL CDR3, and VL CDR4 amino acid sequences according to the IMGT numbering system are as described in claim 1. The antibodies listed are:

7. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The VL CDR2, VL CDR3, and VL CDR4 amino acid sequences are as set forth in claim 1 according to an exemplary numbering system. The antibodies listed are:

8. The antibody according to any one of claims 1 to 7, wherein the antibody is a humanized antibody.

9. The antibody according to any one of claims 1 to 8, wherein the antibody is an IgG antibody.

10. 2. The method of claim 1 , wherein the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody.

9. The antibody described in 9.

11. The antibody of any one of claims 1 to 10, wherein the antibody comprises a kappa light chain.

12. The antibody of any one of claims 1 to 10, wherein the antibody comprises a lambda light chain.

13. The antibody according to any one of claims 1 to 12, wherein the antibody is a monoclonal antibody. 。

14. The antibody of any one of claims 1 to 13, wherein the antibody binds to a Vβ17 antigen.

15. The antibody of any one of claims 1 to 13, wherein the antibody binds to the Vβ17 epitope. 。

16. The antibody of any one of claims 1 to 15, wherein the antibody specifically binds to Vβ17. body.

17. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD R2 and VL CDR3 form the binding site of the Vβ17 for an antigen.

17. The antibody according to any one of 1 to 16.

18. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD R2 and VL CDR3 form a binding site for the Vβ17 epitope; An antibody described in any one of claims 1 to 16.

19. The Vβ17 of any one of claims 1 to 18 is present on the surface of a T cell. antibody.

20. The antibody of any one of claims 1 to 19, wherein the antibody is multivalent.

21. The antibody of claim 20, wherein the antibody is capable of binding to at least three antigens. 。

22. The antibody of claim 20, wherein the antibody is capable of binding to at least four antigens. 。

23. The antibody of claim 20, wherein the antibody is capable of binding to at least five antigens. 。

24. The antibody of any one of claims 1 to 23, wherein the antibody is a multispecific antibody.

25. 1. A multispecific Vβ17 antibody, comprising: (a) a first binding domain that binds to Vβ17, said first binding domain comprising: A first binding domain comprising a Vβ17 antibody according to any one of claims 1 to 23; (b) a second binding domain that binds to a second target that is not Vβ17. Isomeric Vβ17 antibody.

26. The multispecific Vβ17 antibody of claim 25, wherein the antibody is a bispecific antibody.

27. The multispecific Vβ17 antibody of claim 25, wherein the antibody is a trispecific antibody.

28. The multispecific Vβ17 antibody of claim 25, wherein the antibody is a tetraspecific antibody.

29. 29. The method of claim 25, wherein the second binding domain binds to an antigen of the second target. A multispecific Vβ17 antibody according to any one of claims 1 to 4.

30. The second binding domain binds to an epitope of the second target.

9. A multispecific Vβ17 antibody according to any one of claims 8.

31. The method of claim 25 to 30, wherein the second binding domain specifically binds to the second target.

2. The multispecific Vβ17 antibody according to any one of claims 1 to 11.

32. The VH CDR1, VH CDR2, VH CDR3, VH CDR4 of the second binding domain VL CDR1, VL CDR2, and VL CDR3 are directed against an antigen of the second target. A multispecific Vβ17 antibody according to any one of claims 25 to 31, which forms a binding site. 。

33. The VH CDR1, VH CDR2, VH CDR3, VH CDR4 of the second binding domain VL CDR1, VL CDR2, and VL CDR3 bind to the epitope of the second target. A multispecific Vβ1 according to any one of claims 25 to 31, which forms a binding site for 7 antibodies.

34. The method according to any one of claims 25 to 33, wherein the second target is present on the surface of a target cell.

2. A multispecific Vβ17 antibody as described herein.

35. 35. The method of claim 25, wherein the second binding domain that binds to the second target is multivalent.

2. The multispecific Vβ17 antibody according to any one of claims 1 to 11.

36. 3. The method of claim 2, wherein the second binding domain is capable of binding to at least three antigens.

6. A multispecific Vβ17 antibody according to claim 5.

37. 3. The method of claim 2, wherein the second binding domain is capable of binding to at least four antigens.

6. A multispecific Vβ17 antibody according to claim 5.

38. 3. The method of claim 2, wherein the second binding domain is capable of binding to at least five antigens.

6. A multispecific Vβ17 antibody according to claim 5.

39. The multiplex antibody of any one of claims 25 to 38, wherein the second target is CD123. Specific Vβ17 antibody.

40. each of the second binding arms that bind to CD123 comprises (i) an amino acid sequence of SEQ ID NO: 40 The amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 of VH are VH comprising VH CDR1, VH CDR2, and VH CDR3 having the sequence (ii) a VL CDR1, a VL CDR2, and a VL CDR3, each having the amino acid sequence of SEQ ID NO: 41 VL CDR1, VL CDR2, and VL CDR3 amino acid sequences 40. The multispecific Vβ17 of claim 39, comprising: antibody.

41. A multispecific antibody that binds to Vβ17, (a) a first binding domain that binds to Vβ17, said first binding domain comprising: (1) (i) a VH CDR1 of a VH having the amino acid sequence of SEQ ID NO: 25, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence of SEQ ID NO:

26. The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence 、 (2) (i) a VH CDR1 of a VH having the amino acid sequence of SEQ ID NO: 7, VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequences and (ii) a VH comprising an amino acid sequence of SEQ ID NO: 8, a VH comprising a VH CDR2, and a VH CDR3, The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the sequence (3) (i) a VH CDR1 of VH having the amino acid sequence of SEQ ID NO:9, VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequences and (ii) a VH comprising a VH CDR2, a VH CDR3, and a VH comprising a VH CDR4, The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the acid sequence (4) (i) VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 19, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence of SEQ ID NO:

22. The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence 、 (5) (i) a VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 19, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence of SEQ ID NO:

23. The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence 、 (6) (i) a VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 19, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence of SEQ ID NO:

24. The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence 、 (7) (i) VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 20, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence of SEQ ID NO:

22. The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence 、 (8) (i) VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 20, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence of SEQ ID NO:

23. The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence 、 (9) (i) VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 20, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence of SEQ ID NO:

24. The amino acid sequence of VL is VL CDR1, VL CDR2, and VL CDR3. VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence 、 (10) (i) VH CDRs of VH having the amino acid sequence of SEQ ID NO: 21, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2 and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

22. VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence A VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence L. (11) (i) VH CDRs of VH having the amino acid sequence of SEQ ID NO: 21, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2 and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

23. VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence A VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence L. (12) (i) VH CDRs of VH having the amino acid sequence of SEQ ID NO: 21, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2 and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

24. VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence A VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence L, or (13) (i) VH CDRs of VH having the amino acid sequence of SEQ ID NO: 46, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2 and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

49. VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence A VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence L, and a first binding domain comprising (b) a second antibody that binds to a second target, the second target being BCMA, DLL3, PSMA, or KLK2. and a binding domain of

42. The VH CDR1, VH CDR2, VH CDR3, VL of the first binding arm The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are numbered according to the Kabat numbering system.

42. The multispecific Vβ17 antibody of claim 41 , according to the system.

43. The VH CDR1, VH CDR2, VH CDR3, VL of the first binding arm The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are shown in accordance with the Chothia numbering system. A multispecific Vβ17 antibody according to claim 41, in accordance with the system.

44. The VH CDR1, VH CDR2, VH CDR3, VL of the first binding arm The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are numbered according to the AbM numbering system.

42. The multispecific Vβ17 antibody of claim 41 according to

45. The VH CDR1, VH CDR2, VH CDR3, VL of the first binding arm The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are numbered as Contact A multispecific Vβ17 antibody according to claim 41, in accordance with the system.

46. The VH CDR1, VH CDR2, VH CDR3, VL of the first binding arm The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are identified according to the IMGT numbering system.

42. The multispecific Vβ17 antibody of claim 41 , according to the method.

47. The VH CDR1, VH CDR2, VH CDR3, VL of the first binding arm The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are shown in the exemplary numbering system.

42. The multispecific Vβ17 antibody of claim 41 , according to the method.

48. The method according to any one of claims 25 to 38 or claims 41 to 47, wherein the second target is BCMA.

2. A multispecific Vβ17 antibody according to claim 1.

49. The second binding arm that binds to BCMA comprises (i) each of the amino acids of SEQ ID NO:95 Amino acids of VH CDR1, VH CDR2, and VH CDR3 of VH having the following sequence: VH comprising VH CDR1, VH CDR2, and VH CDR3 having the sequence ii) VL CDR1, VL CDR2, VL DDR3, VL EDR4, VL EDR5, VL EDR6, VL EDR7, VL EDR8, VL EDR9, VL EDR10, VL EDR11, VL EDR12, VL EDR13, VL EDR14, VL EDR15, VL EDR16, VL EDR17, VL EDR18, VL EDR19, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences and a VL comprising VL CDR3. 。

50. The method according to any one of claims 25 to 38 or claims 41 to 47, wherein the second target is DLL3.

2. A multispecific Vβ17 antibody according to claim 1.

51. each of the second binding arms that bind to DLL3 is selected from the group consisting of (i) an amino acid sequence of SEQ ID NO:694; The amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 of VH are VH comprising VH CDR1, VH CDR2, and VH CDR3 having the sequence (ii) a VL CDR1, a VL CDR2, and a VL CDR3, each having the amino acid sequence of SEQ ID NO: 695 VL CDR1, VL CDR2, and VL CDR3 amino acid sequences R2, and a VL comprising a VL CDR3. 7 antibodies.

52. The method according to any one of claims 25 to 38 or claims 41 to 47, wherein the second target is PSMA.

2. A multispecific Vβ17 antibody according to claim 1.

53. the second binding arm that binds to PSMA is (1) (i) a VH CDR1 of a VH having the amino acid sequence of SEQ ID NO: 730, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

731. VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence A VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence L. (2) (i) a VH CDR1 of a VH having the amino acid sequence of SEQ ID NO: 732, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

733. VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence A VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence L. (3) (i) a VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 734, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

735. VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence A VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence L. (4) (i) a VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 736, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

737. VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence A VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence L, or (5) (i) a VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 899, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

900. VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence A VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence L. The multispecific Vβ17 antibody of claim 52.

54. The method according to any one of claims 25 to 38 or claims 41 to 47, wherein the second target is KLK2.

2. A multispecific Vβ17 antibody according to claim 1.

55. the second binding arm that binds to KLK2 is (i) an amino acid sequence of SEQ ID NO: 887, The amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 of VH are VH comprising VH CDR1, VH CDR2, and VH CDR3 having the sequence (ii) a VL CDR1, a VL CDR2, and a VL CDR3, each having the amino acid sequence of SEQ ID NO: 888 VL CDR1, VL CDR2, and VL CDR3 amino acid sequences R2, and a VL comprising a VL CDR3. 7 antibodies.

56. The VH CDR1, VH CDR2, VH CDR3, VL of the second binding arm The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are numbered according to the Kabat numbering system.

56. The multispecific antibody of claim 40, 49, 51, 53, or 55 according to the system. sexual Vβ17 antibody.

57. The VH CDR1, VH CDR2, VH CDR3, VL of the second binding arm The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are shown in accordance with the Chothia numbering system.

56. The method of claim 40, 49, 51, 53, or 55 according to the system. Specific Vβ17 antibody.

58. The VH CDR1, VH CDR2, VH CDR3, VL of the second binding arm The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are numbered according to the AbM numbering system.

56. The multispecific V according to claim 40, 49, 51, 53 or 55, β17 antibody.

59. The VH CDR1, VH CDR2, VH CDR3, VL of the second binding arm The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are numbered as Contact 56. The method of claim 40, 49, 51, 53, or 55 according to the system. Specific Vβ17 antibody.

60. The VH CDR1, VH CDR2, VH CDR3, VL of the second binding arm The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are identified according to the IMGT numbering system.

56. The multispecific antibody of claim 40, 49, 51, 53 or 55 according to the method of claim 40, 49, 51, 53 or 55. Vβ17 antibody.

61. The VH CDR1, VH CDR2, VH CDR3, VL of the second binding arm The VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are shown in the exemplary numbering system.

56. The multispecific antibody of claim 40, 49, 51, 53 or 55 according to the method of claim 40, 49, 51, 53 or 55. Vβ17 antibody.

62. A multispecific Vβ17 antibody capable of binding to Vβ17 on the surface of T cells. a first means and a second means capable of binding to a second target that is not Vβ17. M, multispecific Vβ17 antibodies.

63. The multispecific Vβ of claim 62, wherein the second target is present on the surface of a target cell. 17 antibodies.

64. A nucleic acid encoding an antibody according to any one of claims 1 to 63.

65. A vector comprising the nucleic acid of claim 64.

66. A host cell comprising the vector of claim 65.

67. 67. A kit comprising the vector of claim 66 and a package therefor.

68. A kit comprising an antibody according to any one of claims 1 to 63 and a package thereof.

69. A method for the treatment of a cancer, comprising administering to the patient an antibody according to any one of claims 1 to 63, and a pharma- ceutically acceptable carrier. Pharmaceutical compositions.

70. 70. A method of producing the pharmaceutical composition of claim 69, comprising administering to the patient a pharma- ceutical composition ... combining said compound with a carrier to obtain said pharmaceutical composition.

71. A method for activating T cells expressing Vβ17, comprising:

2. A method comprising contacting a subject with the antibody of claim 1.

72. The contacting step reduces the expression of CD69, CD2 5, and / or the method of claim 71, resulting in increased expression of granzyme B.

73. 1. A process for generating antibodies that bind to two or more target molecules, the process comprising: serves to obtain a first binding domain that binds to Vβ17 present on T cells. and a second binding domain that binds to a second target on the surface of the target cell. and a step for binding to Vβ17 present on T cells and a second target on the surface of the target cell. and providing an antibody that binds to the target protein.

74. To serve to obtain a second binding domain that binds to a second target on the surface of a target cell. The above steps are repeated n times, and the Vβ17 present on the T cell binds to n target molecules. The method further comprises n steps for performing the function of providing a first binding domain, wherein n is at least 74. The process of claim 73, wherein both are 2.

75. A method for directing T cells expressing Vβ17 to target cells, comprising the steps of: contacting the multispecific Vβ17 antibody of any one of claims 1 to 4 with the target cell. and wherein the second target is present on the surface of the target cell, and the contacting step comprises contacting the T A method of directing a cell to said target cell.

76. A method for inhibiting the growth or proliferation of a target cell, comprising the steps of: The multispecific Vβ17 antibody described herein is administered to a target cell on the surface of which the second target is present. and contacting said target cell with said target cell expressing said Vβ17. and wherein said contacting step is in the presence of a T cell that is capable of inhibiting the growth or proliferation of said target cell. Bring, method.

77. A method for eliminating target cells in a subject, comprising the steps of: The multispecific Vβ17 antibody of the present invention is administered to a target cell having a second target present on its surface. contacting said target cell, said contacting comprising: wherein said contacting step is in the presence of T cells and results in elimination of said target cells.

78. A method for treating a disease in a subject comprising administering an effective amount of any one of claims 25 to 63.

2. The method of claim 1, further comprising administering to the subject the multispecific Vβ17 antibody of claim 1, wherein the disease is The second target is present on the surface of the target cell and is attracted in whole or in part to the target cell. How to wake someone up.

79. 79. The method of claim 77 or 78, wherein the subject is a human.

80. Any one of claims 77 to 79, wherein the subject is in need of the method. The method according to

81. 2. The method of claim 1, wherein the second target is present on the surface of a target cell, the target cell being a cancer cell. 5 to 63, or any one of claims 75 to 80. The method according to any one of claims 1 to 5.

82. (i) the cancer cells are selected from the group consisting of adrenal cancer, anal cancer, appendix cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, Cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gestational trophoblastic cancer, head and neck cancer, Hodgkin's lymphoma, intestinal Cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, neuroendocrine tumors, Non-Hodgkin's lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, paranasal sinus cancer, skin cancer, soft tissue sarcoma Cells from spinal cancer, stomach cancer, testicular cancer, pharyngeal cancer, thyroid cancer, uterine cancer, endometrial cancer, vaginal cancer, or vulvar cancer and (ii) the second target is angiopoietin, BCMA, CD19, CD20, CD 22, CD25 (IL2-R), CD30, CD33, CD37, CD38, CD52, CD56, CD123 (IL-3R), cMET, DLL / Notch, EGFR, Ep CAM, FGF, FGF-R, GD2, HER2, mesothelin, nectin-4, PAP, PDGFRα, PSA, PSA3, PSMA, RANKL, SLAMF7, STEAP1 , TARP, TROP2, VEGF, or VEGF-R, and / or (iii) the second target is CEA, immature laminin receptor, TAG-72, HPV E6, HPV E7, BING-4, calcium-dependent chloride channel 2, cyclin- B1, 9D7, EpCAM, EphA3, Her2 / neu, telomerase, mesothelin , SAP-1, surviving, BAGE family antigen, CAGE family antigen, GA GE family antigens, MAGE family antigens, SAGE family antigens, XAGE family antigens Milli antigen, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan- A, MART-1, Gp100, pmel17, tyrosinase, TRP-1, TRP-2 , P. Polypeptide, MC1R, prostate specific antigen, β-catenin, or BRCA1 82. The multispecific Vβ17 antibody or method of claim 81 .

83. 82. The multispecific Vβ17 antibody of claim 81, wherein said second target is CD123. is the method.

84. 82. The multispecific Vβ17 antibody of claim 81, wherein the second target is BCMA. method.

85. 82. The multispecific Vβ17 antibody of claim 81, wherein said second target is DLL3. method.

86. 82. The multispecific Vβ17 antibody of claim 81, wherein the second target is PSMA. method.

87. 82. The multispecific Vβ17 antibody of claim 81, wherein said second target is KLK2. method.

88. (i) The adrenal cancer is adrenocortical carcinoma (ACC), adrenocortical carcinoma, pheochromocytoma, or Neuroblastoma, (ii) the anal cancer is squamous cell carcinoma, cloacal carcinoma, adenocarcinoma, basal cell carcinoma, or uterine carcinoma or melanoma, (iii) the appendix cancer is selected from the group consisting of neuroendocrine tumors (NETs), mucinous adenocarcinomas, goblet cell carcinomas, and thyroid cancers. id, intestinal type adenocarcinoma, or signet ring cell adenocarcinoma; (iv) The cholangiocarcinoma is extrahepatic cholangiocarcinoma, adenocarcinoma, hilar cholangiocarcinoma, hilar region cholangiocarcinoma, distal cholangiocarcinoma, Bile duct cancer or intrahepatic cholangiocarcinoma, (v) the bladder cancer is selected from the group consisting of transitional cell carcinoma (TCC), papillary carcinoma, squamous carcinoma, and squamous cell carcinoma. carcinoma, adenocarcinoma, small cell carcinoma, or sarcoma; (vi) The bone cancer is a primary bone cancer, a sarcoma, an osteosarcoma, a chondrosarcoma, a sarcoma, a fibrosarcoma, a malignant fibrosarcoma, a ... fibrous histiocytoma, giant cell tumor of bone, chordoma, or metastatic bone cancer; (vii) the brain cancer is astrocytoma, brain stem glioma, glioblastoma, meningioma, ependymoma, oligodendroma, Dendroglioma, mixed glioma, pituitary carcinoma, pituitary adenoma, craniopharyngioma, germ cell tumor, pinealoma tumor, medulloblastoma, or primary CNS lymphoma; (viii) The breast cancer is breast adenocarcinoma, invasive breast cancer, non-invasive breast cancer, breast sarcoma, metaplastic carcinoma , adenocystic carcinoma, phyllodes tumor, angiosarcoma, HER2 positive breast cancer, triple negative breast cancer, is inflammatory breast cancer, (ix) the cervical cancer is squamous cell carcinoma or adenocarcinoma; (x) the colorectal cancer is colorectal adenocarcinoma, primary colorectal lymphoma, gastrointestinal stromal tumor , leiomyosarcoma, carcinoid tumor, mucinous adenocarcinoma, signet ring cell adenocarcinoma, gastrointestinal carcinoid tumor or melanoma, (xi) the esophageal cancer is adenocarcinoma or squamous cell carcinoma; (xii) The gallbladder cancer is adenocarcinoma, papillary adenocarcinoma, adenosquamous carcinoma, or squamous cell carcinoma. , small cell carcinoma, or sarcoma, (xiii) The gestational trophoblastic disease (GTD) is selected from the group consisting of hydatidiform mole, gestational trophoblastic neoplasm (GTD), and gestational trophoblastic neoplasm (GTD). TN), choriocarcinoma, placental site trophoblastic tumor (PSTT), or epithelioid trophoblastic tumor ectocal tumor (ETT) (xiv) The head and neck cancer is laryngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, nasal cavity cancer, sinus cancer, salivary gland cancer. cancer, oral cancer, oropharyngeal cancer, or tonsillar cancer; (xv) the Hodgkin's lymphoma is classical Hodgkin's lymphoma, nodular sclerosis, mixed cell type , lymphocyte-rich, lymphocytopenic, or nodular lymphocyte-predominant Hodgkin lymphoma ( NLPHL) (xvi) The intestinal cancer is small intestine cancer, small bowel cancer ncer), adenocarcinoma, sarcoma, gastrointestinal stromal tumor, carcinoid tumor, or lymphoma; (xvii) the kidney cancer is renal cell carcinoma (RCC), clear cell RCC, papillary RCC, chromophobe Primary RCC, collecting duct RCC, unclassified RCC, transitional cell carcinoma, urothelial carcinoma, renal pelvic carcinoma, or is a renal sarcoma, (xviii) The leukemia is acute lymphocytic leukemia (ALL), acute myeloid leukemia ( AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairless leukemia (HCL), or myelodysplastic syndrome (MDS), (xix) the liver cancer is hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocellular carcinoma, Hemangiosarcoma or liver metastasis, (xx) The lung cancer is small cell lung cancer, small cell carcinoma, combined small cell carcinoma, non-small cell lung cancer, lung Adenocarcinoma, squamous cell lung cancer, large cell undifferentiated carcinoma, pulmonary nodule, metastatic lung cancer, adenosquamous carcinoma , large cell neuroendocrine carcinoma, salivary gland type lung carcinoma, pulmonary carcinoid, mesothelioma, sarcomatoid carcinoma of the lung, or malignant granular cell lung tumor, (xxi) the melanoma is selected from the group consisting of superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, malignant melanoma, Lentigo melanoma, amelanotic melanoma, desmoplastic melanoma, ocular melanoma, or metastatic melanoma That is, (xxii) the mesothelioma is pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, or testicular mesothelioma It is a tumor. (xxiii) the multiple myeloma is active or smoldering multiple myeloma; (xxiv) The neuroendocrine tumor is a gastrointestinal neuroendocrine tumor, a pancreatic neuroendocrine tumor, or Most of the cases are pulmonary neuroendocrine tumors. (xxv) The non-Hodgkin's lymphoma is anaplastic large cell lymphoma, lymphoblastic lymphoma. , peripheral T-cell lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoplasmacytic lymphoma lymphoma, marginal zone B-cell lymphoma, MALT lymphoma, small cell lymphocytic lymphoma, Burkitt's lymphoma Lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), precursor T-lymphoblastic leukemia / lymphoma, acute lymphocytic leukemia (ALL), adult T-cell lymphoma Tumor / leukemia (ATLL), hairy cell leukemia, B cell lymphoma, diffuse large B cell DLBCL, primary mediastinal B-cell lymphoma, primary central nervous system (CNS) lymphoma lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, mucosa-associated lymphoid tissue (MA LT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, lymphoplasmocytic lymphoma Follicular lymphoma, B-cell non-Hodgkin's lymphoma, T-cell non-Hodgkin's lymphoma, natural killer -cell lymphoma, cutaneous T-cell lymphoma, Alibert-Bazin syndrome, Sézary syndrome, Hara Cutaneous anaplastic large cell lymphoma, peripheral T cell lymphoma, angioimmunoblastic T cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), systemic ALCL, enteropathy-type T cell lymphoma hepatosplenic gamma / delta T-cell lymphoma (EATL), (xxvi) the oral cancer is selected from the group consisting of squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinoma, lymphoma, Benign oral tumors, eosinophilic granulomas, fibromas, granular cell tumors, keratoacanthomas, leiomyomas, osteochondroma Osteoma, lipoma, Schwannoma, neurofibroma, papilloma, genital condyloma, verrucous xanthomas , pyogenic granuloma, rhabdomyoma, odontogenic tumor, leukoplakia, erythroplakia, squamous cell carcinoma of the lip, basal cell carcinoma lip cancer, oral cancer, gum cancer, or tongue cancer, (xxvii) the ovarian cancer is ovarian epithelial cancer, mucinous epithelial ovarian cancer, endometrial epithelial ovarian cancer, Clear cell epithelial ovarian cancer, Undifferentiated epithelial ovarian cancer, Ovarian low malignant potential tumor, Primary peritoneal cancer, Fallopian tube cancer, Embryonic Cell tumors, teratomas, undifferentiated ovarian germ cell carcinomas, endodermal sinus tumors, sex cord-stromal tumors, sex cord-gonadal stromal tumors Tumor, ovarian stromal tumor, granulosa cell tumor, granulosa theca tumor, Sertoli-Leydig tumor , ovarian sarcoma, ovarian carcinosarcoma, ovarian adenosarcoma, ovarian leiomyosarcoma, ovarian fibrosarcoma, Krukenberg A tumor or ovarian cyst. (xxviii) The pancreatic cancer is selected from the group consisting of exocrine pancreatic cancer, endocrine pancreatic cancer, and pancreatic adenocarcinoma, islet cell carcinoma, and the like. cystic or neuroendocrine tumors, (xxix) The prostate cancer is prostate adenocarcinoma, prostate sarcoma, transitional cell carcinoma, small cell carcinoma. or a neuroendocrine tumor, (xxx) the sinus cancer is selected from the group consisting of squamous cell carcinoma, mucosal cell carcinoma, adenoid cystic cell carcinoma, acinar cell carcinoma, Cellular carcinoma, sinonasal undifferentiated carcinoma, nasal cavity cancer, paranasal sinus cancer, maxillary sinus cancer, ethmoid sinus cancer, or nasopharyngeal cancer That is, (xxxi) the skin cancer is basal cell carcinoma, squamous cell carcinoma, melanoma, Merkel cell carcinoma, Kaposi's sarcoma (KS), actinic keratosis, cutaneous lymphoma, or keratoacanthoma, (xxxii) the soft tissue cancer is angiosarcoma, dermatofibrosarcoma, epithelial sarcoma, Ewing's sarcoma Sarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST), Kaposi's sarcoma, leiomyosarcoma, liposarcoma, prostate Differentiated liposarcoma (DL), myxoid / round cell liposarcoma (MRCL), well-differentiated liposarcoma ( WDL), malignant fibrous histiocytoma, neurofibrosarcoma, rhabdomyosarcoma (RMS), or synovial sarcoma It is a tumor. (xxxiii) The spinal cancer is a spinal metastatic tumor. (xxxiv) The gastric cancer is selected from the group consisting of gastric adenocarcinoma, gastric lymphoma, gastrointestinal stromal tumor, and carcinoid tumor. gastric carcinoid tumor, type I ECL cell carcinoid tumor, type II ECL cell carcinoid tumor or type III ECL cell carcinoid; (xxxv) the testicular cancer is seminoma, nonseminoma, embryonal carcinoma, yolk sac carcinoma, trophoblastic carcinoma, or trophoblastic carcinoma. Carcinoma, teratoma, gonadal stromal tumor, Leydig cell tumor, or Sertoli cell tumor 、 (xxxiv) The pharyngeal cancer is selected from the group consisting of squamous cell carcinoma, adenocarcinoma, sarcoma, laryngeal cancer, pharyngeal cancer, nasal Pharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, laryngeal squamous cell carcinoma, laryngeal adenocarcinoma, lymphoepithelioma , spindle cell carcinoma, verrucous carcinoma, undifferentiated carcinoma, or lymph node carcinoma; (xxxv) the thyroid cancer is selected from the group consisting of papillary carcinoma, follicular carcinoma, Hurthle cell carcinoma, and thyroid medullary carcinoma. fibroid-like carcinoma or undifferentiated carcinoma, (xxxvi) The uterine cancer is endometrial cancer, endometrial adenocarcinoma, endometrioid carcinoma, serous Adenocarcinoma, adenosquamous carcinoma, uterine carcinosarcoma, uterine sarcoma, uterine leiomyosarcoma, endometrial stromal sarcoma, or undifferentiated sarcoma, (xxxvii) the vaginal cancer is squamous cell carcinoma, adenocarcinoma, melanoma, or sarcoma. or (xxxviii) claim 82, wherein the vulvar cancer is squamous cell carcinoma or adenocarcinoma.

2. A multispecific Vβ17 antibody or method according to claim 1.

89. 2. The method of claim 1, wherein the second target is present on the surface of a target cell, the target cell being a B cell. 5 to 63, or any one of claims 75 to 80. The method according to any one of claims 1 to 5.

90. The second target is CD1a, CD1b, CD1c, CD1d, CD2, CD5, CD 6, CD9, CD11a, CD11b, CD11c, CD17, CD18, CD19, C D20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, C D29, CD30, CD31, CD32a, CD32b, CD35, CD37, CD38 , CD39, CD40, CD45, CD45RA, CD45RB, CD45RC, CD4 5RO, CD46, CD47, CD48, CD49b, CD49c, CD49d, CD5 0, CD52, CD53, CD54, CD55, CD58, CD60a, CD62L, C D63, CD68, CD69, CD70, CD72, CD73, CD74, CD75, C D75S, CD77, CD79a, CD79b, CD80, CD81, CD82, CD8 3, CD84, CD85E, CD85I, CD85J, CD86, CD92, CD95, CD97, CD98, CD99, CD100, CD102, CD108, CD119, C D120a, CD120b, CD121b, CD122, CD124, CD125, CD 126, CD130, CD132, CD137, CD138, CD139, CD147, CD148, CD150, CD152, CD162, CD164, CD166, CD16 7a, CD170, CD171, CD175, CD175s, CD180, CD184, CD185, CD192, CD196, CD197, CD200, CD205, CD20 1a, CDw210b, CD212, CD213a1, CD213a2, CD 215, CD217, CD218a, CD218b, CD220, CD221, CD222, CD 224, CD225, CD226, CD227, CD229, CD230, CD232, CD252, CD252, CD254, CD255, CD256, CD257 CD25 8, CD259, CD260, CD261, CD262, CD263, CD264, CD 267-270, CD272, CD274, CD275, CD277, CD279, CD 283, CD289, CD290, CD295, CD298, CD300, CD300c , CD305, CD306, CD307a, CD307b, CD307c, CD307d , CD307e, CD314, CD215, CD316, CD317, CD319, CD 321, CD327, CD328, CD329, CD338, CD351, CD352, CD353, CD354, CD355, CD356, CD357, CD358, CD36 90. The multispecific V of claim 89, which is CD360, CD361, CD362, or CD363. β17 antibodies or methods.

91. 90. The multispecific Vβ17 antibody of claim 89, wherein said second target is BCMA. method.

92. An antibody that binds to Vα10.2, (1) (i) a VH CDR1 of a VH having the amino acid sequence of SEQ ID NO: 568, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

569. VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence A VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence L, or (2) (i) a VH CDR1 of a VH having the amino acid sequence of SEQ ID NO: 570, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences and (ii) a VH comprising a VH CDR2, and a VH CDR3, each of which has the sequence represented by SEQ ID NO:

571. VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence A VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence An antibody comprising:

93. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD 92. The VL CDR2, VL CDR3 and VL CDR4 amino acid sequences are according to the Kabat numbering system. The antibody described in

94. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The VL CDR2, VL CDR3 and VL CDR4 amino acid sequences are numbered according to the Chothia numbering system.

92. The antibody described in 92.

95. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The VL CDR2, VL CDR3 and VL CDR4 amino acid sequences are according to the AbM numbering system. The antibodies listed are:

96. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The VL CDR2, VL CDR3 and VL CDR4 amino acid sequences are according to the Contact numbering system.

92. The antibody described in 92.

97. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD 93. The VL CDR2, VL CDR3 and VL CDR4 amino acid sequences according to the IMGT numbering system. The antibody described.

98. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD 93. The VL CDR2, VL CDR3 and VL CDR4 amino acid sequences according to the exemplary numbering system of claim 92. The antibody described.

99. The antibody, (i) is a humanized antibody; (ii) optionally, an IgG1, IgG2, IgG3, or IgG4 antibody; is an IgG antibody; (iii) comprises a kappa light chain or a lambda light chain; and / or (iv) An antibody described in any one of claims 92 to 98, which is a monoclonal antibody.

100. 100. The antibody of claim 92, wherein the antibody binds to the Vα10.2 antigen. antibody.

101. 101. The antibody according to any one of claims 92 to 100, wherein the antibody binds to the Vα10.2 epitope. The antibodies listed are:

102. 102. The method of claim 92, wherein the antibody specifically binds to Vα10.

2. The antibody described.

103. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD and VL CDR2, VL CDR3 and VL CDR4 form a binding site for the Vα10.2 antigen. The antibody of any one of claims 92 to 102.

104. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD VL CDR2 and VL CDR3 form a binding site for the Vα10.2 epitope. The antibody of any one of claims 92 to 103.

105. 105. Any one of claims 92 to 104, wherein the Vα10.2 is present on the surface of a T cell. The antibody described in

106. The antibody of any one of claims 92 to 105, wherein the antibody is multivalent.

107. The antibody of any one of claims 92 to 106, wherein the antibody is a multispecific antibody. 。

108. The antibody of any one of claims 92 to 107, wherein the antibody is a bispecific antibody.

109. 10. The method of claim 10, wherein the antibody further binds to a second target, the second target being BCMA. 7 or 108. An antibody according to claim 7 or 108.

Images